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ABSTRACT
The analgesic and anti-inflammatory effects of the nonsteroidal anti­
inflammatory drugs (NSAIDs) ketoprofen (2.2 and 3.63 mg/kg) and phenylbutazone 
(4.4 mg/kg) were compared in equine models of acute synovitis and chronic hoof 
pain. The eicosanoids, prostaglandin Ej (PGE?) and leukotriene B4 (LTB4), increased 
dramatically in synovial fluid after carrageenan-induced synovitis of the intercarpal 
joint. PGE2 concentrations in untreated horses peaked at 9 hours while LTB4 
concentrations peaked in all horses at 3 hours. Synovial fluid concentrations of both 
eicosanoids returned to near baseline by 48 hours. Lameness, joint temperature, and 
synovial fluid volume, protein and nucleated cells increased at 3 to 12 hours with 
reduction to near baseline levels by 48 hours. NSAIDs when given intravenously 
decreased joint concentrations of PGE^ but LTB4 levels were unaffected by drug 
administration. Both drugs decreased the signs of inflammation and lameness, but 
phenylbutazone was more effective. These data suggest that leukotrienes are involved 
in equine synovitis and the development of specific leukotriene inhibitors may be of 
therapeutic value. The plasma half-life of ketoprofen (2.2 mg/kg) in normal horses 
(0.88 hours) was higher than horses with synovitis (0.55 hours). Synovial fluid levels 
of ketoprofen in horses with synovitis were 6.5 times higher than normal horses at one 
hour. The area under the synovial fluid concentration curve for horses with synovitis 
was greater than in normal horses. These data suggest that the inflamed joint may 
serve as a site of sequestration for ketoprofen. Digital vein eicosanoid levels from
horses with hoof pain from chronic laminitis were not different than those in normal 
horses. Although hoof pain and lameness could not be attributed to eicosanoids, both 
effects were reduced by the systemic administration of NSAIDs. Ketoprofen at a dose 
of 3.63 mg/kg (phenylbutazone equimolar dose) reduced hoof pain and lameness to 
a greater extent than the 2.2 mg/kg dose and phenylbutazone. These effects were still 
present at 24 hours for 3 of the 4 measures of hoof pain. These data suggest that 
phenylbutazone was more potent in alleviating acute joint inflammation whereas 
ketoprofen at a dosage rate of 1.65 times the therapeutic dose was more potent in 
alleviating chronic pain and lameness in horses.
CHAPTER 1 
GENERAL INTRODUCTION
This dissertation is organized in the journal style. A global introduction and 
literature review precede separate chapters on specific themes, which are followed by 
a general conclusion chapter. The literature review (Chapter 2) encompasses three 
areas that were relevant to the course of this dissertation research: inflammation, pain 
and the use of nonsteroidal anti-inflammatory drugs to alleviate these conditions. 
Chapters 3 through 6 describe the development of models and analytical techniques 
along with the experiments used in the testing of the overall research hypothesis and 
specific objectives. Chapter 7 consists of an overall summary of results, conclusions 
and indications for future research.
This dissertation research was designed to bring further understanding to the 
mechanisms and alleviation of pain and inflammation in the horse. Inflammation 
occurs in many forms in the horse. This pathological process results in significant 
morbidity and often, mortality. Musculoskeletal inflammation in particular shortens 
the working life of the horse and results in considerable pain. Our treatment options 
at present are limited to a few steroidal and nonsteroidal agents that have been 
approved for use in the horse. Many of these products are older drugs that were 
originally used in humans. Researchers of nonsteroidal anti-inflammatory agents have 
tried to identify novel drugs that are more efficacious in relieving inflammation and 
pain than traditional drugs. This research has lead to the discovery of a more
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complex array of inflammatory mediators and modulators. Since the discovery of the 
pro-inflammatory leukotrienes, emphasis has been placed on developing inhibitors of 
lipoxygenase and specific leukotriene antagonists.
The research hypothesis of this dissertation is that nonsteroidal anti­
inflammatory drugs (NSAIDs) that inhibit the cyclooxygenase and lipoxygenase 
mediated breakdown of arachidonic acid are potentially more effective alleviators of 
pain and inflammation than NSAIDs that solely inhibit cyclooxygenase. The overall 
objective of this research was to compare the putative cyclooxygenase and 
lipoxygenase inhibitor, ketoprofen to the cyclooxygenase inhibitor, phenylbutazone in 
equine models of acute joint inflammation and chronic pain. Prostaglandin Ej (PGEj) 
and leukotriene B4 (LTB4) were chosen as measures of cyclooxygenase and 
lipoxygenase activity, respectively, based on their potent inflammatory and pain 
mediating properties. Specific objectives were as follows:
1) Develop a self-limiting, reproducible model of acute synovitis which 
increases prostaglandin Ej (PGEj) and leukotriene B4 (LTB4) concentrations in 
synovial fluid and produces other measurable joint inflammatory responses.
2) Compare the magnitude and time course of the anti-inflammatory and 
eicosanoid inhibitory effects of ketoprofen and phenylbutazone in the acute synovitis 
model.
3) Compare the ability of ketoprofen and phenylbutazone to reduce the clinical 
signs of acute synovitis.
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4) Compare the time course of the anti-inflammatory effects of ketoprofen with 
its plasma and synovial fluid drug concentrations.
5) Determine whether digital vein eicosanoid concentrations are greater in 
horses with chronic laminitis than normal horses.
6) Providing that there are higher eicosanoid concentrations in laminitic versus 
normal horses, correlate the severity of hoof pain with the eicosanoid concentrations.
7) Determine the magnitude and time course of the eicosanoid inhibitory effects 
of ketoprofen and phenylbutazone in horses with chronic laminitis.
8) Objectively quantitate and compare the analgesic effects of ketoprofen and 




This review will focus on the specific types of inflammation and pain 
associated with the experimental models used in this dissertation research. Emphasis 
will be placed on the particular drugs and eicosanoids which influence inflammation. 
Experimental models of joint inflammation will be discussed. In particular, 
carrageenan-induced joint inflammation and the clinical diseases of arthritis, synovitis 
and chronic laminitis will be reviewed in detail. The properties of the eicosanoids, 
prostaglandin Ej and leukotriene B4 will be discussed as well as the inhibition of these 
substances by the nonsteroidal anti-inflammatory agents (NSAIDs), ketoprofen and 
phenylbutazone. A discussion of acute and chronic pain will also be included.
B. Inflammation
Inflammation is a local, defensive process elicited by tissue insult resulting 
ultimately in destruction, dilution or isolation of the offending agent and injured 
tissues. This dynamic process in most cases restores homeostasis, but if unregulated 
may have deleterious effects on the affected tissue or organ. Inflammation was 
originally described by the first century writings of the Roman, Cornelius Celsus as: 
rubor et tumor cum calore et dolore, "redness (erythema) and swelling (edema) with 
heat and pain (nociception and hyperalgesia)." The founder of modem cellular 
pathology, Rudolph Virchow, added the fifth cardinal sign of inflammation, functio
4
laesa or loss of function [1]. Inflammation typically occurs in three phases: 1) an 
acute transient phase characterized by local dilation of arterioles, capillaries, and 
venules resulting in increased blood flow and increased vascular permeability with 
exudation of fluids and plasma proteins; 2) a delayed subacute phase marked by 
infiltration of leukocytes and phagocytic cells; and 3) the chronic proliferative phase 
in which tissue degeneration and fibrosis lead to healing or chronic inflammation. 
[2,3].
1. Stimuli
Inflammation may be elicited by a number of stimuli including: infectious 
agents such as microbial organisms and parasites, ischemia, antigen-antibody 
interactions, exposure to radiation or electrical energy, extreme temperatures, 
mechanical trauma and noxious chemicals [3,4]. Experimentally, chemical irritants 
have been used extensively to mimic the inflammatory response.
Regardless of the etiology, most forms of acute and chronic inflammation 
involve the cellular and humoral components of the immune system. The inciting 
cause is first recognized as a foreign antigen by surface antibodies on B lymphocytes 
or via macrophage presentation to receptors on T lymphocytes. This recognition leads 
to the production of pro-inflammatory substances which result in transitory 
vasoconstriction followed by arteriolar and precapillary vasodilation, capillary 
recruitment, and increased vascular permeability due to contraction of endothelial 
cells. Fluid and protein exudation follow as blood flow is first increased then 
decreased resulting in hyperemia and congestion. Leukocytes marginate within the
vessels and adhere to vascular endothelium. Ultimately, these cells migrate to the 
inflammatory locus and begin degranulating, leading to destruction of the inciting 
agent and surrounding tissue. Destruction of the antigen is the responsibility of the 
phagocytic cells: neutrophils; monocytes and in some cases, eosinophils. The tissue 




Inflammation is mediated and in some cases modulated by various autocoids 
or local hormones. The eicosanoids are a family of lipid-derived autocoids that 
include the prostaglandins, thromboxanes, leukotrienes and the lipoxins. Eicosanoids 
are derived from 20-carbon polyunsaturated essential fatty acids [5]. Arachidonate is 
the most abundant precursor of the eicosanoids and it is derived from dietary linoleic 
acid. Arachidonic acid is then esterified to the phospholipids of cell membranes or 
other complex lipids.
i. Release o f arachidonate
Arachidonic acid is released from cellular lipids de novo by acyl hydrolases. 
This release is closely regulated and occurs in response to reduced oxygen tension, 
thrombin generation, hormones, immunologic reactions, ultraviolet light, tumor- 
producing agents or other irritant stimuli that interact with membrane bound receptors 
coupled to guanine nucleotide-binding regulatory proteins. These G proteins then 
either directly activate phospholipase C and or A2 or indirectly activate these enzymes
through an increase in cytosolic calcium. Phospholipase A2 hydrolyzes the ester bond 
of membrane phospholipids such as phosphatidylcholine and phosphatidylethanolamine 
to release arachidonate. Phospholipase C cleaves the phosphodiester bond, resulting 
in the formation of a 1,2-diglyceride leading to the release of arachidonic acid [6]. 
Once arachidonic acid is freed it may be acted upon by the cyclooxygenase or the 
lipoxygenase enzyme systems to produce eicosanoids (Figure 1). In addition, 
arachidonic acid may be metabolized by the epoxygenase pathway in neutrophils 
through a cytochrome P-450-dependent mixed-function oxidase leading to the 
formation of unstable epoxides [7].
ii. Enzymes
The first enzyme in the production of prostaglandins is prostaglandin 
endoperoxide synthase or as it is more commonly called, fatty acid cyclooxygenase. 
This microsomal enzyme is present in all cells, except mature erythrocytes [6]. This 
enzyme has two activities; one is an endoperoxide synthase activity that oxygenates 
and cyclizes arachidonate acid to form the cyclic endoperoxide prostaglandin G2 
(PGG2) and a peroxidase activity that converts PGG2 to prostaglandin H2 (PGHj) by 
reducing the 15-hydroperoxy group to a 15-hydroxy. Isomerases synthesize 
prostaglandin E* (PGEj), prostaglandin D2 (PGD^ and prostaglandin (PG F^ from 
PGH2. The unstable endoperoxide PGH2 is also metabolized to thromboxane A2 
(TXAj) and prostacyclin (PGI2) [8], The specific prostaglandins produced vary with 
different cells or tissues depending upon the synthases and isomerases present [9]. 
Lipoxygenase enzymes are found in the pulmonary tissue, platelets and leukocytes [6].
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Figure 1: Enzymatic release and metabolism of arachidonate.
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Lipoxygenases are a group of membrane-associated enzymes that oxygenate 
polyunsaturated fatty acids to lipid hydroperoxides [10]. The enzymes require a fatty 
acid substrate with two cis double bonds separated by a methylene group and are 
regulated by the presence of calcium [6]. The arachidonate metabolites of 
lipoxygenase are called hydroperoxyeicosatetraenoic acids (HPETEs). This enzyme 
system, like the cyclooxygenase enzyme, goes through an activation phase where it 
generates metabolites that act as positive and then negative feedback regulators 
[10,11]. Lipoxygenases differ in their specificity for placing the hydroperoxy group 
and tissues differ in the lipoxygenases they contain. For instance, platelets have only 
12-lipoxygenase while leukocytes have 5-, 12-, and in some species, 15-lipoxygenases 
[12]. The HPETEs are unstable intermediates analogous to PGG2 or PGH2 and are 
further degraded by a series of enzymes. HPETEs may be converted to hydroxy fatty 
acids (HETEs) by a peroxidase or nonenzymatically. In a relatively newly elucidated 
pathway 12-HPETE can undergo a molecular rearrangement to form the hepoxillins 
while 15-HPETE may be converted by leukocytes to the lipoxins [6]. The 5- 
lipoxygenase enzyme leads to the synthesis of the pro-inflammatory leukotrienes 
through the metabolite, 5-HPETE. Leukotriene A synthase catalyzes the formation 
of the unstable 5,6-epoxide leukotriene A4 (LTA4) from 5-HPETE. Leukotriene B4 
(LTB4) or (5S, 12R)-dihydroxy-6,14-cw-8, lO-f/ww-eicosatetraenoic acid is formed 
from LTA4 by LTA hydrolase. Alternatively, LTA4 can be nonenzymatically 
hydrolyzed to diastereomers of 5,6-dihydroxyeicosatetraenoic acid (5,6-diHETE), and 
6,8,10-rra/w-14-c«-diastereomers of 5,12-diHETE [13]. These hydrolysis products
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have little biological importance as compared to LTB4. In a separate microsomal 
pathway, LTA4 may be conjugated with glutathione at the 6 position to form the 
sulfidopeptide leukotrienes: LTC4, D4, E», and F4. LTC4, LTD4 and LTE4 are also 
known as the slow-reacting substances of anaphylaxis [13]. 
mi. Prostaglandins 
Prostaglandins are named according to substitutions on the cyclopentane ring 
and numbered according to the number of double bonds in the alkyl side chains [5]. 
The number 1 carbon is located at the carboxyl terminus. Prostaglandins of the 
subscript 2 series are the major ones in mammals and this nomenclature denotes 
derivation from arachidonic acid whereas the subscript 1 and 3 series may come from 
other polyunsaturated fatty acid precursors [5,14]. Prostaglandins of the E and D type 
are hydroxy ketones while the F a series are 1,3 diols [6]. Many tissues have specific 
prostaglandin receptors through which cell function is regulated via two second 
messenger systems: regulation of intracellular synthesis of cyclic AMP by activation 
or inhibition of adenylate cyclase and stimulation of phospholipase C resulting in the 
formation of inositol-1,4,5-triphosphate leading to a rise in intracellular calcium. 
These messenger systems in turn regulate various protein kinases which control 
cellular activity [6].
By most reports, the predominant stable prostaglandin product of leukocytes 
is PGEj [15]. PGEj produces long lasting dermal erythema and increased blood flow 
in cutaneous vessels and superficial vessels. PGE2 produces little plasma exudation 
alone, but potentiates exudation after injection of chemical irritants, histamine and
11
bradykinin [16,17]. Prostaglandins increase vascular permeability in conjunction with 
serotonin and bradykinin by inducing vascular leakage in venules [18]. The effect 
of PGE2 on plasma exudation has been studied in the skin of horses [19]. When PGE2 
was co-administered with bradykinin the volume of plasma exudate increased 
markedly. This synergistic effect was not seen with PGEj and histamine in equine 
skin. PGEj has similar activities as PGEj, but it is less abundant [6]. In contrast to 
other species, PGE2 is chemotactic for equine neutrophils at concentrations of 1 and 
10 ng/ml [20].
The functions of T and B cells are modified by PGEj in vitro at concentrations 
similar to inflammatory exudates (10-8 M). Secretion of interleukin-2 is inhibited by 
PGE2 in T cells accounting for inhibition of mitogen and antigen-induced T cell 
proliferation by PGEj [9]. This inhibition and the inhibitory effects of PGEj on B cell 
proliferation is associated with elevated intracellular levels of cyclic AMP [9,18]. 
Human rheumatoid T cells are particularly susceptible to this effect of PGEj which 
leads to a deficient production of interferon and other lymphokines [9]. Several other 
inflammatory modulation activities have been demonstrated by PGE, and PGE2 such 
as: inhibition of LTB4 production [21], inhibition of lysosomal enzyme release [22], 
inhibition of 0 2 release and inhibition of neutrophil activation [23]. Thus, there 
appear to be paradoxical anti-inflammatory properties as well as pro-inflammatory 
effects associated with prostaglandins.
Prostanoids are not stored but are synthesized de novo and rapidly metabolized 
and excreted in the urine. TXA2 and PGI2 hydrolyze in less than 2 minutes to the
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more stable compounds, TXBj and 6-keto PGFlo, respectively [9]. PGF2a can be 
metabolized by a 9-keto reductase to form PGEj in some tissues [6]. PGEj is 
metabolized initially to 15-keto-13, W-dihydro-PGEj [24]. This reaction is catalyzed 
by 15-hydroxy prostanoate dehydrogenase and A13-reductase which are present in most 
tissues, but are found in high concentrations in the liver, kidney and lung [24]. The 
metabolites of prostaglandins are cleared from the circulation very quickly [25] by one 
or two steps of /?- and w-oxidation in the lung and liver [24,26]. 
iv. Leukotrienes
Leukotrienes of the subscript 4 series are derived from arachidonic acid. Other 
polyunsaturated fatty acid precursors give rise to the 3 and 5 series [5]. Receptors for 
LTB4, LTC4 and LTIVLTE* have been identified which respond by activation of 
phospholipase C. LTB4 receptors have been found on neutrophils and monocytes, 
while receptors for LTD4 and E4 have been found on smooth muscle cells [6].
LTB4 promotes leukocyte adherence, chemotaxis and degranulation [27,28]. 
The chemotactic properties of LTB4 are particularly potent, both in vitro and in vivo. 
This activity is dependent upon the cis-trans-trans-triene structure [13]. LTB4 has 
been demonstrated to be a potent chemotactic agent for equine [20] and bovine 
neutrophils [29]. In the horse, maximum chemotactic activity is reported to be 
obtained at concentrations that are higher than other species [20]. LTB4 promotes the 
secretion of inflammatory products by neutrophils including active oxygen molecules, 
hydrogen peroxide, superoxide and hydroxyl radical and other degradative enzymes 
[30]. Also, LTB4 increases vascular permeability and plasma exudation in the cheek
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pouch [13] and this effect is greatly potentiated by the co-administration of bradykinin 
or PGE2 in the rabbit, guinea pig and rat [31,32]. LTC4 and LTB4 may stimulate the 
production of gamma interferon. LTB4 is a potent inhibitor of human T cell 
mitogenesis. This inhibition may be accounted for by the ability of LTB4 to induce 
maturation and enhance the activity of T-suppressor and cytotoxic cells [9]. LTA4 can 
be transcellularly metabolized to LTB4 by erythrocytes or in blood plasma [10,33]. 
The w-oxidation enzymes responsible for metabolism and inactivation of these 
compounds are part of the cytochrome P-450 family and like the prostaglandins utilize 
P-450 reductase [10]. The neutrophil is primarily responsible for sequestering and 
metabolizing LTB4 to 20-hydroxy-LTB4 which is then excreted in the urine [10]. 
However, complete /8-oxidation accounts for the major route of metabolism for LTB4 
[34].
b. Other mediators 
Vasoactive amines, kinins, cytokines, plasma-derived factors, leukocytic 
products and phospholipid products play important roles in the pathogenesis of 
inflammation. Many of these mediators act synergistically with the eicosanoids in 
perpetuating inflammation as well as pain.
Histamine was one of the first chemicals described as an inflammatory 
mediator. When released by basophils, mast cells and platelets, it initiates the early 
vascular responses and maintains this effect for 30 to 60 minutes [4]. Intradermally 
administered histamine produces arteriolar dilation and also results in a flare of 
erythema in the surrounding tissue. The kinins, bradykinin and kallidin are liberated
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by the action of kallikrein enzymes on serum kininogen [4], Bradykinin and histamine 
potentiate vascular permeability in conjunction with the eicosanoids [17]. Bradykinin 
has been shown to stimulate phospholipase A2 activity and PGE2 release [35]. 
Serotonin and histamine increase vascular permeability exclusively at the level of the 
post-capillary venules [36]. Serotonin also has vasodilatory properties. However, the 
actions of serotonin differ among animal species. In rodents this amine is contained 
within tissue mast cells and has permeability increasing properties. This property is 
not shared by man or many other species [36].
The volume of plasma exudation following intradermally administered 
histamine, bradykinin, serotonin or the E-series of prostaglandins varies between 
species [19]. Histamine and bradykinin, but not serotonin, produced circular lesions 
when injected intradermally into thoracic skin of horses [19]. According to this study, 
histamine was more potent than bradykinin on a molar basis in producing vascular 
leakage and lesion formation in the horse.
Interleukin-1 is a polypeptide produced in macrophages, synovial fibroblasts 
and other cells after infection, injury or antigenic challenge. This cytokine has 
hormone-like effects systemically, but also produces distinct local effects. It acts as 
a pro-inflammatory substance by inducing endogenous pyrogen fever, stimulating 
cellular metabolism and promoting eicosanoid release [37]. Blockade of the 
interleukin-1 receptor inhibits PGEz and LTB4 generation in human monocytes [38]. 
Interleukin 1 acts synergistically with many other cytokines including tumor necrosis 
factor [37]. Tumor necrosis factor is also associated with eicosanoid production [39].
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Plasma derived factors such as complement also potentiate the release of the 
eicosanoids from cells [18,40]. Complement fragments and prostaglandin act 
synergistically to produce intradermal edema in rabbits [36,41].
Neutrophils are known to release prostaglandins of the E type during 
phagocytosis and release of lysosomal enzymes [18]. The lysosomal products of 
neutrophils are classified as: cationic proteins, acid proteases and neutral proteases. 
These enzymes are responsible for increased vascular permeability, chemotaxis of 
monocytes and immobilization of neutrophils, degradation of basement membranes 
under an acid pH, release of kinin from plasma kininogen and the degradation of 
collagen, elastin, renal basement membrane, cartilage and fibrin [1].
The tachykinin neuropeptides, substance P, neuropeptide Y, calcitonin gene- 
related peptide and the neurokinins A and B play important roles in the regulation of 
inflammation and immune response in peripheral tissues and in the central nervous 
system [42]. Substance P is most likely responsible for the local flare response after 
intradermally injected histamine. This neurokinin is also thought to mediate 
neurogenic inflammation as it induces increased vascular permeability after stimulation 
of C-fibers [36].
Platelet-activation factor, like the eicosanoids, is derived from membrane 
phospholipids and is synthesized de novo. This compound is produced by 
inflammatory cells, platelets, endothelial cells and renal tissues. It induces 
bronchospasm, hypotension, neutropenia, thrombocytopenia, increased vascular 
permeability and is chemotactic for leukocytes [6].
16
3. Models of acute inflammation
Inflammatory models used to assess the potencies and duration of action of 
anti-inflammatory drugs in animals include the intradermal or subcutaneous injection 
of carrageenan, zymosan, Bordetella pertussis, and immune complexes [43]. Dermal 
inflammation has been produced by the application of ultraviolet light [44], 
inflammatory mediators [41] and compound 48/80 [41,44-46]. The mammary gland 
of ruminants has been used as a unique acute inflammation model. Intramammarily 
injected lipopolysaccharides in goats produced a self-limiting inflammation that 
resolves within one week [47], Many of these models are also used in pain research 
and in some cases they may produce a chronic inflammation.
a. Subcutaneous inflammation
Most models of subcutaneous inflammation involve the injection of 
carrageenan. These models were developed in laboratory rodents and have been 
adapted for use in the horse. Other methods of producing subcutaneous inflammation 
in the horse have been reported such as the subcutaneous injection of a counterirritant 
consisting of iodine, ether and soybean oil [48]. This method was used to test the 
antiinflammatory effects of the metalloprotein, orgotein. 
i. Carrageenan
The sulphated mucopolysaccharide carrageenan has been used experimentally 
to produce local inflammation in rabbits, rats, dogs, horses and pigs [49-53]. The 
major source of carrageenan is the alga Chondrus crispus which grows abundantly in 
the area known as Carragheen near Waterford, Ireland. Carrageenan can also be
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extracted from the seaweed Gigartina stellata. The extracted mucopolysaccharide can 
be treated with potassium chloride to form two fractions: the gel fraction, k -  
carrageenan, and the non-gel forming X-carrageenan. A-Carrageenan is primarily 
composed of sulfated D-galactose residues with a molecular weight between 3.5 and 
4 x 105. A-Carrageenan is the more potent fraction in producing acute and chronic 
inflammation, anticoagulation and toxicity. Carrageenan when administered 
subcutaneously appears to be very poorly absorbed systemically. However, some 
absorption may occur in the rat [54].
The toxicity of intradermal carrageenan is thought to progress through a 
complicated pathway that was elucidated by Vinegar, et al. [55]. The inflammatory 
response to carrageenan is thought to be mediated by histamine, serotonin, bradykinin, 
the eicosanoids [54] and activation of the complement system [56]. After injection of 
carrageenan into the rat paw it is absorbed by mast cells resulting in cytoplasmic 
injury and degranulation with initiation of the arachidonic acid cascade. Hyperemia 
and an increase in tissue osmotic pressure ensues along with direct damage to 
endothelial cells by carrageenan. Within 90 to 240 minutes, neutrophils infiltrate the 
damaged tissue and phagocytize remaining carrageenan. Carrageenan causes 
degranulation of lysosomes resulting in cellular lysis and further arachidonic acid 
release. PGEj and bradykinin are thought to be the primary mediators of the 
exudation of fluid within the first few hours of inflammation [57]. The eicosanoids 
are responsible for the hyperemia, increased vascular permeability and hyperalgesia 
that follows. By 12 hours the monocytes infiltrate the damaged tissue to phagocytize
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the cellular debris. These cells may also experience lysosomal rupture or they may 
retain partially degraded carrageenan for extended periods [54,58]. Fibroblast 
proliferation occurs after 2 to 8 days and the tissue returns to normal by 15 days post­
injection [55].
Carrageenan was first used as a phlogistic agent to produce subplan tar 
inflammation in the rat paw by Benitz and Hall in 1959 [59], and described in detail 
by Winter in 1962 [60]. Inhibition of the edema produced by subcutaneously 
administered carrageenan is commonly used by the pharmaceutical industry to evaluate 
NSAIDs [60]. Subplan tar carrageenan in the rat hind paw model results in peak 
inflammatory swelling by 4 hours after injection [61]. The same authors have 
reported that subcutaneous carrageenan in the neck of rats results in peak swelling by 
16 hours. In these models edema is measured in the rat paw by plethysmography and 
mercury displacement and by neck circumference [62]. Other researchers have used 
subcutaneous carrageenan in the rat to form an abscess that may be removed and 
weighed [44]. PGEj has been measured in the rat hindpaw after carrageenan 
injection. The animals were euthanized and 100 grams of tissue were then extracted 
and assayed for PGE^ [63]. Carrageenan has been administered subcutaneously in the 
thoracic region of horses in an effort to produce a model for NSAID evaluation. 
There was an increase in lesion diameter and plasma extravasation for 5 hours after 
administration [19].
Many of these workers use a 2% solution of carrageenan in water or isotonic 
saline. However, the optimal strength of a solution of carrageenan in producing
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inflammatory effects was 1 % as determined by Gardner [49] in guinea pig skin. He 
noted little increase in inflammation with the 2% solution, while the higher viscosity 
of this solution made it difficult to inject.
These subcutaneous models are limited to the measurement of edema and pain 
in response to paw pressure. Other models have been developed for the measurement 
of white blood cells, protein, enzymes, drugs and inflammatory mediators in the 
exudate. Polyester sponges soaked with 2% carrageenan have been implanted 
subcutaneously along the ventral midline in rats [50,64-66]. The sponges are 
removed, immersed in heparinized saline, centrifuged and the supernatant assayed for 
PGE2. This method allows for the determination of leukocyte numbers and protein 
concentration as well as drug concentration in the inflammatory exudate.
Higgins and Lees [67,68] describe two experimental models of non-immune 
inflammation in the ponies using carrageenan as the inflammatory agent that were 
adapted from rodent models. In one model, sterile carrageenan-impregnated polyester 
sponge strips were implanted into subcutaneous neck pouches in ponies. The second 
model involved the insertion of polypropylene tissue cages subcutaneously into the 
necks of ponies. Carrageenan was injected intracaveally into the cages. Sponges and 
exudate from the tissue cages were removed in a serial fashion and assayed for 
eicosanoids, protein and cellularity. PGEj, TXBj and 6-keto-PGFla were detected in 
inflamed fluid obtained from both models [69-71]. LTB4 was also detected in the 
inflammatory exudates of both models [69,72,73]. Mean total leukocyte counts and 
total protein were increased in both models after carrageenan stimulus. PGEj and
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LTB4 have been identified and quantified by radioimmunoassay (RIA) in carrageenan- 
induced inflammatory exudates from several species as seen in Tables 1 and 2.
b. Synovitis
i. Joint anatomy
Diarthrodial joints consist of articulating surfaces of bone covered by hyaline 
cartilage, a synovial membrane, synovial fluid within the joint cavity, a joint capsule, 
and surrounding ligamentous structures. The equine synovial membrane is more 
villous than other animals and the villi may project considerably into the joint space 
[74]. The synovial membrane is a modified mesenchymal tissue consisting of two 
layers [75]. The intima is made up of an incomplete cell layer that overlies the 
subintimal connective tissue layer. These layers constitute a selective barrier in the 
joint that allows for the passage of molecules of less than approximately 12,000 
daltons in molecular weight [76]. The synoviocytes of the intimal layer are usually 
1 to 4 cells thick and are not connected by desmosomes or supported by a basement 
membrane [77]. The synovial lining cell layer is often incomplete in the horse [74] 
and human [77]. Synoviocytes are pleomorphic, but have been classified into two 
types in many species, including the horse [78,79]. Type A synoviocytes resemble 
macrophages structurally and functionally and may be part of the mononuclear 
macrophage system [80]. Type B cells appear to be more like fibroblasts in that they 
contain large amounts of endoplasmic reticulum [79] and may secrete hyaluronic acid 
into the joint fluid [77]. These cell types most likely represent distinct cell 
populations rather than different functional states of the same cell line as the type A
Table 1: Mean peak PGE2 concentrations from carrageenan-induced inflammation models.
METHOD/
SPECIES










12 hrs. 197.0 RIA [70]
Tissue
cage/horse
8 hrs. 84.8 RIA [69]
Tissue
cage/horse
12 hrs. 66.4 RIA [71]
Sponge/horse 4 hrs. 12.2 RIA [73]
Sponge/horse 12 hrs. 12.8 RIA [70]
Sponge/rat 8 hrs. 20-30 RIA [65]
Sponge/rat 24 hrs. 65.0 RIA [66]
Table 2: Mean peak LTB4 concentrations from carrageenan-induced inflammation models.
METHOD/
SPECIES








Tissue cage/horse 8 hrs. 1.74 RIA [72]
Tissue cage/horse 4 hrs. 2.50 RIA [69]
Sponge/horse 4 hrs. 9.60 RIA [73]
Sponge/rat 6 hrs. 6.90 RIA [65]
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cell, unlike the B cell, may be derived from the bone marrow [77]. Unlike epithelial 
cells, the rate of cell division in synovial lining cells from normal joints is low [77]. 
Blood vessels, lymphatics and myelinated and nonmyelinated nerve fibers are found 
in the subintimal layer. The majority of the nerve endings have been described in the 
fibrous joint capsule with some free nerve endings in the membrane [75], The nerve 
supply to the membrane appears to be primarily vasomotor in nature. However, 
nociceptive fibers have been demonstrated in the synovial membrane of humans [81]. 
Further, the equine synovial membrane has evidence of sensory innervation with 
neuropeptide transmitters located perivascularly [82].
ii. Pathophysiology 
Synovitis is characterized by inflammation of the synovium without gross 
disturbance of the articular cartilage or disruption of major supporting structures. 
Non-infectious synovitis results from physical or chemical damage to the soft tissue, 
such as by repetitive overextension, subluxation or intra-articular injection of 
chemicals [83]. Synovitis involves the classic mediators and modulators of 
inflammation: histamine, serotonin, prostaglandins, leukotrienes and lysosomal 
products along with the activation of the kinin, complement and clotting systems [84].
During synovitis, hypertrophy and hyperplasia of the synovium occur, and an 
increased number of synovial lining cells are found in the synovial fluid [79,85,86]. 
An increase in vascularity of the synovial villi occurs and inflammatory cells infiltrate 
the subintimal layer. Degenerative changes in equine synoviocytes that occur during 
synovitis include: increase in organelles including lysosomes; dilation and vesiculation
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of the rough endoplasmic reticulum; mitochondrial condensation; dilation of the 
nuclear envelope; and ultimately, loss of plasma membranes [79]. Lysosomal enzymes 
and collagenase produced by synoviocytes, chondrocytes and inflammatory cells 
perpetuate the synovitis and may degrade the cartilage matrix leading to arthritis [80]. 
Also, these lysosomal enzymes, along with hyaluronidase and oxygen-derived free 
radicals produced by neutrophils and macrophages are capable of degrading hyaluronic 
acid [80,83,84]. Interleukin-1 produced by macrophages and synoviocytes induces the 
production of PGEj, neutral proteases and collagenase by synoviocytes and 
chondrocytes [87-89]. PGE2 inhibits proteoglycan synthesis in articular cartilage [80] 
and is a potent vasodilator in the synovial microcirculation [90]. Substance P also 
stimulates the production of PGE2 and collagenase by rheumatoid synoviocytes [91]. 
This neuropeptide has been demonstrated in perivascular neural filaments from normal 
equine synovia and in synovial fluid. Elevated concentrations were found in arthritic 
middle (intercarpal) joints as compared to normal joints [92].
iii. Clinical signs
Clinical signs of acute synovial inflammation include: synovial effusion with 
distension of the joint capsule; increased skin temperature over the joint; hypertrophy 
and hyperplasia of the synovia resulting in a palpable thickening of the membrane; a 
decrease in the range of motion of the joint; and lameness in the affected limb. 
Synovial effusion develops as the result of an imbalance between production and 
removal of synovial fluid [75]. Inflammatory mediators such as bradykinin, 
prostaglandins and histamine increase synovial membrane vascular permeability [17]
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and the metabolic rate of synoviocytes [37]. As the inflammation progresses, the 
permeability of the synovial membrane increases and proteins accumulate in the joint 
resulting in an increase in fluid osmotic pressure. Local production of thromboxanes 
from platelet aggregation cause congestion of the microvascular bed leading to 
congestion and heat production [93]. As fluid accumulates within the joint, the 
synovial pressure rises leading to joint instability and a reduction in the effective blood 
supply to the articular cartilage. Hypoxic acidosis and lowered glucose concentration 
in the fluid may result in a decreased nutritional state of the cartilage [83].
A decrease in the range of motion in these joints results from the edema, 
hypertrophy and hyperplasia of the synovial membrane [83]. The effusion of synovial 
fluid often results in pain and overt lameness [94]. In humans there is a positive 
linear correlation between intra-articular pressure and joint pain [95]. The 
inflammatory mediators released by local tissue destruction in the joint activate 
nociceptors and also sensitize these receptors through lowering of activation thresholds 
[96,97]. The neuromediators such as substance P from primary afferent neurons and 
the interaction of norepinephrine with sympathetic postganglionic neurons in the 
synovium further result in hyperalgesia and potentiation of the inflammatory response 
[98]. These factors contribute to the process known as neurogenic inflammation 
which is an important component of rheumatoid arthritis and other forms of joint 
inflammation [99],
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iv. Experimental induction 
Synovitis has been experimentally induced in horses, ponies, calves, dogs and 
rats by the intra-articular injection of a variety of chemical substances. The intra- 
articular injection of monosodium urate crystals in dogs [100,101] and calves 
[102,103] has been used as a model of the synovitis that occurs during gouty arthritis. 
Autogenous hyaline cartilage has been used to produce acute synovial inflammation 
in dogs [104].
The metalloprotein orgotein, which is often administered intra-articularly as 
an anti-inflammatory agent, has been shown to produce a marked inflammatory 
response in horses characterized by an increase in leukocytes and protein within 24 
hours [86]. This inflammatory reaction lasted for up to one week. Sodium 
monoiodoacetate has been used to induce synovitis in immature horses [105]. 
Inflammatory changes were seen 12 hours after injection. No articular cartilage 
damage was seen after 14 days. Synovitis has been induced in horses [39] and ponies 
by the intra-articular injection of E. coli lipopolysaccharide into the intercarpal joint 
[106,107]. These authors suggested that this model mimics acute bacterial infection. 
The horses with endotoxin-induced synovitis had peak PGE2 and tumor necrosis factor 
levels two hours after injection. The ponies in the study by Firth et al. became lame 
within 2 hours and the synovial fluid protein, leukocyte and alkaline phosphatase 
levels increased significantly by this time post-injection [106]. Synovial fluid analyses 
showed abnormalities even at 6 days post-injection. In addition, there were marked
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changes in attitude, temperature, appetite, arterial pressure, pulse and respiration. 
These abnormalities persisted for up to 20 hours for some parameters.
In a series of experiments by Lowther and Gillard [108-110], carrageenan was 
injected into rabbit stifles. A single injection of sterile carrageenan (0.3 ml of a 1 % 
solution of carrageenan in water) produced synovitis with an increase in synovial 
tissue levels of cathepsin D and acid phosphatase, two lysosomal enzymes. When 
more than two injections were administered into the same joint, visible cartilage 
erosion was seen. The single injection produced a decrease in the rate of 
proteoglycan synthesis corresponding to a 40% loss in glycosaminoglycan content in 
the articular cartilage for 3 to 7 days after injection. The rate of synthesis of 
proteoglycan increased significantly in the following days resulting in a net 
replacement of proteoglycans lost during the early phase of inflammation. The 
authors also established by autoradiographic studies that very little carrageenan 
penetrated the cartilage matrix. They concluded that the inflammatory response in the 
synovium affects the synthetic ability of the articular cartilage. It has been postulated 
that the pathophysiology of carrageenan-induced joint inflammation includes a 
component of neurogenic inflammation as the pretreatment of carrageenan injected 
joints with capsaicin or a substance P antagonist resulted in a significant suppression 
in inflammation [111].
Carrageenan was used to induce synovitis in the intercarpal joint of the horse 
in order to evaluate the superoxide production by stimulated neutrophils and the 
inhibition of this effect by NSAIDs in vitro [52]. The authors described a dramatic
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increase in synovial fluid leukocyte numbers which peaked at 4 hours and an increase 
in synovial fluid lysosome concentration which peaked at 24 hours. They did not 
describe the severity or time course of the clinical effects of carrageenan-induced 
synovitis such as lameness, heat production and joint effusion. Further, the quality 
and quantity of the synovial fluid was not discussed.
The above described substances used to produce synovitis vary markedly in the 
severity and duration of inflammation they caused. Some of these compounds have 
the potential to produce cartilage damage (see arthritis section) and in some cases 
result in systemic alterations.
c. Arthritis
i. Pathophysiology 
Some degree of synovitis occurs in most types of equine joint disease. In the 
majority of these diseases, the synovial inflammation varies only in intensity [75]. 
Mcllwraith [112] has suggested that the inciting cause of degenerative joint disease is 
synovitis rather than direct damage to the cartilage. The relationship between the 
synovium and articular cartilage is complex and in vitro and in vivo evidence suggests 
that structural and function alteration in one tissue intimately affects the other [83].
Traumatic arthritis or osteoarthritis occurs as a result of inherent instability or 
trauma to the articular cartilage or subchondral bone [83]. Osteoarthritis is associated 
with degeneration of the articular cartilage resulting in splitting and fragmentation 
(fibrillation) with resorption and sclerosis of bone (ebumation in severe cases) and 
synovitis [75,113]. In horses, the term degenerative joint disease is used to
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distinguish chronic inflammation resulting in degenerative changes from acute joint 
inflammation [114].
One consistent feature of the articular cartilage in equine degenerative joint 
disease is the decrease in glycosaminoglycans [76]. The loss of these proteoglycan 
aggregates may be mediated by interleukin-1 and PGE^ from the synovia and 
chondrocytes which activate neutral metalloproteoglycanases [80]. The inflamed 
synovial membrane is also a source for the degradative lysosomal enzymes and 
reactive oxygen species which lead ultimately to cartilage degeneration [76].
ii. Experimental induction 
Experimental arthritis has been induced in laboratory animals by the intra- 
articular injection of the polyene antibiotic filipin [115,116], fibrin complexes [117], 
polycations [118], various bacterial agents, distilled water, papain, histamine, 
mucopolysaccharides, physiologic saline, carbolic acid, hydrochloric acid, tincture of 
iodine, xylene, turpentine, formaldehyde, and formalin [119]. Intradermal 
Mycobacterium butyricum induces a polyarthritis in rats that also serves as a model 
of chronic pain (see section on models of chronic pain) [120].
Serial intra-articular injections of carrageenan have been used to induce 
articular damage in dogs [51,121-123] and rabbits [49,108]. In contrast to the other 
species, the specific-pathogen free pig did not experience articular cartilage damage 
after three separate weekly injections of carrageenan [53]. The reason for this 
difference is not clear, although only two pigs were given repeated injections. 
Arthritis has been induced in horses by surgical means [124], injection of bacteria
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[125], amphotericin [126], serial injections of the polyene antibiotic filipin [112,127], 
repeated injections of sodium monoiodoacetate [128] and combinations of the above 
[129].
PGEj [130-134] and LTB4 [133,135-138] have been identified in synovial fluid 
from human patients with various forms of arthritis. Monocytes from patients with 
rheumatoid arthritis have been shown to produce large amounts of LTB4 [139]. 
Further, plasma PGE2 [140] and serum LTB4 [141] levels of patients with rheumatoid 
arthritis are reportedly higher than normal controls and the time course of changes of 
PGE2 in blood plasma levels reflects the disease dynamics [140]. In vitro research on 
cells from humans with rheumatoid arthritis indicates that activated synovial lining 
cells produce PGEj whereas LTB4 originates mainly from synovial fluid neutrophils 
[142], Studies in other inflammatory exudates have also shown that the primary 
arachidonic acid products of neutrophils are leukotrienes [7]. PGE2 has been 
quantitated by radioimmunoassay (RIA) in synovial fluid of normal horses (26.5 pg/ml 
+ /- 3.33) and those with various forms of clinical arthropathy (144.9 pg/ml +/- 
22.19). In the arthritic horses, PGEj concentrations were reduced after treatment with 
corticosteroids and antibiotics [143].
Eicosanoids have also been quantified in synovial fluid during experimental 
arthritis. Synovial fluid from dogs with carrageenan-induced arthritis contained PGE^ 
(peak 9.5 ng/joint) and LTB4 (peak 279.2 pg/joint) as measured by reversed phase 
high performance liquid chromatography (RP-HPLC) [51]. Additional data is 
presented in Tables 3 and 4.
Table 3: Mean peak synovial fluid PGE2 concentrations from various species.
METHOD/
SPECIES










2 days 12.5 RIA [118]
Clinical
arthritis/horse
N/A 0.144 RIA [143]
Rheumatoid
arthritis/human
N/A 0.119 RIA [134]
N/A = Data not available
Table 4: Mean peak synovial fluid LTB4 concentrations from various species.
METHOD/ TIME OF PEAK PEAK ANALYTICAL REF.





10 weeks 3.14 RP-HPLC [123]
Rheumatoid
arthritis/human
N/A 0.34 RP-HPLC [135]
Osteoarthritis/
human
N/A 0.81 Bioassay [136]
N/A = Data not available
RP-HPLC = Reversed phase high performance liquid chromatography
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C. Pain
Pain is defined by the International Association for the Study of Pain as "an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage" [144]. Pain in animals has been described as an aversive sensory and 
emotional experience which elicits protective motor actions, results in learned 
avoidance and may modify species-specific traits of behavior, including social 
behavior [145]. Pain is an important homeostatic mechanism that serves to warn the 
organism away from the inciting cause or to inform it of a existing pathology. 
Nociception, the response to the application of a noxious stimulus, involves peripheral 
receptors and the transmission of the signal along neural pathways leading to the 
perception of pain [145]. Nociceptors are a group of undifferentiated terminals 
lacking a specialized receptor apparatus [146]. Nociceptive impulses are carried by 
small myelinated afferent A-delta fibers which are associated with sharp, stabbing, 
well localized pain, and unmyelinated C-fibers which are responsible for dull, 
burning, diffusely localized pain [147]. These C-fibers conduct pain very slowly and 
are responsible for second pain. They make up 70% of all afferents [41]. The C- 
fiber group also contains efferent fibers of the sympathetic nervous system which 
release substance P and in this capacity they may mediate chronic pain and neurogenic 
inflammation [147,148].
Two general types of central neurons are involved in nociception, nociceptive 
specific neurons that respond only to painful stimuli and polymodal neurons that 
respond to noxious and non-noxious stimuli. These neurons lie in the dorsal horn of
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the spinal cord and have input from A-Delta, C-fibers and in the case of polymodal 
neurons, low threshold mechanosensitive Afl-fibers [147]. Impulses are carried from 
these neurons to central terminals in the thalamus via axons in the spinothalamic and 
spinocervicothalamic tracts [149]. The thalamus is connected to the cerebral cortex 
by both ascending and descending projections which are responsible for recognition 
and modification of nociceptive input [150].
1. Acute pain
Nocifensive reflexes from acute pain are manifested by the peripheral nervous 
system in flexion and withdrawal responses and changes in the autonomic nervous 
system such as vasospasm and inhibition of the gastrointestinal and genitourinary 
tracts. These autonomic responses usually result in an increase in ventilation and 
hypothalamic activity with an increase in cardiovascular and endocrine function [151]. 
The autonomic changes in response to painful stimuli also include increased plasma 
concentrations of epinephrine and norepinephrine [152]. Cortical responses are more 
complex and result in avoidance behavior.
In animals and man the threshold at which peripheral nociceptors start to 
discharge does not always coincide with the pain reaction threshold. The pain 
reaction threshold is usually higher than the nociceptive threshold of the peripheral 
neuron as central control centers affect the pain reaction threshold. Care must be 
taken to distinguish between pain reaction and simple spinal reflexes. In animals with 
complete spinal transection, pain reaction is absent but the animal may have 
exaggerated spinal reflexes. Pain reaction in animals may also be manifested by
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turning the head towards the stimulus, respiratory changes, pupillary dilation, 
aggression towards the stimulus and vocalization [145]. The assessment of pain in 
animals is difficult without knowledge of the previous condition and behavior of the 
animal. Animals may also manifest acute pain by alterations in normal behavior 
including: restlessness, guarding, vocalization, self-mutilation, reluctance to move or 
recumbency, abnormal posture, altered feeding or sleep cycles and aggression or 
agitation [153].
2. Chronic pain
Chronic pain in humans is the most frequent cause of suffering and disability 
that seriously impairs the quality of life [154,155]. Chronic pain is defined as that 
which persists a month beyond the usual course of an acute disease or reasonable time 
for an injury to heal, or pain that recurs at intervals for months or years [155]. 
Chronic pain is predominantly due to prolonged excitation of nociceptors such as 
occurs in arthritis, peripheral vascular disease and chronic musculoskeletal disorders 
[155]. This peripheral mechanism of chronic pain is associated with the release of 
various algogenic substances in the tissue such as bradykinin, serotonin, histamine, 
substance P and the prostaglandins. Central mechanisms are involved in chronic pain 
syndromes associated with neuropathy [154]. In contrast to acute pain, the autonomic 
responses usually decrease progressively during the course of chronic pain and may 
disappear [151].
Behavioral changes in animals associated with chronic pain include: reluctance 
to move or recumbency, anorexia, grooming abnormalities, depressed attitude,
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constant licking, rubbing or scratching of an area and altered feeding or sleep cycles 
[153].
3. Mediators
Numerous algogenic substances are responsible for the various expressions of 
pain seen in acute and chronic conditions such as: allodynia-pain resulting from a non- 
noxious stimulus to normal skin; hyperalgesia-excessive sensitivity of polymodal 
nociceptors; and hyperpathia-abnormally exaggerated subjective response to painful 
stimuli [155]. Hydrogen ions, serotonin, histamine, bradykinin and prostaglandins 
have excitatory effects on nociceptors as application of these substances to skin blisters 
in humans results in pain. These compounds have dramatic effects on 
microcirculation as discussed in the inflammation section. These effects may further 
add to the excitability of nociceptors [147].
Prostaglandins and leukotrienes are considered mediators of hyperalgesia rather 
than pain. When administered alone they do not produce substantial pain except when 
administered in high doses [156]. Prostaglandins facilitate pain evoked by physical 
stimuli [157] and potentiate pain induced by histamine and bradykinin [147,156]. 
PGEj does not directly alter the resting discharge of nociceptive afferents, but it 
produces a dose-dependent increase in the firing rate after stimulation [157]. PGE^ 
and PGI2 have been used to produce hyperalgesia to mechanical stimulation in the rat 
hind paw. In this model, PGI2 produces immediate hyperalgesia while PGEj produces 
more potent effects lasting for more than 6 hours [158]. PGE^ when injected intra- 
articularly in dogs produces incapacitation of the injected joint for more than four
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hours [158]. The hyperalgesic effect of prostaglandins in the inflamed rat paw can 
be completely blocked by the administration of indomethacin [98]. Prostaglandins are 
involved in the hyperalgesia that is produced by the local injection of bradykinin and 
in norepinephrine-potentiated hyperalgesia [98,159]. It is known that prostaglandins 
of the E series are released upon sympathetic nerve stimulation where they may 
represent a trans-synaptic feedback process [160,161]. Prostaglandins are also 
released from cholinergic synapses after stimulation of the phrenic nerve [162],
In addition to these peripheral algogenic effects, evidence exists for a central 
role in the facilitation of the pain message by prostaglandins. Prostaglandins are 
thought to be released centrally in response to nociceptive input. High intensity 
stimulation of peripheral nerves in the cat [163] and frog [164] result in the release 
of prostaglandins in the spinal cord. Intrathecal injections of PGEj produce 
hyperalgesia and block endogenous opioid-mediated analgesia. These effects are dose- 
dependent and are reduced by the intrathecal administration of NSAIDs [165]. These 
researchers concluded that prostaglandins inhibit the bulbospinal noradrenergic 
component of the endogenous pain control pathway by inhibiting the spinal release of 
norepinephrine. It is clear from the literature that although prostaglandins are not 
essential for nociception, when released peripherally they facilitate transmission of 
nociceptive impulses and within the central nervous system they inhibit tonic 
modulatory systems [163].
LTB4 produces hyperalgesia in the rat paw that is independent of 
cyclooxygenase and bradykinin activity [166]. LTB4 was approximately three times
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more potent on a molar basis than bradykinin in this model. This effect was shown 
to be dependent on neutrophils as the depletion of these cells prevented the 
hyperalgesic action of LTB4 [166] Similar concentrations of PGE2 produced 
hyperalgesia, but this effect was independent of neutrophils [166] and was not 
synergistic with LTB4 [32]. Further studies have shown that neutrophils in response 
to chemotactic factors such as LTB4, Af-formyl-methionyl-leucyl-phenylalanine 
(fMLP), or C5a produce hyperalgesia by generating hyperalgesic 15-lipoxygenase 
products [167,168].
The nonapeptide bradykinin is one of the most potent pain-producing 
substances. Bradykinin produces pain in man when applied intradermally, 
intraarterially or intraperitoneally. However, intramuscular administration of 
bradykinin did not produce pain in man whereas hypertonic saline and histamine did 
[169]. Other researchers have reported that bradykinin excites small afferent fibers 
of cutaneous and muscular origin. [170]. The hyperalgesia induced by bradykinin is 
dependent on norepinephrine as the effect is not seen after the intradermal injection 
of bradykinin in sympathectomized rats [98], Bradykinin also facilitates the release 
of the prostaglandins through phospholipase A2[159]. Administration of NSADDs 
attenuates the hyperalgesic effect of bradykinin in the rat paw [166].
Substance P from sensory nerve fibers participates in neurogenic inflammation. 
Orthodromic or antidromic excitation of substance P containing neurons results in 
release of the mediator. This results in an increase in capillary permeability,
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vasodilation and edema [36,147]. However, this peptide when administered locally 
is not directly algogenic and does not excite nociceptors [157].
Norepinephrine is thought to mediate pain in damaged tissue (hyperalgesia) but 
not in normal tissue. In rats made hyperalgesic by the application of irritants to the 
hindpaw, the injection of norepinephrine significantly reduced the nociceptive 
threshold, presumably through prostaglandin release [98].
4. Models of acute pain
There are several methods described in the literature for the production of 
stimuli and quantification of responses in various models of pain. These 
methodological differences make it difficult to compare nociceptive thresholds from 
differing pain modalities [150]. It is known that the potency of analgesics differ 
depending on the model and type of stimuli employed [171]. Furthermore, different 
analgesic systems may be activated by noxious stimulation of different body regions 
[172]. Therefore, caution should be used when attempting to compare data from 
different pain models and regions of the body.
The ideal nociception model should distinguish between responses to noxious 
and non-noxious stimuli. The nociceptive stimulus should be quantifiable, repeatable 
and precise in order to minimize variability. Nociceptive responses associated with 
the stimulus should be reduced dose dependently by analgesics. Further, there should 
be no lasting tissue damage [144,173]. As repeated presentation of the painful 
stimulus often results in response modification such as conditioning, the stimulus 
should be applied in a limited fashion [144], Since animals are not able to verbally
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express pain, measurable nociceptive responses often include autonomic changes in 
blood pressure, heart rate, respiratory rate, etc. and somatomotor responses such as 
the tail flick, writhing, vocalization and limb withdrawal.
Acute pain models can be classified according to the type of stimulus into 
chemical, electrical, mechanical and thermal methods. Various chemicals have been 
used to excite peripheral nociceptors. Formalin when injected into the footpad of a 
rat and cat causes measurable pain responses such as paw licking lasting for 
approximately one hour [155,173]. Chemicals such as acetic acid, acetylcholine, 
alloxan, bradykinin, hydrochloric acid, hypertonic saline, lipoxidase, MgS04, 
oxytocin, phenylquinone, serotonin, epinephrine, tryptamine and ATP have been 
injected into the peritoneal cavity of mice and rats to produce a writhing response. 
Analgesic efficacies are determined by measuring the latency to the fust writhe and 
the frequency of writhing [144,174]. ATP and acetylcholine are considered inducers 
of inflammatory-type pain whereas MgS04 produces a non-inflammatory pain [175]. 
Lactic acid has been injected into the paravertebral muscles of horses as a model of 
acute myositis. Pain responses such as flinching and kicking were graded after digital 
pressure on the injected area [176].
Electrical stimulation of the rat tail produces three types of pain responses 
according to the intensity of the stimulus. Low intensity stimulation produces a tail 
withdrawal. Moderate stimulation produces a brief vocalization and higher voltages 
produce vocalization after termination of stimulus [144,174]. Electrical stimulation 
of the tooth pulp has been used in rats [144] and horses [177]. The tooth pulp is
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thought to be innervated exclusively by A delta and C-fibers which are nociceptive 
fibers. However, non-nocifensive AB-fibers are also stimulated in this model [178]. 
The animal responds by lifting the head or by the jaw-opening reflex.
Selective stimulation of the mechanoceptors is accomplished by applying high 
pressure. These techniques stimulate low pressure mechanoceptors in addition to the 
high pressure receptors. Some techniques use hair or nylon strings of different 
diameters and lengths (Von Frey’s hairs) as stimuli [144]. Artery clips have been 
applied to the tails, ears, paws, and toes of rodents and the resulting biting behavior 
quantitated. Similarly, the compression of the tail or toe of the animal results in 
flexor reflexes or vocalization. These methods lack precision in the amount of 
mechanical pressure applied [174]. A more precise model of mechanical pain has 
been produced in sheep using a device that presses a blunt pin at a set pressure against 
the dorsum of the radius [179]. A similar model has been developed for the horse 
[180]. The rat paw yeast test of Randall and Selitto is used to induce hyperalgesia and 
test NSAIDs [181]. The drug is administered one hour after yeast challenge and 
pressure is applied to the inflamed paw until the animal struggles or vocalizes [174],
The classic thermal model is the tail-flick method in rats and mice. This 
model is used as a standard screening procedure for analgesics and is highly correlated 
with their effectiveness in relieving pain in humans. A radiant heat stimulus is applied 
to the blackened area of the tail and the latency to tail flick is measured [173]. A 
similar test involves placing the rodent’s tail in water kept at 45 to 65' C [144]. 
Another model of thermal pain in the rodent involves placing the animal in a closed
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container with heat applied to the floor. The responses noted include agitation, rapid 
withdrawal of the paw, licking of the paws and jumping [144]. Thermal thresholds 
have been measured in sheep using a heated device applied to the pinna. The sheep 
responds by flicking the ear or shaking the head [179]. In the horse, thermal 
stimulation of the withers and lateral fetlock has been used to evaluate pain thresholds. 
The horse responds by twitching the skin over the withers or by lifting the forefoot 
after stimulation of each region [182,183]. Thermal devices have been implanted over 
the radial periosteum of ponies in an attempt to model deep pain. The response to 
this stimulus was noted as slow and unreliable [184-186].
Reflex behaviors such as the tail-flick, toe pinch and the jaw-opening reflex 
are not measures of pain reaction, but are nociceptive reflexes. Some of these simple 
reflexes are considered spinal reflexes as they may be elicited in animals with spinal 
transection [173].
5. Models of chronic pain
Chronic pain in humans and animals is frequently encountered in a clinical 
setting and is often extremely difficult to alleviate. Most of the experiments in pain 
research utilize acute rather than chronic paradigms. However, chronic pain in not 
simply a prolongation of acute pain. There are distinct central changes associated 
with chronic pain [41]. Therefore, knowledge gained from these acute pain models 
is often not applicable to the alleviation of the chronic pain state. A few chronic pain 
models have been developed in animals. The paucity of models of chronic pain in 
animals is in part due to the important ethical considerations in using animals that may
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suffer needlessly. Some of models of chronic pain have been described previously 
under models of acute inflammation. Most models of arthritis produce lasting tissue 
damage resulting in a perpetuation of inflammation into the chronic state. They may 
then be used for the study of chronic pain [173]. In addition several models of 
neuropathic pain have been developed by severing peripheral nerves [187].
a. Adjuvant models
Freund’s adjuvant models of cutaneous inflammation and polyarthritis involve 
the inoculation of a paraffin oil suspension of heat-killed Mycobacterium butyricum 
into the footpad or dermal tissue at the base of the tail of rats. The cutaneous model 
results in inflammation within 4 hours and peaks within 1 to 2 days. The affected 
limb is hyperalgesic and edematous for 1 week to 10 days [173]. In the adjuvant- 
induced arthritis model, animals experience a temporary polyarthritis with an 
increased severity in the hindlimbs. Inflammation of the base of the tail, periorbital 
region, snout, ears and penis occur as well. Behaviorally, the animals exhibit an 
increased stress reaction, show frequent scratching activity and are more aggressive. 
Weight loss and a decrease in spontaneous locomotion are also evident. This 
condition is fully developed 22 to 28 days post-induction and is usually associated with 
a slow recovery to normal by the 55th day. Pain is inferred from the increased 
scratching behavior in these animals as it is alleviated by morphine and other 
analgesics [120]. Other authors have used this model to evaluate nociception by 
applying pressure to the inflamed hind paw and determining the vocalization threshold
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[188] and to demonstrate self-administration of NSAIDs and narcotic analgesics 
[189,190].
Several investigators have demonstrated that joints from adjuvant-induced rats 
are hyperalgesic in that there is a lower threshold to mechanical stimuli and the areas 
known to be involved in nociception from the peripheral receptor to the cortex are 
markedly altered. A-delta and C-nociceptor afferents, which are normally sensitive 
only to noxious stimuli, were stimulated by non-noxious mechanical means in this 
model of rat arthritis [191]. The mechanosensitivity of the myelinated and 
unmyelinated units of the medial articular nerve of the knee was also increased in this 
model [192]. Similar results were found in sheep with chronic pain from foot rot. 
These sheep had lowered mechanical thresholds in the affected limb. It is likely that 
these effects are brought about by peripheral changes as the local injection of lidocaine 
returned the thresholds to control values [179].
Central neuronal changes have been demonstrated in animals with chronic pain. 
In decerebrate rats with adjuvant-induced arthritis there was an increased activity of 
dorsal horn cells and a high degree of responsivity to light mechanical stimuli. The 
superficial dorsal horn cells driven from inflamed areas converted from responding 
only to noxious stimulation to responding to mild mechanical stimuli [193]. Dorsal 
horn neurons in decerebrate rats showed an increase in cutaneous receptive field after 
repeated excitation of C-fiber afferents. These neurons also began responding to low 
threshold stimuli such as brush and touch [194], Recordings from the ventrobasal 
complex of the thalamus in arthritic rats indicate that there is an increased proportion
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of the neurons responding to the light pressure or flexion and extension of the diseased 
joints as compared to normal animals [195]. These responses were reduced by 50% 
after the injection of the NSAID, diclofenac, indicating possible prostaglandin 
involvement [196]. The analgesic effect of diclofenac was more potent in arthritic rats 
as compared to normal animals.
The somatosensory cortex also is altered during states of chronic pain. Central 
somatosensory neurons of animals with chronic inflammatory pain show a marked 
increased sensitivity to moderate mechanical stimulation of inflamed tissues and 
surrounding areas as compared to normal animals [197].
b. Laminitis
Laminitis is one of the major causes of chronic hoof pain in the horse [198]. 
Horses afflicted with the acute form of this disease experience extreme pain and are 
often euthanized. The chronic form is associated with debilitation, decreased fertility, 
lameness and pain which may last for the life of the animal. Equine laminitis has 
multiple etiologies and the pathophysiology is complex and incompletely understood 
[199]. This disease is not simply defined as inflammation of the laminae of the foot 
as was once described, but is peripheral vascular disease with ischemic necrosis of the 
laminae associated with hoof pain [200]. The pathology within the foot is a 
manifestation of a systemic metabolic disorder that affects the cardiovascular, 
endocrine and renal systems.
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/. Hoof anatomy
The distal phalanx or coffin bone is covered by intermeshing dermal and 
epidermal laminae which support the bone within the hoof capsule. The insensitive 
laminae are composed of the epidermis except for the stratum germinativum which 
with the dermis makes up the sensitive laminae [200]. The circulation of the hoof is 
complex and unique owing to its role in thermoregulation and nutrition to the 
proliferating epidermis. The laminar microvasculature arises from distal branches of 
the digital arteries so that laminar blood flow is in a distal to proximal direction with 
the dorsal laminae being the last to receive blood [201]. Numerous arteriovenous 
anastomosis are found within the foot which open to decrease vascular resistance and 
increase the blood flow to the limbs in order to cool the body [202]. The veins of 
the hoof and lower limbs are thick muscular structures and there are no venous valves 
in the foot [203].
Sensory receptors in the equine foot include lamellated corpuscles in the dermis 
of the heel similar to Pacinian corpuscles and free nerve endings containing calcitonin 
gene related peptide-like immunoreactivity in the solar dermis and epidermis [204]. 
The myelinated corpuscles in the heel are likely to be involved in relaying 
proprioceptive information during locomotion. In contrast, the free nerve endings 




Numerous etiologies have been identified that produce laminitis: ingestion of 
toxic quantities of wheat, com and barley grains resulting in carbohydrate overload; 
ingestion of large quantities of water; ingestion of high quality, rapidly growing, 
succulent grasses or legumes by obese animals; excessive weight bearing or 
application of severe concussive forces to the foot; severe bacterial infection or viral 
respiratory disease; exposure to black walnut shavings; ingestion of beet tops [200]; 
and high doses of corticosteroids [205,206]. Experimental laminitis has been 
produced by the administration by aqueous extract of black walnut (JugIans nigra) 
[207,208] and more commonly by the oral administration of large amounts of 
carbohydrates [209].
iii. Pathophysiology
It has been hypothesized that a laminar ischemia develops acutely due to 
decreased capillary perfusion from opening of arteriovenous shunts. This results in 
a lowering of vascular resistance and an increase in total hoof blood flow as may be 
noted clinically by an increase in hoof temperature and a bounding digital pulse that 
persists through the chronic phase of the disease. Several groups have measured an 
increase in total digital blood flow [210] and have demonstrated regions of 
hypoperfusion within the dorsal laminae [208,211,212], Other workers have not 
supported the hypothesis that lamellar ischemia is the primary cause of acute laminitis 
[213], while others have noted a decrease in total digital blood flow [208]. These 
discrepancies are due primarily to the techniques used to determine blood flow and
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these results should be interpreted with caution [214]. Allen et al., concluded that 
profound increases in postcapillary resistance, and capillary pressures predispose the 
foot to interstitial fluid volume accumulation and increased tissue pressure in the 
prodromal stages of laminitis [215]. The increased tissue pressure in this noncompliant 
compartment results in hoof pain [214] which accounts for the increased plasma 
catecholamine concentration seen in horses developing laminitis [199,216]. These 
catecholamines further exacerbate ischemia through vasoconstriction of digital vessels 
[217]. Systemic hypertension occurs in the developing phase, but it is secondary to 
hoof pain and is also mediated through the sympathetic nervous system [199]. This 
hypertension is thought to be a positive feedback mechanism from the digital 
vasoconstriction and is often present in the chronic forms of the disease [218].
Evidence for disseminated intravascular coagulopathy exists in horses 
developing laminitis as platelet numbers drop before the development of lameness 
along with the development of other coagulation abnormalities [199]. Other workers 
have not detected significant changes in platelet number or function in horses with 
experimental laminitis [219].
Bacterial endotoxin has been incriminated as a mediator or inciting cause in 
laminitis as many horses with endotoxemia develop laminitis [220] and horses with 
carbohydrate overload laminitis have a increase in plasma endotoxin that is associated 
with lameness [221]. Endotoxemia is associated with increase plasma levels of LTB4 
[222], PGEj, TXBj and PGF2„ and the administration of NSAIDs prevents many of 
the effects of experimentally induced endotoxin [223]. The association between
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endotoxin-induced eicosanoid production and the development of laminitis is theorized 
but has yet to be proven due to the inability to produce laminitis with experimentally- 
induced endotoxemia. Further the role of eicosanoids in equine laminitis has not been 
evaluated [220].
Early histological changes in the foot include endothelial cell swelling and 
edema, laminar distortion, epithelial hyperplasia, microvascular thrombosis, 
congestion and hemorrhage [220,224-226]. There is no evidence of inflammatory cell 
influx, but edema and vacuolation of the dermal tissue with necrosis and atrophy of 
the epidermal laminae occurs [220,224]. In severe cases of laminitis, degeneration 
of the laminar interdigitation occurs causing the distal phalanx to separate from this 
supporting structure and rotate within the hoof capsule [201]. Ventral deviation or 
distal displacement of the distal phalanx is due to the biomechanical forces exerted on 
the foot including the downward load of the weight of the horse exerted on the bony 
column and the proximal pull of the deep digital flexor from its insertion on the 
ventral surface of the distal phalanx [220]. The tearing force exerted against the toe 
during midstride also acts to separate the distal phalanx from the hoof wall [227]. 
The rotation forces on the distal phalanx may cause penetration of the bone through 
the sole just dorsal to the apex of the frog. The degree of rotation as determined 
radiographically can be used as a prognostic indicator [228]. In extremely acute 
cases, the laminae surrounding the distal phalanx die resulting in a total separation 
from the bone [229]. In these obviously terminal cases no rotation occurs as the bony 
column sinks in the hoof capsule.
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Chronic laminitis is classified by greater than 48 hours of continual pain from 
a laminitic episode or when rotation of the distal phalanx occurs [200]. Angiographic 
studies in horses with chronic laminitis have shown irregular digital vascular patterns 
with areas of avascularity in the cerium [230]. Hyperplasia of the dermal and 
keratinizing epidermal laminae [224] occurs dorsally in the hoof wall which creates 
a wedge of tissue that forces the epidermal and dermal laminae apart. This is 
evidenced on the sole as ’seedy toe’ or an abnormally large white line. This wedge 
is thought to perpetuate the rotation of the distal phalanx [200]. Diverging hoof 
growth rings that are wider at the heels are often present giving the hoof a concave 
dorsal surface. Due to the ischemic necrosis within the laminae and large white line, 
these horses have an increased tendency for abscessation and cracks which may also 
cause hoof pain and lameness [231]. The gait of these horses is characteristic as the 
foot strikes the ground in a heel-toe fashion. The solar surface of the foot is 
particularly sensitive to the pressure of the hoof tester over the sole, midway between 
the apex of the frog and the toe [231]. Horses with severe chronic laminitis often 
have difficulty remaining in the standing position for any substantial length of time 
due to the pain associated with weight bearing. If pain is severe, prolonged periods 
of recumbency may occur which lead to the formation of decubital ulcers, reduced 
body condition and impaired ventilation. Furthermore, since weight bearing by the 
foot is essential for normal circulation, prolonged recumbency may lead to thrombus 
formation within the digital vascular system further exacerbating laminitis [231,232].
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Analgesics temporarily reduce the pain and suffering associated with laminitis 
and allow the animal to more comfortably stand and ambulate, thereby promoting 
blood flow to the foot and reducing the adverse effects of long term recumbency. In 
addition, some analgesics lower plasma catecholamine concentrations that are 
associated with nociception and stress [152]. When released, these endogenous 
amines are thought to produce vasoconstriction of the digital vasculature, resulting in 
ischemia which further exacerbates laminitis [200]. According to Hood, horses that 
are treated early with systemic analgesics have a lower incidence of rotation than those 
treated late in the course of the disease [199]. Phenylbutazone (4.4 mg/kg) is 
regarded as the single most important therapeutic agent in treating laminitis [231,233]. 
NSAIDs are thought to be particularly useful in treating the coagulopathy because of 
their inhibitory effects on eicosanoid formation and platelet function [199,234], PGF^ 
and thromboxane are known to be potent constrictors of digital arteries and veins with 
the veins being more responsive than the arteries [217], Although it is known as a 
vasodilator, PGEj was less potent in producing digital artery dilation as compared to 
acetylcholine, acepromazine, isoxsuprine and prostacyclin [235]. During experimental 
laminitis, the administration of phenylbutazone returned hypertensive horses to 
normotension. These authors found that most horses (85%) recovered from the 
laminitic episode without rotation following the administration of phenylbutazone 
while housed in soft sand stalls [199].
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D. Nonsteroidal anti-inflammatory agents
1. Mechanism of action
a. Cyclooxygenase inhibition 
The medicinal effect of the bark of the willow tree has been known for 
centuries. The active ingredient in the bark is salicin, a bitter glycoside. It was first 
used for the treatment of rheumatic fever and gout which led to the development of 
the first NSAID, aspirin or acetylsalicylic acid, that was then commercially prepared 
and marketed by Bayer. The NSAIDs are a chemically diverse group of compounds, 
although most are weak organic acids (pKa 3.0 to 5.5 for carboxylic or enolic acids, 
pKa 9-10 for phenolic acids) [236]. These drugs share common features in that most 
are antipyretic, anti-inflammatory and analgesic.
In 1971 Vane [237] demonstrated that aspirin and indomethacin inhibited 
prostaglandin formation in guinea pig lung in a dose dependent manner. In that same 
year, Smith and Willis [238] demonstrated that the administration of two tablets of 
aspirin to human volunteers resulted in deficient prostaglandin production in platelets 
one hour later. These experiments supported the increasing evidence that 
prostaglandins participated in the pathogenesis of fever and inflammation. Further 
work showed there to be an overall positive correlation between the concentrations of 
NSAIDs that block prostaglandin synthesis in vitro and doses in which they exert 
analgesic, anti-inflammatory, and antipyretic activities in animals [239,240]. Inhibition 
of platelet function and prolongation of bleeding times with some NSAIDs have also 
been shown to be a result of cyclooxygenase inhibition [238].
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Aspirin acetylates and irreversibly inactivates the cyclooxygenase in platelets 
[241] and in human synovial microsomes [242] through covalent bonding. Other 
NSAIDs such as indomethacin, meclofenamic acid and flurbiprofen inhibit 
cyclooxygenase reversibly at first and then essentially irreversibly by non-covalent 
binding in a stereospecific and time-dependent manner to subunits of the prostaglandin 
endoperoxide synthase enzyme [243]. This time-dependent effect appears to depend 
on the presence of a halogen and a carboxyl group [244]. Other drugs such as 
ibuprofen and mefenamic acid are not able to inactivate the enzyme and are 
considered reversible inhibitors [244] Some of these drugs such as phenylbutazone 
inhibit the enzyme more efficiently when the concentration of lipid hydroperoxides is 
reduced [245].
There is good correlation between the rank order of potencies in reducing 
edema and prostaglandin concentrations in vivo, although the doses required to prevent 
edema are usually much higher (Table 5) [64], Inhibition of lysosomal release by 
NSAIDs has been documented for several compounds but the rank order of potency 
of these drugs does not correlate with their anti-inflammatory activity [8].
b. Leukocyte migration
NSAIDs have been shown to inhibit leukocyte migration in carrageenan- 
induced inflammation in the rat [50,246]. However, the doses producing this effect 
are generally much higher than those which prevent erythema and hyperalgesia [8]. 
However, therapeutic doses of indomethacin, piroxicam and ibuprofen reduce the 
function of neutrophils in human subjects [247]. Further, doses approximating the
Table 5: Rank order of potency of NSAIDs in inhibiting carrageenan-induced edema and 
prostaglandin synthesis (as determined by bioassay) in vivo in the rat. Adapted from Higgs et al., 
1976 and 1983 [8,64].












therapeutic ranges of flunixin and phenylbutazone decreased the LTB4-induced 
chemotaxis of canine neutrophils ex vivo [248]. The inhibitory effects of NSAIDs on 
neutrophils are not thought to be mediated by cyclooxygenase inhibition but by 
uncoupling protein interactions within the plasmalemma [247]. In contrast, low doses 
of phenylbutazone (0.05 mg/kg), indomethacin [50], aspirin and flurbiprofen [15] 
stimulate leukocyte counts in the rat carrageenan model. This modulation of leukocyte 
migration was not correlated with cyclooxygenase inhibition. There may be some 
potentiation of lipoxygenase at low doses of some NSAIDs which could account for 
the increased number of leukocytes. Or perhaps NSAIDS modify leukocyte migration 
by another mechanism. NSAIDs have been shown to inhibit several enzyme systems 
independently of cyclooxygenase such as: superoxide anion generation by a NADPH 
oxidase system in neutrophils; mononuclear cell phospholipase C activity; and the 
conversion of 12-HETE from 12-HPETE in platelets [247]. Further, many of these 
drugs uncouple oxidative phosphorylation; alter the uptake and membrane 
incorporation of arachidonate; and inhibit anion transport in the human erythrocyte, 
rabbit choroid plexus and renal tubular epithelium [247].
c. Lipoxygenase inhibition 
At therapeutic doses most NSAIDs do not inhibit the formation of leukotrienes. 
However, the pyrazolone derivative phenidone [249], the propionic acid derivative 
benoxaprofen [250], hydroxamic acids [251] and the phenylpyrazoline analogues of 
phenidone, BW755C and BW540C [252] have been shown to be both cyclooxygenase
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and lipoxygenase inhibitors. These analogues are effective in reducing inflammation 
in the horse but are not available clinically [253].
It has been shown that several NSAIDs may actually potentiate in vitro 
lipoxygenase product formation through shunting of the arachidonic acid substrate into 
the leukotriene pathway following cyclooxygenase inhibition [250,254], 
Cyclooxygenase blockade during acute anaphylaxis in guinea pigs augments the 
production of the slow-reacting substances of anaphylaxis and LTB4 [255]. In 
contrast, some prostaglandins inhibit the formation of lipoxygenase products from 
activated neutrophils [21].
d. Distribution into inflamed tissues 
NSAIDs bind extensively to albumin (90 to 99%) and may achieve high 
concentrations in an inflammatory site due to the increase in vascular permeability and 
exudation of plasma proteins including albumin. The clinical anti-inflammatory effect 
of NSAIDs in human arthritics correlates directly with the degree of plasma protein 
binding [256]. NSAIDs bound to albumin are thought to be released by the 
degradation of albumin by lysosomal enzymes at the site of inflammation [257]. This 
one way flow of albumin serves to increase the tissue concentration of the drug [258]. 
Also the lowered pH of the inflamed environment serves to keep these planar, anionic 
molecules unionized and thus increasing membrane permeability [247]. Ion trapping 
is postulated to occur intracellularly as the environment inside the cell is relatively 
alkaline compared to the acidic inflamed tissue [259-261]. The effect may also occur 
in gastric and renal tubular epithelium cells which border acidic extracellular fluids
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[258,262]. The optimal pK8 for this effect is reported to be between 4 and 5 [263]. 
In autoradiographic studies in rats, acidic NSAIDs were found to reach high 
concentration in the stomach wall, liver, blood and bone marrow, kidney cortex and 
in inflamed tissue. The non-acidic NSAIDs were equally distributed throughout the 
body [264]. Further, acidic salicylates reached levels in inflamed chicken joints that 
were three times higher than in control joints. The inflamed joint levels approximated 
the corresponding plasma levels at 2 hours post-dose [265].
e. Pain relieving effects 
NSAIDs do not produce analgesia in normal tissues and in most cases they do 
not elevate simple pain thresholds in experimental models in which thermal, electrical 
or mechanical stimuli are applied to normal tissues. However, these drugs are 
particularly effective in situations where an inflammatory response is present and the 
area is hypersensitive to mechanical stimuli. In these situations, NSAIDs usually do 
not completely block the painful response, but only reverse the hyperalgesia [163]. 
In electrophysiologic experiments in rats made hyperalgesic by the induction of 
adjuvant arthritis, systemically administered aspirin reduced the afferent discharge 
from affected joints within 20 to 30 minutes after injection [197]. Similar results were 
obtained from the local application of aspirin and lysine acetylsalicylate [266]. These 
experiments further add to the evidence that prostaglandins are involved in the 
mediation of pain and inflammation.
Early studies in the dog spleen demonstrated that NSAIDs produce analgesia 
peripherally [267,268]. Local injection of small amounts of NSAIDs into
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inflammatory lesions confirmed this peripheral site of action [269]. However, 
prostaglandins are released from the spinal cord during noxious stimulation [270] and 
intrathecal administration of prostaglandins lower nociceptive thresholds [269,271]. 
The intrathecal administration of NSAIDs reduces nociception and the simultaneous 
intrathecal and peripheral administration of NSAIDs produce synergistic effects [269]. 
A central component of the analgesia seen with NSAIDs has been demonstrated since 
intraventricular administration of these drugs reduced the hyperalgesia caused by 
carrageenan in the rat hind paw [272] and in the adjuvant-induced arthritis rat model 
[273]. A thalamic site of action is also likely as the administration of NSAIDs are 
found to reduce the nociceptive impulses from stimulation of the sural nerve in 
arthritic rats [148]. There are three possible central sites of action that have been 
identified: the hypothalamus [274], the periaqueductal grey area and the thalamus 
[148]. The mode of action of these drugs has been attributed to prostaglandin 
inhibition in neural tissues. However, there may be other yet unknown mechanisms 
as several NSAIDs such as salicylic acid, paracetamol and phenazone possess potent 
analgesic and antipyretic properties but are less efficacious anti-inflammatory agents 
or prostaglandin inhibitors in some models [275]. In a review of the literature by 
McCormack and Brune in 1991, they were unable to find a correlation between 
antinociceptive activity and inhibition of prostaglandin synthesis for the antipyretic 
analgesics [258]. Further work with enantiomers of flurbiprofen have shown that the 
S-enantiomer, which is almost solely active in cyclooxygenase inhibition, is
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approximately equal in antinociceptive activity as the /?-enantiomer which has almost 
no cyclooxygenase inhibitory properties [276].
2. Ketoprofen
Ketoprofen [(±)-2(3-benzoylphenyl)propionic acid] was synthesized in France 
by Rhone-Poulenc chemists in 1967, three years after the prototype ibuprofen [277]. 
This drug is approved in humans for the treatment of rheumatoid arthritis, 
osteoarthritis, and mild-to-moderate pain [278]. Ketoprofen was approved for the 
alleviation of musculoskeletal pain and inflammation in the horse in 1990. Few studies 
have been published on the anti-inflammatory and analgesic effects in the horse. 
Kinetic and metabolism studies in the horse are just now being published.
a. Pharmacokinetics
The kinetics of ketoprofen in man are well established. The terminal half-life 
is 1.8 hours after an intravenous dose. The volumes of distribution in man are low, 
approximately 4 L for the volume of the central compartment and 10 L for the steady 
state volume [278]. The drug like most NSAIDs is highly bound (>  90%), 
presumably to albumin primarily [279]. In human patients with various forms of 
arthritis, the area under the curve (AUC) for total (unbound and bound ketoprofen) 
was greater in serum than synovial fluid. However, the free fraction (unbound drug) 
AUC was similar for both. Further, the mean residence time in the joint was about 
three times that in serum which helps to explain the discrepancy of a longer duration 
of therapeutic effect than serum half-life [280]. The drug is conjugated and excreted 
primarily as an inactive metabolite in the urine. Further, a small percentage of the
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drug is excreted in the urine as an hydroxylated metabolite [278], Ketoprofen has 
been shown to have extensive tissue penetration into human tonsils [281] and crosses 
the blood-brain barrier quite rapidly [282]. This is due to the high lipid solubility of 
ketoprofen which has a heptane/water partition coefficient of 3.5 at pH 7 [282].
Sams et al. have reported plasma kinetics of ketoprofen in the horse [283]. 
This group determined that the half life is short in the horse (90 minutes). Protein 
binding was extensive with 92.8% bound at 0.5 ng//xl and 91.6% at 10 /ttg/ml. Renal 
elimination of unchanged ketoprofen and a base-labile conjugate accounted for 22.4% 
of total clearance and was due to both tubular secretion and filtration. Little tubular 
resorption occurred as horses have alkaline urine which serves to keep the drug 
ionized in the urine. In the Sams study, approximately 42.8% of the dose was not 
recovered from the urine. This was possibly due to the formation of a metabolite that 
was not recovered by the extraction method. The conjugate may be a glucuronide that 
has undergone intramolecular acyl migration rendering the compound resistant to /3- 
glucuronidase hydrolysis [283]
The 2-arylpropionic acids contain a chiral center and are usually administered 
as a racemate. In man, approximately 10% of the drug was found to invert from the 
R to the S enantiomer upon oral administration [284]. In the horse, the ratio of the 
S to R enantiomer increased over time and attained a ratio of 70:30 less than one hour 
after intravenous administration [285,286]. Cyclooxygenase inhibition is 
accomplished by the S-enantiomer primarily [287,288]. Metabolic chiral inversion of 
the R- to the S-enantiomer occurs after administration through the probable mediation
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of coenzyme A [289]. However, ketoprofen exhibits little stereoselectivity in its 
pharmacokinetics as the enantiomers have similar plasma time-courses and do not 
appear to interact with one another in man [284]. Some degree of stereoselective 
binding to albumin may occur but this binding does not appear to affect the disposition 
or kinetics of total (unbound and bound) enantiomer concentration in the therapeutic 
range in man [284].
b. Anti-inflammatory effects 
Ketoprofen has been shown to be a potent reversible inhibitor of prostaglandin 
synthase in several cyclooxygenase enzyme preparations at concentrations within the 
human therapeutic range [277,278,290,291] (Table 6). Values are expressed as the 
inhibitory concentration (IC^), which is defined as the concentration of inhibitor 
necessary for 50 percent inhibition of the enzyme reaction. In addition, ketoprofen 
is a potent inhibitor of inflammation in several models (Table 7). Values are 
expressed as effective dose (EDjq) which is defined as the dosage which gives a 
pharmacological effect equal to 50% of the maximum possible effect or which gives 
the expected pharmacological effect in 50% of the animals tested. As can be seen 
from the following tables ketoprofen demonstrates lower effective doses and inhibitory 
concentrations than many of the other commonly used NSAIDs.
There is equivocal evidence in the literature concerning the effect of ketoprofen 
on the lipoxygenase pathway as can be seen in Table 8. Ketoprofen has been shown 
to increase the SRS-A release in guinea pig lung but inhibited the release from human 
lung [250,292,293]. The production of 5-HETE and 5,12-diHETE, a diasteromer of
Table 6: Inhibitory concentrations [IC50 (/iM)] of various NSAIDs on cyclooxygenase enzymes. 
METHOD KETO- PHENYL- IBU- INDO- BW755C REF.









7.65 5.26 6.26 8.77 6.53 [291]
Rat
platelet
1.45 79.30 N/A 5.90 21.6 [290]
Rat
neutrophil
0.58 15.70 N/A 4.78 11.6 [290]
Rat renal 
medulla
2.20 20.90 N/A 5.07 12.1 [290]
N/A = Data not available 
*IC5o data expressed as -log mol/1
Table 7: Effective doses [ED50 (mg/kg)] of various NSAIDs on inhibition of acute inflammation and pain.





1.89 97.55 N/A 8.17 * [63]
Carrageenan rat 
hind paw edema
9.00 N/A N/A 9.00 [44]
Carrageenan 
abscess in rat




2.50 52.00 45.00 5.70 [15]
Contraction of rat 
colon
0.002 2.00 1.50 0.016 [296]
PAIN MODELS:
U.V. erythema in 
guinea pig
7.50 N/A N/A 10.20 [44]
Rat paw pressure 2.40 37.00 14.00 3.50 [44]
Writhing response 
in mouse
2.30 N/A N/A 2.20 [44]
N/A = Data not available
Table 8: Inhibitory concentrations [ICso (/tM)] of various NSAIDs on lipoxygenase enzymes.
METHOD KETOPROFEN PHENYLBUTAZONE IBUPROFEN INDOMETHACIN BW755C REF.
Soybean 
15-LO
225.00 123 575.00 87.50 65.50 [294]
Soybean 
15-LO





N/A N/A Potentiated N/A [250]
Rat platelet 
12-LO
No effect No effect N/A 916.00 66.20 [290]
Rat PMN 
5-LO
No effect N/A N/A 332.00 55.70 [290]
N/A = Data not available
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LTB4, from rabbit neutrophils was inhibited by ketoprofen [250]. The lipoxygenase 
inhibition appeared to be dose-related in humans [292], but not in the rabbit model 
[293]. Ketoprofen and several other NSAIDs have been shown to inhibit soybean 
lipoxygenase [294] while other researchers report no effect in the enzyme system 
[290]. The concentrations required to inhibit lipoxygenase are generally higher than 
those that inhibit prostaglandin synthase activity. These studies underscore the 
variability that other researchers have noted in the drug’s effect on lipoxygenase 
activity. Such data varies depending on the source of the lipoxygenase enzyme and 
the species [293,295].
Ketoprofen reduced the PGE tissue concentration in carrageenan-induced hind 
paw inflammation in the rat [63]. Prostaglandin synthesis was also inhibited in the 
guinea pig lung preparation as determined by the perfusion of lung effluent over rat 
colon strips and measurement of the resultant contraction [296]. In human patients 
with rheumatoid arthritis, ketoprofen reduced the synovial fluid concentration of PGE, 
and PGF2(I three hours after intravenous administration of 100 mg of ketoprofen [297]. 
Ketoprofen (10 mg/kg per os) in the rat carrageenan pleurisy model decreased the 
total number of monocytes and slightly increased the number of neutrophils in the 
inflammatory exudate [298]. Ketoprofen (1, 3 or 9 mg/kg) when administered one 
hour before induction of carrageenan-induced pleurisy reduced the volume of exudate 
and leukocyte count in a dose-dependent manner. This effect was greater than that 
produced by the same doses of indomethacin [299]. Alleviation of inflammation has 
been demonstrated when ketoprofen was injected locally into carrageenan abscesses
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in the rat and intra-articularly in dogs with urate-induced arthritis [44]. Ketoprofen 
has demonstrated anti-bradykinin activity in the guinea pig that was 8 times more 
potent than indomethacin [44]. In vitro and in vivo evidence suggests that ketoprofen 
stabilizes lysosomes in the rat. Interestingly, this effect was more marked in rats with 
adjuvant induced arthritis than in normal animals [300].
c. Pain relieving effects 
Ketoprofen has demonstrated analgesic and anti-inflammatory effects in 
rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and acute gout in humans 
[301]. Clinical trials with ketoprofen in humans have shown that it is therapeutically 
equivalent to aspirin, indomethacin and ibuprofen in rheumatoid arthritis and with 
aspirin in osteoarthritis [277]. Ketoprofen when evaluated in human dental pain 
models was more effective than ibuprofen and aspirin [302]. Compared to aspirin, 
ketoprofen was superior in controlling osteoarthritis [277] and postpartum pain [303]. 
This drug provided analgesia similar to that of morphine [303] and produced a longer 
duration of action than acetaminophen plus codeine [304] in clinical cases of post­
operative pain. Ketoprofen is thought to have supraspinal analgesic properties [305]. 
Experiments with normal human volunteers and paraplegic patients that were 
stimulated by electrical impulses applied to the sural nerve have shown that 
intravenous ketoprofen has rapid inhibitory effects on spinal nociceptive reflexes in 
normal subjects while no significant effects were seen in the patients with chronic 
spinal section [306]. The injection of ketoprofen into the cerebral ventricles in rats 
with adjuvant-induced arthritis reduced the discharge of thalamic neurons after ankle
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mobilization. In addition, ketoprofen reduced the spontaneous firing rate in a dose- 
dependent manner [307]. These data provide good evidence for the direct central 
antinociceptive actions of NSAIDs.
d. Clinical studies
Ketoprofen has been evaluated in experimentally-induced endotoxemia in 
neonatal calves [308]. Ketoprofen inhibited the formation of the stable metabolites 
of TXA2 and prostacyclin, TXBa and 6-keto-PGFla, respectively, in plasma. 
However, it failed to significantly alter the degree of leukopenia and hypoglycemia 
associated with the endotoxemia in calves.
Ketoprofen was evaluated in a model of arthritis using Freund’s complete 
adjuvant injected into the carpal joint of horses. Horses became lame and experienced 
swelling, heat and joint pain 5 to 7 days after induction. Horses then received drugs 
once daily and were evaluated for 5 days for maximum joint flexion, stride length and 
lameness. Ketoprofen (2.2 mg/kg intravenously or intramuscularly) was 
therapeutically equivalent to flunixin meglumine (1.1 mg/kg) [309]. The same group 
of investigators evaluated ketoprofen in clinical cases of non-infectious 
musculoskeletal inflammation and the following were scored: lameness; pain on 
palpation or compression; pain on flexion, extension or rotation; swelling; heat; 
reaction after injection; and side effects. Cases included arthritis, laminitis, myositis, 
cellulitis, soft tissue inflammation and minor fractures. Statistical level of significance 
was set liberally at P < 0.10. There were no differences between ketoprofen and 
flunixin meglumine and there were no side effects noted [309].
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In clinical colic studies in horses, significant pain relief occurred at 15 minutes 
after intravenous ketoprofen administration (2.2 mg/kg) and continued for 60 minutes 
after drug administration [310]. This effect lasted up to four hours in some cases 
[311,312]. No difference was seen between ketoprofen (2.2 mg/kg) and flunixin 
meglumine (1.1 mg/kg) in any of the parameters measured [313]. In mares with 
experimentally-induced endotoxemia, ketoprofen (0.5 mg/kg) was equally as effective 
as flunixin meglumine (0.25 mg/kg) in suppressing the effects of the endotoxin. 
These investigators attempted to assay LTB4 in plasma during endotoxemia, but were 
not successful [314].
e. Adverse effects
The safety and toxicity of this drug in the horse has been compared to several 
of the currently used NSAIDs. Ketoprofen was administered intramuscularly in the 
neck and gluteal regions without any noted injection site reaction [315]. Therapeutic 
intravenous doses of ketoprofen (2.2 mg/kg), flunixin meglumine (1.1 mg/kg) and 
phenylbutazone (4.4 mg/kg) were administered every 8 hours for 12 days and 
compared in normal adult horses. Phenylbutazone caused: 1) a decrease in serum 
total protein and albumin concentrations; 2) edema of the small intestine; and 3) 
erosions and ulcers of the large colon. Some horses in the flunixin group and the 
phenylbutazone group developed renal crest necrosis. All NSAIDs including 
ketoprofen caused erosions of the glandular mucosa of the stomach. However, only 
flunixin and phenylbutazone treated horses developed ulcerations of the glandular 
mucosa [316]. Ketoprofen was evaluated in a subacute safety study after the
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intravenous administration of five times the therapeutic dose (11.0 mg/kg). No 
evidence of toxicity was reported in any horses after this 15 day regime. However, 
in drug tolerance studies using 25 times the therapeutic dose for 5 days, horses 
experienced depression, inappetence, icterus, nephritis, hepatitis, and hemorrhagic 
necrosis of the adrenal glands [309].
3. Phenylbutazone
Phenylbutazone is approved for the alleviation of musculoskeletal inflammation 
in the horse and dog. Phenylbutazone is a pyrazolone derivative with a pK, of 4.8 
[162]. In man, this group causes hypersensitivity reactions, diarrhea, vomiting, 
mucosal ulceration, hepatitis, nephritis, sweating, aplastic anemia and agranulocytosis 
[3]. The half-life in man is 72 hours owing to the extensive enterohepatic 
recirculation and renal tubular resorption [162], whereas in horses the reported values 
range from 4.8 [317] to 8.6 [19] hours. The reported half-life in man, like the horse 
varies considerably among subjects [162]. The half life is concentration dependent 
and for this reason it should not be used outside of the therapeutic range [318]. 
Phenylbutazone causes dose-dependent inhibition of superoxide generation at 
concentrations approximating therapeutic levels in humans [319]. This property adds 
to the anti-inflammatory potency of this drug [318]. It also enhances the excretion of 
uric acid which is beneficial in the treatment of gout in man [3]. In ponies, therapeutic 
doses decrease urinary sodium and chloride excretion with a concurrent decrease in 
plasma pH, bicarbonate and carbon dioxide [320]. Phenylbutazone reduces platelet 
function in ponies through both thromboxane/prostaglandin dependent and independent
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pathways [321]. However, unlike aspirin in man, phenylbutazone does not prolong 
bleeding times [321].
a. Anti-inflammatory effects 
Oral phenylbutazone in dogs with experimentally-induced urate arthritis 
significantly reduced the symptoms associated with the synovitis [101]. 
Phenylbutazone (4.4 mg/kg, intravenously) when administered to ponies with 
subcutaneously implanted carrageenan-soaked sponges significantly reduced the PGEj 
production in inflammatory exudates for at least 24 hours but it did not have any 
effect on leukocyte migration [322,323]. The same dose of phenylbutazone 
significantly reduced serum TXBj concentrations for 24 hours [324]. Pre-treatment 
with phenylbutazone also attenuated the endotoxin-induced rise in the stable metabolite 
of prostacyclin in equine plasma [223].
Oral administration of the therapeutic dose of phenylbutazone in ponies with 
carrageenan-induced inflammation also reduced prostaglandin concentrations and 
reduced skin temperatures below the incision line where the sponges were implanted 
[325]. The maximum depression of prostaglandin synthesis occurred at times of peak 
drug exudate concentration [325]. Also in ponies, the tissue cage fluid, peritoneal 
fluid and synovial fluid concentrations of phenylbutazone and the active metabolite, 
oxyphenbutazone were one third to two thirds of the corresponding plasma 
concentrations 6 and 12 hours after intravenous and oral doses of 4.4 mg/kg [323]. 
In another study by the same group, the level of phenylbutazone in inflammatory 
exudates from carrageenan soaked sponges in ponies approximated plasma levels from
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4 to 12 hours after intravenous administration [326], Administration of 14C-labelled 
phenylbutazone in rats with carrageenan-induced inflammation in the hind paw and 
neck resulted in high concentrations in the inflamed areas and also the stomach, small 
intestine and kidney. This effect was attributed to ion-trapping of the acidic drug 
intracellularly in environments with a low pH. Further, in chickens with urate- 
induced arthritis, the synovial fluid concentration of phenylbutazone was higher in 
inflamed joints as compared to normal joints and the concentration in these joints was 
higher than corresponding plasma values [263].
b. Pain relieving effects
Phenylbutazone failed to alter normal pain thresholds in horses as tested by the 
thermal evoked hoof withdrawal and skin twitch reflexes [183]. These results are in 
agreement with the belief that NSAIDs do not produce a true analgesia but inhibit the 
hyperalgesia associated with the sensitization of the peripheral afferent [163,271]. 
Drugs of the pyrazolone class are reported to be less potent analgesics than other 
NSAIDs in animals [318]. In clinical studies phenylbutazone was equivalent to 
naproxen in alleviating pain and joint stiffness in human patients with ankylosing 
spondylitis [327]. In a clinical study involving several species of domestic and exotic 
animals, phenylbutazone treatment resulted in an overall recovery rate from lameness 
of 68.97% [328].
c. Adverse effects
Toxic doses of phenylbutazone produce central nervous system depression, 
anorexia, diarrhea, hypoproteinemia, mucosal ulceration [329] and phlebitis [330].
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The ulcerogenic properties of this drug are more pronounced in the pony owing 
probably to less efficient absorption of oral doses in the gut [318]. Inhibition of 
prostaglandin plays an important role in the pathogenesis of ulcers as the co­
administration of PGE2 with the toxic doses of phenylbutazone resulted in no clinical 
abnormalities [329].
CHAPTER 3
QUANTIFICATION OF EICOSANOIDS IN' EQUINE PLASMA AND
SYNOVIAL FLUID
A. Introduction
The quantitation of eicosanoids in inflammatory, allergic and cardiovascular 
conditions has been performed most commonly using radioimmunoassay (RIA) 
[65,66,70,72,331-333]. Other quantitation techniques have been applied such as 
bioassay [136,334], high performance liquid chromatography (HPLC) [335-337], gas 
chromatography coupled with mass spectrometry (GC/MS) [338,339] and more 
recently, enzyme-linked immunosorbent assay (ELISA) [340-343]. The ELISA 
procedure offers advantages over RIA in that it is easier, faster, less expensive and 
produces no radioactive waste [341,344].
The detection of eicosanoids is complicated by the fact that these substances 
are very potent, having endogenous concentrations of a few pg/ml of plasma. Many 
have short biological half-lives [24]. For example, the in vivo half-life of leukotriene 
B4 (LTB4) in carrageenan exudate was reported as approximately 45 minutes [345]. 
Circulating prostaglandins are metabolized within minutes in the lung and liver [24].
Eicosanoid assays must be specific as both the prostaglandin and leukotriene 
series contain many similar compounds that are produced concurrently from 
polyunsaturated fatty acid precursors, mainly arachidonic acid. Many eicosanoids and 
their metabolites have minor structural differences in functional groups, such as
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hydroxy or keto groups and double bonds, that may make isolation by extraction and 
chromatography difficult [346]. Some eicosanoids are unstable and can undergo non- 
enzymatic degradation depending upon pH conditions or in the presence of albumin 
[24]. For example, the plasma metabolite of prostaglandin Ej (PGEj), 15-keto-13,14- 
dihydro-PGEj forms a bicyclic product by dehydration and an internal addition 
reaction [347].
Further complicating analyses are sampling methods such as venipuncture and 
tissue extraction which can activate phospholipase A2 resulting in ex vivo formation 
of eicosanoids [348]. The coagulation process routinely produces prostaglandins while 
cells such as neutrophils are capable of eicosanoid formation in whole blood. 
Therefore, it is recommended that biological samples be collected into chilled tubes 
containing inhibitors of prostaglandin and leukotriene synthesis and an anticoagulant 
with expedient removal of the cell fraction [348]. One group of investigators 
determined that collection of samples into tubes with ethylenediamine tetraacetate 
(EDTA) resulted in lower prostaglandin levels than those collected with heparin [349]. 
This same group also determined that centrifugation of samples at room temperature 
gave higher thromboxane and prostaglandin levels than samples centrifuged at 4 ' C. 
Subtle differences in these sampling techniques make comparison of eicosanoid 
concentrations obtained from different laboratories difficult.
Extraction of biological fluids before assaying eicosanoids is necessary to 
remove other lipids that may interfere with the analysis or cause erroneously 
calculated concentrations. Reports of assays without prior extraction show higher
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levels of these compounds than those found when extraction preceded the assay [350]. 
Several techniques for extraction have been published including various liquid/liquid 
techniques using organic solvents [333] and, more recently, solid phase extraction 
procedures [351-353]. Most of these methods involve acidification of the biological 
sample in order to protonate the eicosanoid and increase solubility in the organic 
solvents. In some cases purification by normal or reversed phase HPLC after 
extraction is necessary to isolate the compound(s) of interest before assaying by other 
means.
The purpose of this study was to evaluate methods of eicosanoid extraction and 
quantitation in equine plasma and synovial fluid. Specifically, two methods for 
extracting PGE2 and LTB4, and an ELISA method for quantitation of these eicosanoids 
in equine synovial fluid and plasma were examined. As the PGE2 ELISA was reported 
to have cross reactivity with PGEj, a method of validation and confirmation of this 
assay by mass spectrometry was developed.
B. Materials and methods
1. Sample collection
a. Plasma from digital veins 
Blood samples were collected from the digital veins of normal and laminitic 
horses (see also Chapter 6) using a 20 gauge, 1" needle. After 1-2 ml of blood were 
discarded, 10 ml were collected into chilled evacuated siliconized glass tubes 
(Vacutainer, Becton Dickinson, Rutherford, NJ) containing 3.3 /*g/ml of BW755C
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(Wellcome Research Laboratories, Beckenham, Kent, England) as an inhibitor of ex 
vivo eicosanoid synthesis [70] and 10 mg/ml of the anticoagulant, disodium 
ethylenediamine tetraacetate (EDTA) [348] purchased from Sigma Chemical Co., St. 
Louis, MO. Samples were centrifuged at 2,500 rpm for 15 minutes at 4° C (Beckman 
J21B, Palo Alto, CA). The platelet poor plasma was stored in polypropylene 
centrifuge tubes (Sarstedt, Newton, NC) at -20 ° C for 2 days then at -70° C until 
assayed [350].
b. Synovial fluid
Synovial fluid was collected from the left intercarpal joints of 24 horses with 
experimentally-induced synovitis (see also Chapter 4). Synovial fluid was aseptically 
withdrawn from each joint using a 20 gauge, 1" needle and 12 or 20 ml polypropylene 
syringes. The fluid was immediately transferred into tubes containing the inhibitors 
of eicosanoid synthesis. The use of BW755C in this project was discontinued due to 
limited availability. Instead, BWA4C (Wellcome Research Laboratories, Beckenham, 
Kent, England) was used as an inhibitor of ex vivo leukotriene synthesis along with 
indomethacin (Biomol, Plymouth Meeting, PA) as inhibitor of ex vivo prostaglandin 
synthesis. The concentration of BWA4C used was based on the studies on the in vitro 
inhibition of LTB4 in guinea pig blood [343]. Indomethacin was used at a 
concentration recommended by Benedetto [348]. Stock solutions containing 8.64 
mg/ml of BWA4C in dimethylsulfoxide (DMSO) and 6.6 mg/ml indomethacin in 
ethanol were prepared and stored at 4° C. Each chilled evacuated tube (Vacutainer, 
Becton Dickinson, Rutherford, NJ) contained 6.48 /xg/ml of BWA4C, 5 /xglml of
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indomethacin, 1.5 mg/ml of EDTA (K3) and 57 fil saline. As DMSO concentrations 
above 1.5% have been shown to cause hemolysis [354], saline was added to dilute the 
DMSO concentration in each 2 ml tube to 1.5%, with a final concentration in 2 ml 
of synovial fluid of 0.075% [354]. Tubes were then centrifuged at 2,500 rpm for 15 
minutes at 4° C (Eppendorf 5415C, Brinkman Instruments, Westbury, NJ). The cell- 
free synovial fluid was stored in polypropylene micro-centrifuge tubes (Dot Scientific, 
Inc., Flint, MI) at -20° C for 2 days and then at -70° C until assayed.
2. Extraction
Two extraction procedures were evaluated, a liquid/liquid extraction technique 
and a solid phase extraction method. For the digital vein eicosanoid concentration 
study, (see also Chapter 6) and for the mass spectrometry quantitation of PGEj in 
inflamed synovial fluid, a liquid/liquid extraction technique was used. Synovial fluid 
samples described in Chapter 4 were extracted via a solid phase extraction method. 
All reagents were HPLC grade and were purchased from commercial sources. Water 
was triple distilled and filtered (Modulab Polisher I™, Continental Water Systems 
Corp., San Antonio, TX).
a. Liquid/liquid extraction
For plasma samples, 4 ml were extracted for both the LTB4 and PGE^ ELISA 
assays. For the synovial fluid assays, 0.25 ml was used for determination of PGE2 
by ELISA and 0.575 ml was used for samples to be confirmed by mass spectrometry. 
One-half ml of synovial fluid was extracted for LTB4 determination by ELISA. Both 
plasma and synovial fluid were acidified to pH 3.5 with 1 N HC1 in polypropylene
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centrifuge tubes. Three volumes of ethyl acetate were added to extract the 
eicosanoids. After vortexing and centrifugation at 2,500 rpm for 15 minutes (Dynac, 
Becton Dickenson and Company, Parsippany, NJ), the aqueous and organic layers 
were separated. The ethyl acetate was evaporated under nitrogen.
b. Solid phase extraction
i. Preparation
Synovial fluid (0.5 ml) was extracted for LTB4 determination by ELISA. 
Samples processed using this technique contained high concentrations of PGEj 
(Chapter 4) which necessitated reduced volumes of synovial fluid or dilution in order 
to stay within the limits of PGE2 quantitation (10-5000 pg/ml). Volumes of 0.25,
0.125, 0.0625 or 0.01 ml were extracted depending on the anticipated concentration 
of PGE2. For synovial fluid obtained from horses with severe inflammation, serial 
dilutions of synovial fluid were made with water acidified to pH 3 with 1 N HC1 (1:10 
and 1:100) and the diluted sample was then extracted. Sep-Pak Plus™ cartridges 
containing 360 mg of C18 were purchased from the Millipore Corporation, Milford, 
MA. Pre-washed 20 ml syringe barrels (Sherwood Medical, St. Louis, MO) were 
attached to the cartridges and served as reservoirs for the synovial fluid and reagents. 
A modified polypropylene pipet tip was attached to the cartridge in order to direct 
effluent flow. The new cartridges and syringes were washed with 20 ml of hexane 
followed by 20 ml of ethyl acetate and 20 ml of methanol under vacuum from a 
manifold device (Amicon, Lexington, MA) to remove impurities and immunoreactive 
substances according to a modified method of Jubiz [355]. Previously used cartridges
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were washed with 40 ml of hexane, ethyl acetate and methanol before each extraction 
according to a modified method of Powell [351]. Cartridges were used for extraction 
a maximum of three times. Every cartridge was washed immediately before use with 
20 ml of methanol and pH 3 water according to a modified method of Powell [351].
ii. Synovial fluid extraction 
The synovial fluid was acidified to pH 3.5 using 1 N HC1 in a polypropylene 
centrifuge tube. Water (0.5 ml) acidified to pH 3 was added and the sample was 
vortexed for 15 seconds before being transferred to the cartridge reservoir. Care was 
taken not to transfer the precipitated protein as it was shown to clog the cartridge. 
The sample was allowed to flow through the cartridge slowly under slight vacuum 
pressure (<5 inches of mercury). After the sample was evacuated, 6 ml of pH 3 
water was added under vacuum to remove water soluble inorganic salts, amino acids, 
proteins and other polar compounds in the sample [350,351]. This flush was followed 
by 6 ml of hexane under vacuum to remove the neutral lipids in the sample. Finally, 
the cartridges were removed from the vacuum manifold and the eicosanoids were 
eluted from the cartridge with 6 ml of ethyl acetate using gentle pressure applied with 
a syringe plunger. The effluent was collected into polypropylene centrifuge tubes. 
The ethyl acetate was then evaporated under a stream of nitrogen gas.
c. Recovery studies 
Extraction efficiency for plasma and synovial fluid samples was determined 
using 5,6,8,11,12,14,15-3H-PGE2 (200 Ci/mmole) purchased from Advanced 
Magnetics (Cambridge, MA). Radioactivity in disintegrations per minute (dpm) of
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spiked samples and standards was counted on a scintillation counter (Packard Tri 
Carb™, Packard Instrument Co., Downers Grove, IL). Absolute recovery of 3H-PGE2 
and 3H-LTB4 was calculated by expressing the radioactivity (dpm) of 3 extracted 
standards in synovial fluid or plasma as a percent of the mean radioactivity of 3 non­
extracted controls. Recovery was corrected for background radioactivity. Percent 
recovery was determined for both eicosanoids in plasma using the liquid/liquid 
technique and synovial fluid using liquid/liquid extraction, solid phase extraction, and 
also for solid phase extraction using methyl formate as the final eluting agent. The 
coefficient of variation (CV) of each technique was calculated from the mean and 
standard deviation (SD) of the percent recovery.
3. ELISA
Quantitation of plasma and synovial fluid eicosanoids was achieved by 
commercially available PGEj and LTB4 ELISA kits (Advanced Magnetics, 
Cambridge, MA). All reagents, standards and 96-well precoated micro-titer plates 
were provided in the kits. These assays were based on the principle of a competitive 
ELISA where PGE2 or LTB4 in the sample (reconstituted after extraction in buffer 
solution) competed with fixed amounts of alkaline phosphatase labelled PGEj or LTB4 
for binding to a limited number of sites of the specific rabbit antibody (anti-PGI^ or 
LTB4) bound to the microtiter well. Unbound material was removed by washing with 
a buffered saline solution. p-Nitrophenyl phosphate was added to each well as 
substrate for alkaline phosphatase. Color development was terminated following 
incubation at 37° C by the addition of 0.2 N sodium hydroxide. The intensity of the
81
yellow colored product formed was inversely proportional to the amount of unlabelled 
eicosanoid bound to the well. Absorbance (optical density) was read at 410 nm by 
a microtiter plate reader (Dynatech MR5000, Dynatech Laboratories, Alexandria, 
VA). Optical density (OD) results were normalized by subtracting the mean 
absorbance of 2 blank wells (containing only p-Nitrophenyl phosphate and sodium 
hydroxide) from sample ODs. Samples with the greatest color development or optical 
density values (ODs) contained the least PGEj or LTB4. Absorbance was correlated 
with concentration by means of a standard curve ranging from 10 to 5000 pg/ml 
(Figure 2). Quantitation of unknown samples processed in duplicate was achieved by 
averaging the absorbance of sample duplicates and calculation of the concentration 
from the standard curve. All sample concentrations were then corrected for extraction 
efficiency.
a. Intra-assay vari. n 
An estimate of the within run precision or the variation between duplicate wells 
of the same sample run in the same assay under identical conditions was determined 
for PGE2 and LTB4. This represents the variability inherent in the assay, e.g., 
antibody binding, reagent stability, pipet accuracy, or plate reader accuracy. It was 
defined as the CV of duplicate wells and was calculated from the mean optical density 
and SD for each of 5 non-extracted standard concentrations. The CV values were 
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Figure 2: Standard curves from PGE2 and LTB4 ELISAs.
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b. Inter-assay variation
An estimate of the variation of non-extracted standards of PGE^ and LTB4 
assayed in different kits was determined. This value includes variations in incubation 
times, operator technique, manufacturing of kits and intra-assay variance. Inter-assay 
variation was defined as the CVs of 5 standard concentrations run in 9 PGEz assays 
and 4 LTB4 assays. An overall CV was determined by averaging the individual 
concentration CVs to get an overall CV ±  SD. In addition, the correlation coefficient 
of the standard curve was calculated for each assay (SigmaPlot, Jandel Corp., San 
Rafael, CA). The mean correlation coefficient +  SD was calculated for 9 PGEj 
assays and 4 LTB4 assays.
4. PGE^ confirmation
Synovial fluid obtained from the intercarpal joint of one horse 12 hours after 
induction of carrageenan synovitis was extracted using the liquid/liquid technique and 
assayed for PGEz by the ELISA procedure outlined above. A separate aliquot was 
also extracted using the liquid/liquid technique, subjected to purification by a HPLC 
technique and then assayed for PGE2 by GC/MS [356]. The results were then 
compared in an effort to confirm and validate the PGE2 ELISA. Before extraction, 
PGD2 (16 ng/sample or 1.92 ng on the GC column) was added to the synovial fluid 
and served as an internal standard for quantitation by GC/MS.
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a. Eicosanoid standards
PGD2 [(5Z,9o!, 13E, 15S)-9,15-Dihydroxy-1 l-oxoprosta-5,13-dien-l-oic acid] 
was used as the internal standard for PGE2 [(5Z, 1 la , 13E, 15S)-11,15-Dihydroxy-9- 
oxoprosta-5,13-dienoic acid]. Both were purchased from Cayman Chemical Co., Ann 
Arbor, MI and were stored in ethanol at -70° C.
b. Solvents
Liquid chromatography and mass spectrometry grade solvents were obtained 
from commercial sources. HPLC mobile phase A consisted of water, acetonitrile, and 
trifluoroacetic acid in a ratio of 75:25:0.0008 (pH approximately 6). Mobile phase 
B consisted of methanol, acetonitrile and trifluoroacetic acid at a ratio of 60:40:0.002. 
Each mobile phase was filtered through a 0.45 fim membrane filter (FP Vericel™, 
Gelman Sciences, Inc., Ann Arbor, MI).
c. High performance liquid chromatography (HPLC)
Synovial fluid was subjected to HPLC in order to isolate and collect PGE^ 
Samples were analyzed with a Hewlett Packard 1090 High Performance Liquid 
Chromatograph equipped with a variable volume auto-injector and a photodiode array 
detector set at 192 nm (4 nm bandwidth) with a reference spectrum of 450 nm (80 nm 
bandwidth). Instrument control, data acquisition, and peak integration were 
accomplished with Hewlett-Packard HPLC ChemStation software (Waldbronn, 
Germany). A 4 mm x 30 cm reversed phase column packed with 10 /xm 
octadecylsilyl derivatized silica particles (Varian, Walnut Creek, CA) maintained at 
ambient temperature was used. Solvents were run using a gradient between 100%
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mobile phase A and 100% mobile phase B over 40 minutes at a flow rate of 1 
ml/minute. After extraction by the liquid/liquid technique, the synovial fluid samples 
were dissolved in 120 /d of Mobile Phase A and transferred to a 100 gl HPLC 
autosampler vial insert (American Scientific Products, McGraw Park, IL) that allowed 
for complete injection of the sample volume.
Due to the low sensitivity of the diode array detector for PGEj, a radio­
chromatography detector (Series A-500, Radiomatic Instruments and Chemical Co., 
Meriden, CT) was connected in series to the HPLC in order to establish the retention 
time of tritiated PGEj. The scintillation fluid, Flo-Scint II™ (Radiomatic Instrument 
and Chemical Co., Meriden, CT), was pumped through the detector at 4 ml/minute. 
The radioactivity of 3H-PGE2 spiked synovial fluid samples was determined in counts 
per minute (cpm). These samples were run immediately before incurred 
(experimental) samples to determine the retention time of PGEj.
Samples for PGE2 confirmation were injected onto the HPLC and collected 
within ±  0.75 minutes of the predetermined retention time of PGL,. This fraction 
was placed under a stream of nitrogen gas to evaporate the mobile phase and then 
stored at -20° C overnight.
d. Gas chromatography and mass spectrometry (GC/MS)
Standards for PGE2 were prepared using concentrations of 39.6, 79.0, 158.5, 
634.0, 1268.3, and 2536.0 ng/rnl. These values represented 118.9, 237.0, 475.6 pg, 
and 1.9, 3.8 and 7.6 ng of PGE2 injected on the GC column. PGD2 was added to 
each standard as an internal standard at a concentration of 640 ng/ml (1.92 ng on
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column). These standards were derivatized and analyzed immediately before incurred 
synovial samples in order to establish a standard curve for quantitation.
Prior to GC/MS analysis, all samples and standards were derivatized to 
increase molecule volatility and thermal stability [346]. PGE2 and PGD2 were 
esterified at the carboxyl terminus with pentafluorobenzyl bromide (PFB), the keto 
group was oximated (MO) and then the trimethylsilyl ether (TMS) derivative was 
formed at both hydroxy groups (Figure 3). Derivatization was accomplished by 
adding 10 fi\ of methanol, 50 /il of acetonitrile, 2 fd of pentafluorobenzyl bromide and 
1.5 fd of diisopropylethylamine to dried samples in glass vials with teflon-lined caps. 
The samples were vortexed and heated at 60° C for 15 minutes [357]. A 2% solution 
of methoxyamine hydrochloride in pyridine (25 fd) was added and samples were kept 
at room temperature overnight. After drying under nitrogen, 20 fd of water were 
added and the samples were extracted twice with 50 fd of ethyl acetate [358]. After 
drying again under nitrogen, 25 fd of N,0-bis(trimethylsilyl)-trifluoroacetamide 
(BSTFA) with 1 % trimethylchlorosilane (TMCS) were added and samples were heated 
for 15 minutes at 60° C according to a modified method of the manufacturer. All 
derivatizing reagents were purchased from Pierce Chemical Co., Rockford, IL.
Immediately following derivatization, 3 fd of each sample were injected into 
a Finnigan MAT 9610 Gas Chromatograph (Sunnyvale CA) using a modified method 
of Waddel et ah, 1983 [359]. A 30 M DB-5 column (J & W Scientific, Fulsom, CA) 
with 0.25 fim of polymer coating and an internal diameter of 0.22 mm was used in 
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Figure 3: Structure of derivatized PGE2 and PGD2. Dotted lines indicate fragmentation sites that produced 
masses (m/z) monitored by MID.
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temperature was 200° C. This was increased by 30° C per minute to a final 
temperature of 300° C. The injector and transfer line temperatures were set at 220 
and 300° C, respectively. The column was plumbed directly into a Finnigan MAT 
TSQ 4500 Mass Spectrometer (Sunnyvale, CA). The method of ionization was 
negative ion chemical ionization (NICI) using methane as the reagent gas. The ionizer 
source pressure was 0.5 Torr and the ionizer temperature was set at 150° C. Electron 
energy was 70 eV and the emission current was 0.30 mA. The electron multiplier 
was set at 2500 volts.
Data was acquired using multiple ion detection (MID) scanning quadrapole 3 
(Q3) for masses of 524, 434, 344 and 196. This type of selective ion monitoring 
enabled pg detection. The second isomer of PGE2 and PGD2 was used for 
quantitation. The base peak of the second isomer of PGE2 was 524 m/z and 434 m/z 
for PGD2. The abundance of each base peak was obtained from the mass spectrum 
by the computerized summing of scans from the initiation to the termination of 
individual isomer peaks. Baseline noise was subtracted from the summed abundances 
of each peak. Standard curves for quantitation of samples for PGEj confirmation 
were prepared using the ratio of base peak abundances of PGIi, and PGD2.
C. Results
1. Sample collection
Synovial fluid samples from normal equine joints were very viscous. To 
insure that the synovial fluid supernatants were free of cells that could contribute to
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ex vivo eicosanoid formation, 3 samples were evaluated for cellularity by microscopic 
examination of Wright’s stained direct smears. No white blood cells or platelets were 
found and slides contained scant numbers of red blood cells.
Several samples of synovial fluid from horses with acute synovitis were 
subjected to two freeze/thaw cycles before extraction and ELISA in order to determine 
if previously thawed samples could be refrozen and assayed at a later date. Both 
PGE2 and LTB4 levels increased markedly (485.40% and 393.77%, respectively) after 
two freeze thaw cycles.
2. Extraction
Percent recoveries of LTB4 and PGE2 from plasma using liquid/liquid 
extraction and synovial fluid using liquid/liquid extraction, solid phase extraction, and 
solid phase extraction with methyl formate as the final eluting agent are reported in 
Table 9. Recoveries of PGE2 from synovial fluid and plasma using the liquid/liquid 
technique modified from Coker et al., [333] were 67.95 and 43.82%, respectively. 
Recovery of LTB4 from synovial fluid and plasma using this method were 98.39 and 
39.13%, respectively.
Attempts were made to duplicate the solid phase extraction procedure of 
Powell [351,360] using aqueous ethanol as a sample diluent and initial wash followed 
by a water wash, a petroleum ether wash and elution using methyl formate. The 
reported recovery of PGEj from urine and plasma using this method is > 90%. 
However, in the present study this method demonstrated that recoveries of PGE2 and 
LTB4 were poor, in large part due the loss of eicosanoids from the Sep-Pak upon
Table 9: Percent Recovery of PGE2 and LTB4 in synovial fluid and plasma using various techniques.
SYNOVIAL FLUID PLASMA







PGE2 % RECOVERY 67.95 61.04 48.97 43.82
CV 14.11 2.97 8.64 9.55
l t b 4 % RECOVERY 98.39 57.67 65.99 39.13




application of the diluted sample fraction and the initial aqueous ethanol wash. It was 
determined that higher recoveries were obtained using water at pH 3 as the sample 
diluent and initial wash. Further, hexane was substituted for petroleum ether as it was 
found to produce less damage to the plastic syringe plungers. Ethyl acetate was found 
to give approximately equal recoveries (PGEj- 61.04%; LTB4- 57.67%) as the highly 
flammable and irritating methyl formate (PGE2- 48.97%; LTB4- 65.99%) when used 
with this modified method.
The cartridges and reservoirs were washed extensively before use to reduce the 
immunoreactive substances that were shown to interfere with the PGEj assay. Other 
researchers have also reported immunoreactive substances or other impurities from 
Sep-Paks that were not thoroughly washed before use [361,362]. According to Powell, 
cartridges can be re-used [351]. It was determined that cartridges could be re-used a 
maximum of three times without contributing any carryover immunoreactivity if they 
were washed with 40 ml each of hexane, ethyl acetate and methanol before each re­
use.
3. ELISA
The limit of quantitation based on the lowest concentration of the standard 
curve was 10 pg/ml for both assays. According to performance characteristics 
supplied by the manufacturer, the sensitivity of the LTB4 ELISA was 8.9 pg/ml with 
minimal cross reactivity with other leukotrienes, prostaglandins and arachidonic acid 
metabolites (Table 10). The reported sensitivity of PGE2 ELISA was 1.5 pg/ml. The 
reactivity of this kit was low for other eicosanoids and metabolites tested except for
Table 10: Percent cross reactivity of PGE2 and LTB4 ELIS As as determined at 50% B/B0. Standards 
were spiked into assay buffer (data supplied by Advanced Magnetics, Cambridge, MA).
PGEj LTB4
PGEj 100.0% l t b 4 100.0%
PGEX 50.0% 5(S),12(R)-DiHETE 6.7%
PGAj 6.0% 5(S),12(S) -Di-HETE 2 .0%
PGA, 1.9% l t c 4 < 1.0%
PGB, < 1.8% l t d 4 < 1.0%
PGB, < 1.8% l t e 4 < 1.0%
6-keto-PGEj < 1.8% 5-HETE < 1.0%
15-keto-l 3,14-dihydro-PGE, < 1.8% 12-HETE < 1.0%
PGF^ < 1.8% 15-HETE < 1.0%
5-HETE < 1.0% p g d 2 < 1.0%
12-HETE < 1.0 % PGEX < 1.0%
6-keto-PGEla < 1.0% PGE, < 1.0%
p g d 2 < 1.0% Thromboxane B2 < 1.0%
Arachidonic acid < 1.0 % 20-hydroxy-LTB4 < 1.0%
Thromboxane B2 < 1.0% Arachidonic acid < 1.0%
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PGEt which had 50% reactivity with the PGE2 antibody at 50% B/B0 (sample 
OD/blank OD).
a. Intra-assay variation
The intra-assay variance or the within assay precision of the PGE^ and LTB4 
ELISA as expressed as the coefficient of variation are presented in Table 11. 
Individual concentration and overall CVs were less than 10% as recommended by 
Feldcamp and Smith [363].
b. Inter-assay variation
The between assay variability based on the coefficient of variation of 9 PGEj 
assays and 4 LTB4 assays was greater than the intra-assay variation (Table 11). The 
overall repeatability of these assays was 14.32% for PGE2 and 17.28% for LTB4. 
These values are in the range reported for ELIS As [342,364], The mean correlation 
coefficient + SD for the standard curves was 0.9869 ± 0.0102 for PGEj and 0.9850 
±  0.0140 for LTB4.
3. PGEj Confirmation
A gradient of the 2 mobile phases reported by Powell [335] provided good 
chromatography of PGE2 with minor column and flow rate modifications. A 
representative chromatogram of 3H-PGE2 spiked synovial fluid is shown in Figure 4. 
Figure 5 shows liquid chromatograms of 10 f i g  of PGE2 and PGD2 obtained with 
photodiode array detection as well as a radio-chromatogram of 3H-PGE2. Photodiode 
array chromatograms are expressed as milliabsorbance units (mAU) versus time, 
whereas radio-chromatograms are expressed as dpm versus time. The chromatograms




INTER-ASSAY INTRA-ASSAY INTER-ASSAY INTRA-ASSAY
10 16.89 3.00 14.50 3.50
50 15.46 2.38 9.78 3.44
250 10.77 5.32 14.73 3.44
1000 12.52 2.79 18.40 3.04
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Figure 4: Liquid chromatogram with radio-chromatography detection of 3H-PGE2 spiked synovial fluid. The 
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Figure 5: Liquid chromatograms of PGE2 and PGD2 obtained with photodiode array detection at 192 nm and 3H- 
PGE2 obtained with radio-chromatography detection. The slow increase in absorbance over time in the 
chromatograms of PGE2 and PGD2 is due to the solvent gradient. VOOv
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obtained with photodiode array detection at a wavelength of 192 nm show interference 
due to the solvent gradient, making detection of small quantities of PGE^ difficult. 
Thus, the retention time of PGE2 was confirmed before collection of incurred samples 
using 3H-PGE2 with a radio-chromatography detector. 3H-PGE2 eluted between 0.4 
and 0.12 minutes before PGE2 due to the increase in hydrophilicity associated with the 
3H-labelled compound [365]. The retention times of PGE2 and PGD2 were 24.89 
and 25.26 minutes, respectively. PGE2 and PGD2 differ only in the position of the 
hydroxy and keto groups (PGEj-1 l-hydroxy-9-keto; PGD2- 9-hydroxy-l 1-keto). This 
difference accounts for the subtle difference in HPLC and GC/MS retention times.
The limit of detection for PGEj on GC/MS was 118 pg on column (39.6 
ng/ml). A representative chromatogram of a standard solution of PGEj (237 pg on 
column) and PGD2 (1.92 ng on column) is shown in Figure 6 . PGEj and PGD2 
formed syn and anti methoxime isomers [366,367]. The first isomer of PGE^ and 
PGD2 coeluted but their second isomers separated adequately with the PGD2 isomer 
eluting before PGE^, as reported previously [359]. The second isomers were used for 
quantitation by expressing the abundance of each base peak of PGEj to PGD2 as a 
ratio. NICI of these eicosanoids resulted in fragmentation of the molecular ion (M)‘ 
of the compound of interest (parent compound with derivatized functional groups, total 
molecular weight, 705). Cleavage of PFB from the molecular ion (M-PFB)' at the 
ester linkage resulted in the 524 m/z ion. Loss of one TMS as an alcohol resulted in 
the 434 m/z ion. The 344 m/z ion was produced following cleavage of the second 



























Figure 6: GC/MS chromatogram of a standard solution of PGE2 (237 pg on column) and PGD2 (1.92 ng on 
column). The first peak contains the first isomers, while the second and third peaks are the second isomers of 












from the prostaglandin. MID scans showing the intensity of the base peak of the 
second isomer of PGEj (524 m/z) and the base peak of the second isomer of PGD2 
(434 m/z) are shown in Figure 7. The standard curve using concentrations of PGEj 
ranging from 118.9 pg to 7.61 ng on column was linear with a coefficient of 
determination of 0.9981 (Figure 8).
The GC/MS chromatogram of synovial fluid obtained from a horse with 
experimentally-induced synovitis for PGEz confirmation is shown in Figure 9. Scans 
showing base peak abundances of PGE2 and PGD2 are shown in Figure 10. GC/MS 
analysis detected 1.07 ng of PGEj (on column) which was calculated to be 15.49 
ng/ml in the original synovial fluid sample. The ELISA assay of a separate aliquot 
of the same synovial fluid resulted in 20.79 ng/ml of PGE2.
D. Discussion
According to initial studies, PGE2 and LTB4 levels in synovial fluid of horses 
with acute synovitis increased after repeated freeze/thaw cycles. This was not due to 
cellular metabolism of arachidonic acid as these samples contained no cells capable 
of eicosanoid production. The reason for this effect is not readily apparent, although 
it has been seen previously in plasma but not serum [333,349]. Perhaps the 
subcellular particles containing cyclooxygenase and lipoxygenase enzymes metabolized 
the arachidonic acid present in membrane fragments in the synovial fluid. Or perhaps 
eicosanoids bound to proteins and glycosaminoglycans in the synovial fluid are 
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Figure 9: GC/MS chromatogram of a synovial fluid sample from a horse with experimentally-induced synovitis.
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Figure 10: MID scans from the chromatogram in Figure 9. The 
concentration of PGE2 in synovial fluid was 15.49 ng/ml as calculated from 
the standard curve of the relative abundances of PGE2 (bottom) and PGD2 
(top).
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Owing to this effect, all samples reported in the present studies were thawed 
immediately prior to extraction and assay. Results from other laboratories have 
demonstrated that eicosanoids are stable when thoroughly frozen (-20° C) for 
prolonged periods of time [333].
Results from the liquid/liquid extraction technique indicated that this method 
gave good recovery from small volumes of synovial fluid, whereas larger volumes of 
plasma resulted in lower recovery. Solid phase extraction of synovial fluid resulted 
in lower recovery of LTB4 than the liquid/liquid procedure, although the solid phase 
recovery was in the range of reported extraction efficiencies. Recovery of 
leukotrienes using Sep-Paks with modified Powell methods were reported to be 73 % 
[368] and 79% forLTC4 [369] and 57% [362], 73% [345], 89% [355] and 96% [370] 
for LTB4. Recovery of PGEj using solid phase extraction has been reported to be > 
90% [351,368,371] which is higher than the recovery determined in this study. 
Recoveries calculated from serum [368], plasma, urine [351] and tissue culture 
medium [362] may not be comparable to equine synovial fluid due to the viscosity of 
this matrix which could bind or trap eicosanoids.
Solid phase extraction of eicosanoids from biological matrices has largely 
replaced liquid/liquid extraction owing to the specificity, efficiency and rapid 
processing of samples [346]. The technique as originally described by Powell [372] 
is based on the affinity of the eicosanoids for the non-polar octadecylsilyl (ODS) 
packing material of the cartridge. The cartridges function as reversed phase 
chromatography columns [351]. The application of strong organic solvents such as
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hexane or petroleum ether allows for the removal of very non-polar compounds such 
as triglycerides and other lipids. The application of more polar solvents such as 
methyl formate or ethyl acetate elutes the eicosanoids. In the present study, this 
approach allowed for a more selective extraction procedure than the liquid/liquid 
extraction techniques.
Most eicosanoids are small haptens that have only one epitope and are 
unsuitable for the original "sandwich" ELISA where two molecules of antibody 
recognized the same antigen [344]. Most eicosanoid ELISA procedures, including the 
ones described in this study, are of the competitive type where labelled antigen 
competes with sample antigen for binding on the specific antibody. In immunoassay 
procedures the degree of displacement of the antigen from the antigen-antibody 
complex is quantified. The binding of the labelled antigen is inhibited by the antigen 
of interest (PGE2 or LTB4 in the sample). However, cross-reacting substances of 
similar structure and excessive amounts of unrelated compounds may interfere with 
binding. Although too expensive and complicated to be used for routine analysis, 
GC/MS has been used as a validation procedure for immunoassays [373]. GC/MS is 
regarded as the most specific and sensitive method for analysis of eicosanoids. 
Specificity is based on the gas chromatographic retention time of the compound and 
detection of the characteristic fragment ions by mass spectrometry [339].
The HPLC technique used for isolation and collection of PGEj before GC/MS 
has been shown to separate many cyclooxygenase and lipoxygenase metabolites that 
may then be subjected to GC/MS [335,336]. However, in the present study, the use
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of radio-chromatography of tritium labelled standard was needed to confirm the 
retention time of PGEj due to the relative insensitivity of the photodiode array 
detector. This technique proved less expensive than using f i g  quantities of PGE2 on 
the photodiode array detector as the radio-chromatography detector was sensitive to 
ng quantities of tritiated PGE*.
Quantitation of eicosanoids is accomplished most effectively by the highly 
sensitive NICI GC/MS technique [346]. The analysis of PFB derivatives of 
eicosanoids by NICI GC/MS has the advantage of producing a high yield of stable 
ionized products and a low fragmentation rate [346]. The sensitivity of this method 
is due to fragmentation that is primarily directed away from the prostaglandin 
molecule thereby leaving the carbon skeleton intact [366]. Quantitation of eicosanoids 
by GC/MS using stable isotope dilution techniques is most often accomplished using 
deuterated analogues of the compound of interest acting as internal standards. These 
techniques are advantageous in GC/MS due to the similar structure and properties of 
the isotope and native compound [374]. The technique employed in this study, 
whereby a structurally similar compound is used as an internal standard, represents 
a simple and sensitive alternative to the use of deuterated compounds.
Analytical problems have been an obstacle in eicosanoid research. Thus, 
progress in this field is dependent on the advancement and validation of analytical 
techniques [338]. The ELIS As used in these experiments to quantitate PGEj and 
LTB4 in equine synovial fluid and plasma had not been described previously for use 
in the horse. Cross reactivity information obtained from the manufacturer indicated
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that the LTB4 assay was highly specific and sensitive. As unique interfering 
substances from equine synovial fluid are unlikely, validation procedures were not 
performed for LTB4. The PGE2 assay although sensitive, had 50% cross reactivity 
with PGEi. The validation procedures used in the present study confirmed the results 
of the PGE2 ELISA on inflamed equine synovial fluid. GC/MS analysis detected 
15.49 ng/ml of PGEj in the synovial fluid while the ELISA performed on a separate 
aliquot of the same sample resulted in 20.79 ng/ml. These results are in good 
agreement taking into account minor losses of sample during purification by HPLC 
and derivatization before GC/MS. Therefore, the PGE2 ELISA appears to specific for 
this compound in equine synovial fluid, indicating the absence of interferences from 
this matrix.
CHAPTER 4
EFFECT OF KETOPROFEN AND PHENYLBUTAZONE 
ON ACUTE SYNOVITIS
A. Introduction
Synovitis accompanies most forms of equine joint disease [75]. Synovitis is 
characterized by inflammation of the synovium without gross disturbance of the 
articular cartilage or disruption of major supporting structures [83]. Clinical signs of 
acute synovial inflammation include: synovial effusion with distension of the joint 
capsule; increased skin temperature over the joint; hypertrophy and hyperplasia of the 
synovia resulting in a palpable thickening of the membrane; a decrease in the range 
of motion of the joint; and lameness in the affected limb. Eicosanoids and other 
inflammatory mediators contribute to the inflammatory response by increasing 
synovial vascular permeability [17], increasing the metabolic rate of synoviocytes 
[37], and causing congestion of the microvascular bed [93]. As the permeability of 
the synovial membrane increases, proteins accumulate in the joint resulting in an 
increase in fluid osmotic pressure. The resulting effusion of synovial fluid often 
results in pain and overt lameness [94]. In humans there is a positive linear 
correlation between intra-articular pressure and joint pain [95]. The inflammatory 
mediators released by local tissue destruction in the joint activate nociceptors and also 
sensitize these receptors through lowering of activation thresholds [96,97]. Further,
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the release of substance P and other neuropeptides [98] may potentiate the 
inflammatory response and result in neurogenic inflammation [99],
Experimentally, synovitis has been induced in horses, ponies, calves, dogs, 
rabbits and rats by the intra-articular injection of a variety of chemical substances. 
Models of joint inflammation have been used for screening and evaluation of anti­
inflammatory agents [101] The equine joint is a unique site for an inflammatory 
model due to the structure and function of the synovial membrane and the sheer size 
of the joint space. The synovial membrane acts as a selective barrier in the joint in 
that it allows for the passage of molecules of less than approximately 12,000 dal tons 
in molecular weight [76]. Transfer of small molecules to and from the synovial fluid 
occurs readily due to specialized structures within the membrane such as: a synovial 
lining cell layer that is 1 to 4 cells thick and often incomplete [74]; lack of 
desmosomes or a basement membrane [77]; and the presence of fenestrated capillaries, 
secretory and macrophagic cells, surface pores and large numbers of lymphatics [74].
Nonsteroidal anti-inflammatory drugs (NSAIDs) are considered the mainstay 
of treatment for non-septic joint disease in animals [76,375]. It is well documented 
that these agents alleviate the pain and lameness associated with joint inflammation 
[101] through reduction in the peripheral nociceptive impulses from the inflamed joint 
[197] and through central analgesic mechanisms [148,273]. However, few studies 
have described the anti-inflammatory effects of these agents in detail in experimentally 
induced joint inflammation [297].
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The purpose of this study was: 1) to develop a self-limiting, reproducible 
model of acute synovitis which increased prostaglandin E2 (PGE2) and leukotriene B4 
(LTB4) synovial fluid concentrations along with other measurable joint inflammatory 
responses; 2) compare the magnitude and time course of the anti-inflammatory and 
eicosanoid inhibitory effects of ketoprofen and phenylbutazone in the acute synovitis 
model; and. 3) compare the ability of ketoprofen and phenylbutazone to reduce the 
clinical signs of acute synovitis. The approved therapeutic doses of ketoprofen (2.2 
mg/kg) and phenylbutazone (4.4 mg/kg) were used. In addition, the phenylbutazone 
molar equivalent dose of ketoprofen (3.63 mg/kg) was used in order to compare the 
potency of ketoprofen and phenylbutazone. NSAIDs and saline were administered at 
the same time as carrageenan induction in order to determine the anti-inflammatory 
effects of the NSAIDs on developing and acute inflammation.
The intercarpal joint was chosen for induction of synovitis because of its large 
volume of synovial fluid [376] as it communicates with the carpometacarpal joint in 
most (90%) horses [74]. Further, this joint has three access sites: medial and lateral 
to the extensor carpi radialis tendon and at the palmarolateral reflection of the 
intercarpal joint capsule, distal to the accessory carpal bone [377]. As most of the 
horses used in this study were retired racing Thoroughbreds, the left carpus was used 
because of the increased incidence of joint pathology in the right carpus [378,379]. 
Inflammation was induced in each horse only once due to the potential for permanent 
cartilage damage with successive carrageenan injections [108]. Further, it has been
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documented that the prior injection of carrageenan in the rat paw causes hyperalgesia 
to develop much faster when the contralateral paw is injected [272].
B. Materials and methods
1. Experimental animals
Twenty-four mares and geldings (5 American Quarter Horses and 19 
Thoroughbreds) weighing from 410 to 554 kg and ranging from 6 to 13 years of age 
were used. Prior to induction of synovitis, horses were judged to be healthy and 
sound based on physical examination, lameness evaluation, complete blood count, left 
intercarpal synovial fluid clinical pathology analysis and radiographic examination of 
the left carpus. Horses with radiographic or synovial fluid pathology of the 
intercarpal joint were excluded.
All horses were vaccinated at least three weeks prior against eastern and 
western equine encephalomyelitis, influenza, tetanus (Equi-Flu EWT™, Coopers, 
Mundelein, IL) and rhinopneumonitis (Rhinomune™, SmithKline Beecham Animal 
Health, Exton, PA). The horses were dewormed with oxibendazole (Equipar™, 
Coopers, Mundelein, IL). Horses were housed in 10.9 x 12.5 feet stalls and were 
maintained on 5 pounds of a pelleted ration (Purina Horse Chow 100™, Purina Mills 
Inc., St. Louis, MO) containing: a minimum of 10% protein; 2% fat; a maximum of 
25 % fiber; and a vitamin/trace mineral supplement twice daily with mixed grass hay 
(11% protein, 1.4% fat, 24% fiber) and water provided ad libitum.
112
2. Drugs and reagents
a. NSAID solutions for administration
Ketoprofen (Ketofen™) was obtained commercially from Aveco Company, 
Inc., Fort Dodge, IA. Each ml of the sterile solution contained: 100 mg ketoprofen; 
L-arginine, 70 mg; citric acid to adjust pH to approximately 7; and benzyl alcohol, 
0.25 ml as a preservative. Phenylbutazone (Butazolidin™) was obtained commercially 
from Coopers Animal Health, Inc., Kansas City, KS. Each ml of the sterile solution 
contained: phenylbutazone, 200 mg; sodium hydroxide to adjust pH to between 9.5 
and 10.0; and benzyl alcohol, 10.45 mg as a preservative.
b. Carrageenan solution
Carrageenan (type IV; molecular weight, approximately 300,000) was 
purchased from Sigma Chemical Co., St. Louis, MO. This type of non-gelling 
carrageenan was isolated from two seaweed species, Gigartina aciclulaire and 
Gigartina pistillata. It was sterilized in powder form using ethylene oxide (H.W. 
Andersen Products, Haw River, NC) and then mixed to a suspension with sterile
0.9% saline according to a modified method of Higgins and Lees to produce a 1% 
solution [70]. All horses were induced using the same batch of carrageenan as 
different batches are known to vary in their inflammatory potency [380]. Cultures of 
the 1 % solution were made in duplicate on blood agar (aerobic culture medium) and 
in thioglycollate broth (anaerobic culture medium) weekly for the duration of this 
study [381]. These cultures were maintained at 37° C for three days and were 
examined for microbial growth daily. The solution was thoroughly mixed and (0.3
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ml) was drawn up in a sterile 1 ml syringe using a 25 gauge, 1 inch needle on the 
morning of each experimental day.
3. Experimental protocol
a. Overview
In the beginning of each experimental session, horses were evaluated for 
lameness and then brought into the environmentally controlled laboratory and 
restrained in an equine stanchion. The left carpal joint was radiographed and 
measured. The horse was then sedated and after 5 minutes, blood was collected and 
heart rate, respiratory rate and rectal temperature were determined. A thermography 
apparatus was applied to the joint and then it was scrubbed in preparation for 
arthrocentesis. In baseline sessions, synovial fluid was collected. Then at time 0, 
carrageenan was injected into the joint and ketoprofen (2.2 mg/kg and 3.63 mg/kg), 
phenylbutazone (4.4 mg/kg) or saline was administered intravenously. Horses were 
subsequently evaluated according to this protocol at 1, 3, 6, 9, 12, 24 and 48 hours 
after administration.
b. Horse preparation
Each horse was washed and shaved over the entire carpal region 24 hours prior 
to drug administration. Indwelling catheters (14 gauge, 5.7 cm) (Quick-Cath™, 
Baxter Healthcare Corp., Deerfield, IL) were aseptically placed bilaterally in the 
jugular veins of each horse before each session.
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c. Synovial fluid collection and induction o f synovitis 
Horses were sedated with intravenous detomidine HC1 (Dormosedan™, Norden 
Laboratories, Lincoln, NE) at doses of 10 jig/kg before the baseline collection, and 
5.0 ^ig/kg before each post-treatment arthrocentesis to reduce the risk of iatrogenic 
joint hemorrhage and trauma. In addition, all horses were nose twitched during 
arthrocentesis. Before each arthrocentesis the entire left carpal area was scrubbed 
with Hibiclens™ (Stuart Pharmaceuticals, Wilmington, DE) and alcohol at least three 
times with a final scrub directly over the site for arthrocentesis. Sterile needles (20 
gauge, 1 inch), syringes (12 ml or 20 ml) and gloves were used to collect fluid from 
the intercarpal joint while the limb was held in the flexed position by another 
examiner. Immediately following the collection of the baseline synovial fluid sample,
0.3 ml of 1 % solution of sterile carrageenan was injected into the left intercarpal joint 
(dorsolateral aspect) using sterile technique [52]. An independent examiner 
administered the NSAIDs or saline via the left jugular catheter immediately following 
carrageenan injection.
Synovial fluid was then collected from the intercarpal joint at 1, 3, 6, 9, 12, 
and 24 hours after drug and carrageenan administration. Fluid was collected 
altematingly from the dorsolateral and dorsomedial aspect of the intercarpal joints. 
In addition, the palmarolateral access site was used intermittently when the joint 
become effused. Sites for arthrocentesis were rotated in order to minimize iatrogenic 
hemorrhage into the joint capsule. At each time point, the maximum volume of
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synovial fluid available was withdrawn in order to reduce the degree of discomfort in 
the horse caused by joint effusion.
All synovial fluid samples were aliquoted for ketoprofen determination, 
bacterial culture, clinical pathology analysis and eicosanoid determination. Fluid (at 
least 1.5 ml) for the PGEj and LTB4 assay was placed immediately into chilled 
evacuated tubes containing 1.5 mg/ml of ethylenediamine tetraacetate K3 (EDTA) 
(Vacutainer, Becton Dickinson, Rutherford, NJ) with 6.48 /tg/ml of BWA4C, 5 pig/ml 
of indomethacin, and 57 fA saline. Tubes were then centrifuged at 2,500 rpm for 15 
minutes at 4° C (Eppendorf 5415C, Brinkman Instruments, Westbury, NJ). The cell- 
free synovial fluid was stored in polypropylene micro-centrifuge tubes (Dot Scientific, 
Inc., Flint, MI) at -20° C for 2 days, then at -70° C until assayed. Fluid for clinical 
pathology analysis (at least 0.75 ml) was placed into 2 ml evacuated tubes containing 
3 mg/ml of EDTA (Vacutainer, Becton Dickinson, Rutherford, NJ). Fluid for 
ketoprofen determination was processed according to methods described in Chapter 
5.
Synovial fluid volume was recorded and the fluid was graded for hemorrhage 
based on the following scale:
Grade 1: A slight amount of blood contamination, often obtained upon exiting 
the joint.
Grade 2: Moderate blood contamination upon exiting the joint or fluid that 
had a moderate red or brownish-red haze indicating formation of unconjugated 
bilirubin from the breakdown of erythrocytes.
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Grade 3: Very hazy, opaque, red or brownish-red fluid.
Grade 4: Fluid containing a large quantity of frank blood or evidence of 
clotting.
d. Blood collection
All NSAIDS and detomidine were administered via the left jugular catheter. 
The right jugular catheter was used for blood collection before drug and carrageenan 
administration (baseline) and at 1, 3, 6, 9, 12, 24 and 48 hours after drug injection 
for determination of complete blood counts. Blood was also collected for 
determination of plasma ketoprofen concentrations as outlined in Chapter 5. The 
patency of each catheter was maintained after each blood collection with 3 ml of 100 
IU/ml of heparinized saline. Before blood was collected, 2-3 ml was discarded to 
remove any residual heparin from the catheter. Blood (7 ml) was collected with a 18 
gauge, 1.5 inch needle and a 20 ml syringe and then placed immediately into 7 ml 
evacuated glass tubes containing 10.5 mg of EDTA as an anticoagulant (Vacutainer, 
Becton Dickinson, Rutherford, NJ) and stored at 4° C until analysis.
e. Lameness evaluation
Horses were evaluated at a walk and trot on a concrete surface and graded for 
lameness as follows [377]:
Grade 1: The horse exhibited a normal gait at a walk. The trot showed a 
slightly shortened weight bearing phase for the left forelimb with an audible 
cadence abnormality. There was even head and neck lifting for each foot.
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Grade 2: The walk showed stride changes with no abnormal head or neck 
lifting. The trot showed obvious lameness with uneven head and neck lifting. 
Grade 3: The lameness was obvious at a walk and trot with prominent head 
and neck lifting as the left forelimb was weight bearing.
Grade 4: The horse experienced difficulty bearing weight on the left forelimb. 
f  Radiography
The left carpus was radiographed (Min X-Ray 300, Evanston, IL) laterally 
while held in rigid flexion by the examiner, in order to obtain the angle of maximum 
flexion of the joint, using 20.3 x 25.4 cm film cassettes and TML diagnostic film (T- 
Mat™, Eastman Kodak Co., Rochester, NY). After development of the radiographic 
film (RP X-Omat Processor, Eastman Kodak Co., Rochester, NY) lines were drawn 
on the radiographic image along the long axis of the radius and third metacarpal bones 
at the measured midpoint of each diaphysis. The angle formed by the intersection of 
these lines dorsal to the carpus was measured with a standard protractor to provide 
an estimate of the range of motion of the carpus.
g. Joint circumference and effusion grade 
The circumference of the intercarpal joint was measured in cm using a standard 
tape measure. To ensure measurement consistency, the joint was marked with 
fingernail polish in three places (medial, lateral and palmar) in the beginning of each 
experimental session. Each horse was subjectively evaluated for carpal effusion based 
on the following scale:
Grade 1: Slight effusion around the site of carrageenan injection.
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Grade 2: Moderate effusion of the intercarpal joint only without distention of 
the palmarolateral joint pouch.
Grade 3: Marked effusion of the intercarpal joint with distension of the 
palmarolateral joint pouch. Some swelling proximal and distal to the 
intercarpal joint.
Grade 4: Severe swelling of the entire carpal region.
h. Temperature, heart and respiratory rates
Rectal temperature was obtained from a rectal probe (Model RET-1, Sensortek, 
Clifton, NJ) and digital thermometer (Model TH-6D, Sensortek, Clifton, NJ). Heart 
and respiratory rates (bpm) were obtained by auscultation.
i. Carpal thermography
A contact thermography system (Novatherm, Med Tech Products, Inc., 
Dayton, OH) was used to detect thermal emissions from the dorsal surface of the left 
carpus. The detector consisted of a liquid crystalline latex membrane wrapped around 
a pressurized frame with a viewing window. Eight membranes were used with mean 
detection temperatures of 22, 24, 26, 28, 30, 32, 34 and 36° C. Each membrane had 
an approximate temperature range of 4° C. Color changes in the membrane were 
correlated with temperatures by color calibration scales on each membrane 
(approximately 0.8° C change per color). Membranes were held against the dorsal 
surface of the carpus for 60 seconds, withdrawn and immediately photographed 
(Polaroid auto-focus single lens camera with Polaroid instant film (779, ASA 640), 
Polaroid Corp., Cambridge, MA). Room temperature in the laboratory was
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maintained between 23 and 26° C. Isothermic areas on the photographic images were 
calculated using a digitizing tablet and computerized area integration program 
(SigmaScan, Jandel Corp., San Rafael, CA). Each isothermic area was expressed as 
a percent of the total photographed area and the overall temperature of the joint was 
calculated. For each horse, post-injection data were expressed as a percent change 
from baseline in order to minimize variance between horses in basal joint 
temperatures.
4. Synovial fluid analysis
a. Clinical pathology 
Fluid was kept at 4° C and warmed to room temperature (20-22° C) before 
analysis. Fluid was analyzed for cellularity, protein and quality of hyaluronic acid. 
The total number of nucleated cells (neutrophils, large mononuclear cells, 
lymphocytes, eosinophils and basophils) and red blood cells per y\ were determined 
by a multispecies automated hematology analyzer (Baker 9000, Baker Instrument Co., 
Allentown, PA). Samples with total nucleated cell counts of less than 500 cells//d 
were reanalyzed by the direct hemocytometer method [382]. The overall quality of 
the hyaluronic acid in the synovial fluid was determined by the mucinous precipitate 
quality test (MPQ). This serves as a reliable qualitative measure of the concentration 
and polymerization of synovial fluid hyaluronic acid [376]. Synovial fluid (0.5 ml) 
was added to 5 ml of 5% acetic acid and mixed thoroughly. The resultant precipitate 
was subjectively graded as: 1) good- tight ropy mass in clear solution; 2) fair- soft 
mass with some shreds; or 3) poor- shredded, small, soft masses in a turbid solution
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[75]. Synovial fluid protein concentration was analyzed after centrifugation 
(Hemofuge™, American Scientific, manufactured by Heraeus-Christ, Osterod, West 
Germany) at 12,000 rpm for 4 minutes and was determined by a hand held 
refractometer (TS Meter, American Optical, Keene, NH). Values below 2.5 g/dl 
were not determined. These determinations were performed by the Louisiana State 
University, School of Veterinary Medicine, Clinical Pathology Laboratory.
Differential leukocyte counts were made from direct and concentrated synovial 
fluid smears. For samples with total nucleated cell counts less than 7,500 cells/^1, 
5 drops of synovial fluid were concentrated on a glass slide by centrifugation at 1,000 
rpm for 6 minutes (Cytospin 2, Shandon Southern Products, Astmoor Runcorn, 
Chesire, England). Samples with elevated nucleated cell counts (>7,500 cells/jd) 
were examined directly on glass slide smears. Slides were air dried and stained with 
modified Wright’s stain (Hema-Tek™, Miles Laboratory, Inc., Elkhart, IN) using an 
automatic stainer (Hema-Tek™ slide stainer, model 4480, Ames Co.; Miles 
Laboratory, Inc., Elkhart, IN). A standard light microscope with 10X, 40X and 100X 
oil immersion objective lenses was used for all synovial fluid cell counts (Ernst Leitz 
Wetzlar, Germany). Slides were examined for neutrophils, lymphocytes, large 
mononuclear cells (monocytes and macrophages [382]), eosinophils and basophils. 
100 cells were counted for every 30,000 nucleated cells//d.
b. Bacterial culture 
Synovial fluid remaining in the collecting syringe after aliquoting for the other 
assays was diluted with sterile 0.9% saline and cultured in duplicate on blood agar
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plates and in thioglycollate broth tubes. Cultures were incubated at 37° C for 3 days 
and were examined visually for bacterial or fungal growth every 24 hours.
c. Eicosanoid determination
i. Extraction
Synovial fluid (0.5 ml) was extracted before LTB4 determination by ELISA. 
In order to stay within the range of ELISA quantitation for PGE2 (10-5000 pg/ml), 
synovial fluid volumes of 0.25, 0.125, 0.0625 or 0.01 ml were extracted depending 
on the anticipated concentration of PGE^ Further, synovial fluid obtained from some 
horses at times 6, 9 and 12 hours was diluted with water acidified to pH 3 with 1 N 
HC1 (1:10 and 1:100) and the diluted sample was then extracted. Sep-Pak Plus™ 
cartridges containing 360 mg of Clg (Millipore Corporation, Milford, MA) were 
washed and cleaned according to methods described in Chapter 3. The synovial fluid 
was acidified to pH 3.5 using 1 N HC1 in a polypropylene centrifuge tube. One-half 
ml of pH 3 water was added and the sample was vortexed for 15 seconds before being 
transferred to the cartridge reservoir. The sample was allowed to flow through the 
cartridge slowly under slight vacuum pressure (< 5  inches of mercury). After the 
sample was evacuated, 6 ml of pH 3 water was added under vacuum followed by 6 
ml of hexane. The eicosanoids were eluted from the cartridge with 6 ml of ethyl 
acetate using gentle pressure applied with the syringe plunger. The ethyl acetate was 
then evaporated under a stream of nitrogen gas.
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ii. ELISA
Quantitation of plasma and synovial fluid eicosanoids was achieved by 
commercially available PGE2 and LTB4 ELISA kits (Advanced Magnetics, 
Cambridge, MA). These assays were based on the principle of a competitive ELISA 
where PGEz or LTB4 in the sample competed with fixed amounts of alkaline 
phosphatase labelled PGEj or LTB4 for binding to a limited number of sites on the 
specific rabbit antibody (anti-PGEj or LTB4) bound to the microtiter well. 
Absorbance (optical density) was read at 410 nm by a microtiter plate reader 
(Dynatech MR5Q00, Dynatech Laboratories, Alexandria, VA). Samples with the 
greatest color development or optical density values (ODs) contained the least PGEj 
or LTB4. Absorbance was correlated with concentration by means of a standard curve 
ranging from 10 to 5000 pg/ml. All sample concentrations were then corrected for 
extraction efficiency. For a complete description of the ELISA procedure, refer to 
Chapter 3.
5. Hematology
All blood samples were kept at 4° C then warmed to room temperature before 
analysis. Total leukocyte (WBC) and red blood cell (RBC) counts were determined 
by the hemocytometer method [383,384] using the Unopette™ micro-collection system 
(WBC- model 5853; RBC- model 5850, Becton, Dickinson and Company, 
Rutherford, NJ). Determination of whole blood packed cell volume (PCV%) was 
accomplished by centrifugation of glass capillary tubes at 11,700 to 13,700 rpm for 
5 minutes (Autocrit™ II, model 0574, Clay Adams; Becton, Dickinson and Company,
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Parsippany, NJ) [384]. Plasma obtained from the centrifuged capillary tubes was 
analyzed for protein (g/dl) by a hand held refractometer method (TS Meter, American 
Optical, Keene, NH). Plasma fibrinogen was determined by heating these centrifuged 
capillary tubes for 4 minutes at 56° C and then centrifuging again for 5 minutes [384]. 
Protein in the heated plasma was determined by the refractometer. Fibrinogen (g/dl) 
was calculated by subtracting the heated plasma protein concentration from the 
original plasma protein value and multiplying by 1,000. Blood smears were prepared 
on glass slides for differential leukocyte counts, air dried and stained with modified 
Wright’s stain (Hema-Tek™, Miles Laboratory, Inc., Elkhart, IN) using an automatic 
stainer (Hema-Tek™ slide stainer, model 4480, Ames Co.; Miles Laboratory, Inc., 
Elkhart, IN). Cells (100) were differentiated into neutrophils, lymphocytes, 
monocytes, eosinophils and basophils. Platelets were also enumerated from the 
stained blood smears. A standard light microscope with 10X, 40X and 100X oil 
immersion objective lenses was used for all hematological counts (Ernst Leitz, 
Wetzlar, Germany).
6. Study design and statistical analysis
Twenty-four horses received ketoprofen (2.2 mg/kg and 3.63 mg/kg), 
phenylbutazone (4.4 mg/kg) and saline intravenously according to a Latin Square 
design [385]. Each treatment was administered to 6 horses and each horse was used 
only once. Treatments assigned to horses were coded before the initiation of the 
study. All drug administrations, tests and analyses were performed by individuals
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unaware of the treatment code. The treatment code was broken at the end of the 
study.
All data except for eicosanoid concentrations were analyzed using one-way 
analysis of variance (ANOVA) for repeated measures [386,387]. When indicated by 
the ANOVA, multiple comparisons were performed using Tukey’s w procedure [388]. 
Differences between treatments at each time were considered significant when P <
0.05.
PGEj and LTB4 synovial concentration data were analyzed independently using 
an analysis of variance for a split plot design with repeated measures where treatment 
constituted the main plot and the time by treatment interaction was the subplot 
[386,389]. The paucity of synovial fluid available for eicosanoid assay at some time 
points resulted in missing data. This precluded the use of the ANOVA as this 
procedure excludes all the data from a particular horse if only one time point is 
missing. Instead, data were analyzed initially by a univariate approach for overall 
treatment, time, and time by treatment interaction effects. Where indicated by the 
univariate analysis, treatment means (averaged over time) were compared using 
Tukey’s w procedure. Eicosanoid concentrations (averaged over treatments) were 
compared at times 0, 1,3, 6, 9, 12, 24 and 48 hours by Tukey’s w procedure. Post 
treatment times that were found to have significantly (P < 0.05) different eicosanoid 
concentrations than baseline were analyzed for differences between individual 
treatments by pairwise Student’s t tests, using the least squares means procedure to 
adjust for missing data [388,386]. Differences between treatments at each time were
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considered significant when P < 0.05. Multiple comparisons of treatments were thus 
preplanned, i.e. performed only at times indicated by the Tukey’s w procedure, so as 
to not inflate the comparisonwise error rate [388].
C. Results
Before initiation of this project, a pilot study was performed on 2 horses in 
order to refine sampling techniques and assay procedures and to ensure that the 
synovitis was transient with no lasting articular damage. The experimental protocol 
was similar except that these 2 horses were not administered systemic NSAIDs at the 
time of carrageenan induction. The first horse was humanely euthanized for an 
unrelated hindlimb musculoskeletal disorder 72 hours after carrageenan induction. 
The articular cartilage of the intercarpal joint (third and intermediate carpal bones) of 
this horse was grossly and histologically normal. Upon gross examination, the 
synovium was slightly hyperemic and thickened. Histologically, the synovial 
membrane showed a minimal non-suppurative inflammatory response with hypertrophy 
and hyperplasia of the synovial cells resulting in increased folding of the synovial 
villi. Lameness subsided in both of these horses by 24 hours. Synovial fluid 
collected from the second horse 5 months after induction was determined to be normal 
upon clinical pathology analysis. Based on the pilot study results, it was determined 
that the synovitis was transient and many of the parameters returned to near baseline 
by 48 hours.
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Overall treatment effects for all parameters tested in the 24 carrageenan treated 
horses are listed in Table 12. For the clinical parameters, there was a significant 
difference among treatments for synovial fluid volume, lameness grade, carpal 
effusion grade and carpal thermography. For the synovial fluid clinical pathology 
parameters, significant treatment effects were observed for protein and PGEj 
concentrations. For the hematological parameters, only the number of eosinophils and 
basophils showed a significant treatment effect.
1. Synovial fluid volume and appearance
The volume (mean + standard error (SEM)) of synovial fluid in 24 horses 
obtained from the left intercarpal joint at baseline was 4.54 ml ±  0.24. The volume 
of synovial fluid increased over time in all horses after induction. However, 
phenylbutazone significantly reduced the volume of synovial fluid as compared to 
saline at 1, 9 and 12 hours after administration (Figure 11A). Further, 
phenylbutazone significantly reduced the synovial fluid volume as compared both to 
doses of ketoprofen at 9 and 12 hours. The remaining treatments failed to affect 
synovial fluid volume significantly.
No significant treatment effects for subjective grade of hemorrhage were 
obtained. However the mean hemorrhage grade for all horses increased over time 
with a peak at 12 hours. When data were averaged over all horses, the hemorrhage 
grade ranged from 0.83 ± 0.19 at baseline to 3.29 ±  0.19 at 12 hours post-induction 
(Table 13). Synovial fluid samples often contained visible amounts of yellowish 
fibrin. This was removed from the sample before analysis. A few samples with
Table 12: Statistical analysis of overall treatment effects.











0.7151 RBC/jtl 0.4862 RBC/jtl 0.7829
LAMENESS GRADE 0.0015* MPQ grade 0.1296 PCV (%) 0.7261
MAX. FLEXION ANGLE (°) 0.1601 PROTEIN (g/dl) 0.0064* PROTEIN (g/dl) 0.8187
JOINT CIRCUMFER. (cm) 0.3469 NEUTROPHILS 0.8492 FIBRINOGEN (g/dl) 0.8644
CARPAL EFFUSION GRADE 0.0432* MONO. CELLS/M 0.3681 NEUTROPHBLS/mI 0.4993
RECTAL TEMP. (°C) 0.1848 LYMPHOCYTES/pl 0.8936 MONOCYTES//tl 0.4000
HEART RATE (bpm) 0.3653 EQSINOPHILS/fd 0.2448 LYMPHOCYTES//1I 0.4235
RESPIRATORY RATE (bpm) 0.9279 BASOPHILS/^! 0.2670 EOSINOPHILS//*! 0.0047*
CARPAL THERMOGRAPHY
(°C)
0.0072* PGEz (pg/ml) 0.0056* BASOPHELS/mI 0.0375*
ROOM TEMP. (°C) 0.7151 LTB4 (pg/ml) 0.0603 PLATELETS/jtl 0.8886
P = Probability estimate obtained from analysis of variance, treatments include phenylbutazone (4.4 mg/kg), 
ketoprofen (3.63 mg/kg), ketoprofen (2.2 mg/kg) and saline.
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Figure 11: Effect of NSAIDs and saline on (A) lameness grade and (B) volume of synovial fluid obtained at each
arthrocentesis. Statistically significant treatment means as compared to saline are indicated by (*). Carrageenan
and NSAIDs were administered at time 0 (n=6).
Table 13: Means* (±  SEM) of non-significant clinical parameters.
TIME
0 1 3 6 9 12 24 48
HEMORRHAGE 0.83 2.17 2.54 2.63 2.75 3.29 3.09 2.57
GRADE ±0.19 ±0.25 ±0.26 ±0.27 ±0.26 ±0.19 ±0.23 ±0.25
MAX. FLEXION 21.08 22.94 26.13 28.63 27.58 30.21 27.22 24.00
ANGLE (°) ± 1.01 ±0.92 ±1.34 ±1.55 ±1.41 ±2.26 ±1.80 ± 1.01
JOINT 28.72 28.81 28.85 29.24 29.41 29.55 29.47 29.37
CIRCUMFERENCE
(cm)
±0.25 ±0.27 ±0.26 ±0.27 ±0.27 ±0.27 ±0.32 ±0.31
RECTAL 37.85 37.81 37.70 37.90 38.18 38.30 37.98 37.80
TEMPERATURE (°C) ±0.06 ±0.07 ±0.07 ±0.09 ±0.07 ±0.08 ±0.08 ±0.07
HEART RATE (bpm) 29.29 29.67 28.75 30.42 30.63 31.71 29.83 28.87
±0.70 ±0.76 ±0.71 ±0.75 ±0.61 ±0.71 ±0.74 ±0.75
RESPIRATORY RATE 10.79 8.29 8.50 10.96 11.17 13.54 11.83 9.48
(bpm) ±0.57 ±0.40 ±0.40 ±1.05 ±0.85 ±1.56 ±1.35 ±0.70
*Since there were no significant treatment effects for the above parameters, values reported above represent 
averages over 24 horses.
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hemorrhage grades of 4 contained evidence of coagulation. These clots would often 
dissolve upon gentle inversion of the EDTA tube.
2. Lameness grade
All horses but five (3 with phenylbutazone, 4.4 mg/kg; 1 with ketoprofen, 2.2 
mg/kg; and 1 with ketoprofen, 3.63 mg/kg) became lame after carrageenan 
administration. The remaining horses returned to soundness by 48 hours after 
induction (Figure 11B). Ketoprofen (3.63 mg/kg) significantly reduced the lameness 
score as compared to saline at 3 hours post dose. Ketoprofen (2.2 mg/kg) similarly 
reduced lameness at 3 hours and at 6 hours. Phenylbutazone (4.4 mg/kg) reduced the 
lameness score as compared to saline at 6, 9 and 12 hours after administration. 
Further, phenylbutazone significantly reduced lameness as compared to both doses of 
ketoprofen at 12 hours post dose.
3. Maximum flexion angle
There were no significant treatment effects for the maximum flexion angle as 
determined by radiography of the carpus held in rigid flexion by the examiner. 
However, the flexion angle increased over time with a peak at 12 hours. When data 
were averaged over all treatments, the maximum flexion angle ranged from 21.08° 
±  1.10 at baseline to 30.21° ±  2.26 at 12 hours after induction (Table 13).
4. Joint circumference and effusion grade
There were no significant treatment effects for the circumference of the 
intercarpal joint (Figure 12A). The mean circumference ranged from 28.72 cm ± 
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TIME (Hours) TIME (Hours)
□ KETOPROFEN 3.63 m g /k g  
■ KETOPROFEN 2.20 m g /k g
a  PHENYLBUTAZONE 4.40 m g / k g  
a SALINE
Figure 12: Effect of NSAIDs and saline on (A) intercarpal joint circumference and (B) carpal effusion grade.
Statistically significant treatment means as compared to saline are indicated by (*). There were no significant
treatment effects on joint circumference. Carrageenan and NSAIDs were administered at time 0 (n=6).
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Both doses of ketoprofen reduced the subjective grade of joint effusion at 3 
hours as compared to saline. The high dose of ketoprofen also reduced joint effusion 
at 6 hours as compared to saline (Figure 12B). There were no significant effects 
associated with phenylbutazone administration.
5. Temperature, heart and respiratory rates
There were no significant treatment effects for rectal temperature, heart rate 
or respiratory rate (Table 13). Rectal temperature ranged from 37.85° C ±  0.06 at 
baseline to 38.30° C ±  0.08 at 12 hours. Heart rate ranged from 29.29 bpm ±  0.70 
to 31.71 bpm + 0.71 at 12 hours. Respiratory rate ranged from 10.79 bpm + 0.57 
at baseline to 13.54 bpm ± 1.56 at 12 hours.
6. Carpal thermography
Joint temperature increased over time in the saline treated animals with a peak 
at 9 to 12 hours. Phenylbutazone significantly reduced the overall joint temperature 
as compared to saline from 3 to 48 hours after administration (Figure 13A). 
Phenylbutazone also significantly reduced joint temperatures as compared to 
ketoprofen (3.63 mg/kg) at 3 hours and ketoprofen (2.2 mg/kg) from 6 to 24 hours. 
A graph of room temperature is included for comparison in Figure 13B. Room 
temperature was constant over time and there were no significant treatment effects.
7. Synovial fluid clinical pathology
There were no significant treatment effects for total number of nucleated cells 
per ix 1, red blood cells per /*1, MPQ grade and the number of neutrophils, large 
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a SALINE
Figure 13: Effect of NSAIDs and saline on (A) joint temperature as expressed as % change from baseline. The 
graph of room temperature (B) indicates corresponding ambient temperature changes over time. Statistically 
significant treatment means as compared to saline are indicated by (*). There were no significant treatments 
effects of room temperature. Carrageenan and NSAIDs were administered at time 0 (n=6).
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*Since there were no significant treatment effects for the above parameters, values reported above represent averages 
over 24 horses.
there were no significant treatment effects when the differential cell counts were 
expressed as a percent of the total nucleated cell count. There was a significant 
treatment effect on protein concentrations (g/dl). The phenylbutazone-treated horses 
had significantly increased synovial fluid protein concentrations at 12, 24 and 48 hours 
as compared to saline. At 24 hours, phenylbutazone increased the protein 
concentration as compared to both doses of ketoprofen (Figure 14A). The mean 
synovial fluid protein concentrations at baseline were 2.51 g/dl ±  0.01. The peak 
levels occurred at 9 hours for all treatments except phenylbutazone which peaked at 
24 hours. Synovial protein in normal horses as determined by the refractometer 
method is generally reported to be low (less than 2.5 g/dl) [75] as synovial fluid is 
considered a dialysate of blood plasma with hyaluronic acid [74].
The mean number of nucleated cells per /xl of synovial fluid ranged from 0.40 
±  0.08 x 103 at baseline to 155.59 ±  8.64 x 103 at 9 hours (Table 14). Horses 
administered saline had peak levels occurring at 6 hours 202.13 ±  15.22 x 103 while 
the NSAID treated horses tended to have peak levels at 9 hours (Figure 14B). 
Normal levels for the horse are generally reported to be less than 500 cells//fi [382]. 
The cells were predominantly neutrophils from 1 hour to 48 hours with an increasing 
percentage of large mononuclear cells at 24 and 48 hours. There was also an increase 
in the number of red blood cells in the synovial fluid with peak in cell numbers at 3 
hours (Table 14). There was considerable variation in the number of red cells in 
synovial fluid at all time points. The was a moderate decrease in the MPQ grade after 
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Figure 14: Effect of NSAIDs and saline on (A) synovial fluid protein concentration and (B) nucleated cells.
Statistically significant treatment means as compared to saline are indicated by (*). There were no significant
treatment effects on the number of nucleated cells. Carrageenan and NSAIDs were administered at time 0 (n=6).
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mean MPQ grade ranged from 1.17 ± 0.08 at baseline to 2.63 ±  0.13 and 2.63 ± 
0.14 at 6 and 12 hours, respectively (Table 14).
Microscopic examination of synovial fluid smears often revealed protein 
folding and degenerating or dead cells in varying stages of cellular breakdown from 
3 through 24 hours after induction. Vacuolation of large mononuclear cells and 
neutrophils was often seen from 6 to 12 hours. Occasionally, clumps of platelets and 
synovial lining cells were noted.
8. Bacterial cultures
Examination of blood agar plates and thioglycollate broth tubes revealed no 
bacterial growth in any of the carrageenan cultures. Broth tubes and agar plates of 
a few synovial fluid samples contained evidence of bacterial or fungal growth. 
However, the growth was not consistent between duplicates or subsequent samples. 
Based on these inconsistencies and the clinical signs of the horses, these samples were 
most likely contaminated with non-pathogenic flora from the air or person performing 
the microbial culture.
9. Synovial fluid eicosanoid concentrations
The mean baseline concentration of PGEj was 0.42 ng/ml + 0.07 (Figure 
15A). The concentrations of PGEj increased dramatically over time with peak levels 
occurring at 9 hours (79.19 ng/ml ±  33.83) in horses administered saline. For all 
horses, concentrations returned to near baseline levels by 48 hours. There was a 
significant overall treatment effect for PGEz when data was analyzed over all sampling 
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Figure 15: Effect of NSAIDs and saline on synovial fluid (A) PGE2 and (B) LTB4 concentrations. Statistically
significant treatment means as compared to saline are indicated by (*). There were no significant treatment
effects (P = 0.0603) on LTB4 concentration. Carrageenan and NSAIDs were administered at time 0 (n=6). u>
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comparison procedure indicated that ketoprofen (2.2 mg/kg) and phenylbutazone 
reduced the PGE2 concentrations as compared to saline. Tukey’s procedure was then 
used to compare eicosanoid concentrations (averaged over treatments) at each post­
dose time to baseline, in order to determine when the concentrations were different 
from baseline. The results indicated that means for time 6 , 9 and 12 hours were 
significantly different from baseline means. Based on the significant time effect, 
individual treatment means at 6, 9 and 12 hours were compared using the Student’s 
t tests. At 6 hours, phenylbutazone and ketoprofen (2.2 mg/kg) significantly reduced 
the PGEj concentrations as compared to saline. At 9 hours post administration, both 
doses of ketoprofen and phenylbutazone reduced PGEj as compared to saline. At 12 
hours after administration, only phenylbutazone reduced levels when compared to 
saline. Ketoprofen (3.63 mg/kg) produced PGE2 concentrations significantly greater 
than phenylbutazone and ketoprofen (2.2 mg/kg) at 6 and 9 hours.
LTB4 concentrations were associated with no significant (P = 0.0603) overall 
treatment effects (Figure 15B). The mean baseline concentration was 0.04 pg/ml ±  
0.01. Levels peaked at 3 hours post-dose (1.26 pg/ml +  0.37) and returned to near 
baseline values by 9 hours.
10. Hematology
No treatment effects were obtained for WBC count, RBC count, plasma protein 
(g/dl), fibrinogen (g/dl), PCV (%) or platelet count (Table 15). However there was 
a significant treatment effect for the number of eosinophils and basophils per /il 
(Figure 16A and B). At 1 hour post-dose, eosinophils in phenylbutazone treated
Table 15: Means* (±  SEM) of non-significant hematological parameters.
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Figure 16: Effect of NSAIDs and saline on the number of blood (A) eosinophils and (B) basophils. Statistically
significant treatment means as compared to saline are indicated by (*). Carrageenan and NSAIDs were
administered at time 0 (n=6).
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horses were greater than saline and both doses of ketoprofen. At 6 hours, 
phenylbutazone treated horses had higher eosinophil counts than ketoprofen (2.2 
mg/kg) and saline. At 9 and 12 hours, phenylbutazone also was associated with 
higher numbers of eosinophils than saline. At 12 hours, basophils in horses 
administered phenylbutazone were higher than both doses of ketoprofen and saline. 
However, the eosinophil and basophil numbers were not outside of the normal ranges 
(eosinophils- 0.0-0.8 x 103 cells//xl; basophils- 0.0-0.3 x 103 c e l l s / [390]. Mean 
peripheral blood WBC counts were within normal ranges except at 12 hours when the 
mean count rose to 12.58 x 10’ cells//xl + 0.56 (normal range for the horse is 6-12 
x 10’ cells//xl [390]). This leukocytosis was due to a mature neutrophilia in most 
horses. The mean neutrophil count at this time was 8.44 x 103 + 0.43 cells/^1 
(normal range for the horse is 3-6 x 103 cells//xl [390]). Further, although the total 
WBC counts were not increased, many horses were neutrophilic at 3, 6, 9 and 24 
hours after induction. No other hematologic abnormalities were noted.
D. Discussion
Carrageenan-induced synovitis has been used previously in the horse to isolate 
leukocytes from an inflammatory exudate, but the clinical effects and eicosanoid 
concentrations in synovial fluid were not described [52]. A pilot study was performed 
initially to determine the clinical effects of intra-articular carrageenan and to refine 
methodology. The pilot study showed that the carrageenan-induced synovitis produced 
no articular damage 72 hours after administration, although there was still evidence
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of synovial inflammation. No synovial fluid abnormalities were noted 5 months after 
induction. Horses with carrageenan synovitis (n=24) appeared clinically normal 
within 2 weeks following induction with no lameness, heat, effusion or palpable 
thickening of the joint capsule or synovial membrane. These results indicate that the 
horses experienced a transient synovitis that resulted in no obvious lasting damage to 
the joint. Thus our initial objective of inducing self-limiting inflammation was 
achieved.
The volume of synovial fluid obtained from the left intercarpal joint and the 
size of these joints (effusion grade and joint circumference) rose dramatically after 
induction of synovitis. Phenylbutazone reduced the synovial fluid volume at the time 
of peak inflammation (9-12 hours) to a greater extent than either dose of ketoprofen. 
However, phenylbutazone did not reduce the subjective grade of effusion while both 
doses of ketoprofen produced significant reduction at 3 hours and there was no 
significant treatment effect on joint circumference. These parameters all measure joint 
distension, but they have subtle qualitative differences which may account for the 
discrepancies in treatment effects. An increase in effusion grade accounted for 
increases in subcutaneous and periarticular edema as well as synovial fluid distension, 
whereas the volume of synovial fluid reflected the amount of synovial fluid obtained 
from the intercarpal joint only. The circumference of the intercarpal joint appeared 
to be a less sensitive estimate of joint distension than the effusion grade and synovial 
fluid volume, due to presence of bony protuberances on the equine carpus. The
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swelling and effusion associated with synovitis in the early stages of development 
often occurred between these prominences and thus were not directly measurable.
Carrageenan-induced synovitis produced a variable degree of lameness: 5 
horses out of 24 did not show lameness at any time post-induction and while a few 
horses became markedly lame, others were only slightly effected. Despite this 
variability, there were significant treatment effects. Phenylbutazone more effectively 
relieved lameness than either dose of ketoprofen. There appeared to be no clear 
ketoprofen dose related effect, as the high dose (phenylbutazone molar equivalent 
dose) of ketoprofen had a short lived effect at 3 hours and the therapeutic dose 
reduced lameness from 3 to 6 hours.
Phenylbutazone reduced the overall temperature of the joint in the early stages 
of the inflammatory process with effects lasting to 48 hours after administration. This 
effect was greater than the therapeutic dose ketoprofen for most of the times tested. 
As the surface temperature of the joint is related to blood flow to the region, these 
results may indirectly reflect that phenylbutazone inhibits carrageenan-induced 
vasodilation over an extended period. A similar time course has been observed 
previously for phenylbutazone in a carrageenan-induced subcutaneous inflammation 
model [325].
The number of nucleated cells in synovial fluid rose dramatically with peak 
levels occurring at 6 to 9 hours. This primarily neutrophilic exudate was likely 
attributable to the increase in the synovial fluid concentration of the potent chemotactic 
agent, LTB4 [27,28]. In addition, PGEj has been shown to be chemotactic for equine
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neutrophils and both of these eicosanoids play a significant role in the recruitment of 
neutrophils to the site of inflammation [20]. These results are similar to leukocyte 
numbers from tissue cage studies with carrageenan. However, the number of cells 
obtained from joint fluid were an order of magnitude higher than the tissue cage [67]. 
Cellular migration was likely impeded in the tissue cage model as compared to the 
synovitis model by the presence of fibrous tissue around and within the polypropylene 
device. Synovitis accompanying clinical cases of degenerative joint disease in the 
horse results in nucleated cell counts of up to 10,000 cells//xl [75]. Nucleated cell 
counts in excess of 50,000 cells//w.l with a predominance of neutrophils in clinical 
equine cases usually indicates septic arthritis [75,94]. Based on the cell count, protein 
concentration and the MPQ grade, this model of experimentally-induced synovitis 
appeared to be quite similar to clinical cases of equine joint infection [114].
There were no significant treatment effects associated with the number of 
nucleated cells in the inflamed synovial fluid or any of the other clinical pathology 
parameters except for protein concentration. The effects of NSAIDs on leukocyte 
numbers in inflammatory exudate are contradictory and have not been correlated with 
cyclooxygenase inhibition [15]. Ketoprofen when administered within the therapeutic 
dose range has been shown to reduce leukocyte counts in other carrageenan-induced 
inflammation models [15,299]. Phenylbutazone (4.4 mg/kg) did not affect leukocyte 
numbers in an equine model of subcutaneous inflammation as compared to control 
[323], while low doses of phenylbutazone and other NSAIDs stimulated leukocyte 
migration [50]. Phenylbutazone increased the synovial fluid protein concentration in
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the late stages of the inflammatory process. This unexpected effect is likely due to 
the significant reduction in synovial fluid volume associated with phenylbutazone 
treatment.
Erythrocytes are not usually found in normal synovial fluid unless 
contamination occurred during arthrocentesis (iatrogenic hemorrhage) [376]. 
However, hyperemia of the synovial membrane during synovitis greatly increases the 
potential for hemorrhage into the joint [75]. Further, joints in this study were 
aspirated 8 times over a 48 hour period which increased the likelihood of hemorrhage 
into the joint cavity. The iatrogenic hemorrhage in these joints most likely contributed 
to the total nucleated cell counts [382]. The eosinophils and basophils noted in the 
synovial fluid are likely the result of intra-articular hemorrhage as eosinophils are rare 
constituents of synovial fluid and basophils have not been reported to be present in 
non-hemorrhagic synovial fluid [376]. In addition, blood contamination of synovial 
fluid could have contributed to eicosanoid production (refer to data described in 
Chapter 6). However, this probably had little impact on the treatment effects of these 
parameters as the grade of hemorrhage was not significantly different among 
treatments.
There was no bacterial growth in the carrageenan cultures and synovial fluid 
cultures. Joint infection in these horses cannot be ruled out definitively as it is not 
uncommon for synovial fluid from infected joints to culture negatively [75]. 
However, the rapid reversal of lameness and the decrease in the number of synovial 
fluid nucleated cells over time in all horses would indicate non-septic synovitis.
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There was a dramatic increase in PGEj concentrations in the synovial fluid 
after carrageenan administration. The peak concentration in horses administered 
saline was approximately 200 times the baseline level at 9 hours. The LTB4 
concentrations also increased markedly in all horses. Peak levels were 14 times over 
baseline concentrations at 3 hours in horses administered saline. The peak levels of 
PGEj and LTB4 in control animals were similar to those found in subcutaneous 
models of carrageenan-induced inflammation [69-72]. The LTB4 levels were in the 
range of reported concentrations from carrageenan-induced arthritis in dogs [123] and 
clinical osteoarthritis in man [136]. However, the PGE2 levels were generally higher 
in this study than those reported in polycation-induced arthritis [118] and clinical joint 
diseases in man [143] and the horse [134]. PGEj levels from carrageenan models are 
apparently higher than those in other forms of inflammation. In vitro research on 
cells from humans with rheumatoid arthritis indicates that activated synovial lining 
cells produce PGEj whereas LTB4 originates mainly from synovial fluid neutrophils 
[142], although monocytes from patients with rheumatoid arthritis have also been 
shown to produce large amounts of LTB4 [139]. In the horse, chondrocytes and 
synovial cells secrete PGEj with very little contribution from PGE, [391]. Studies in 
other inflammatory exudates have also shown that the primary arachidonic acid 
products of neutrophils are leukotrienes [7,392].
There was considerable variability in the magnitude in the peak eicosanoid 
levels after carrageenan administration in these horses. Despite the variability among 
and within horses, there were significant treatment effects at 6 , 9 and 12 hours for
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PGE2, but not for LTB4. Phenylbutazone apparently inhibited cyclooxygenase activity 
longer than ketoprofen in this model of acute inflammation. Studies have indicated 
that phenylbutazone is more potent in producing cyclooxygenase inhibition and 
reducing carrageenan-induced edema than ketoprofen [8,64], In contrast, others have 
shown that ketoprofen is more potent in producing cyclooxygenase inhibition [290], 
and in carrageenan-induced inflammatory models [44,63] and pain models [44], In 
this study, the therapeutic dose of ketoprofen reduced PGE2 concentrations longer than 
the high dose. This lack of a dose-response effect with ketoprofen may in part be due 
to the small difference between the two doses chosen coupled with the large degree 
of variability associated with PGE2 concentrations. Unexpectedly, at 6 and 9 hours 
the 3.63 mg/kg dose of ketoprofen resulted in higher PGE2 concentrations than the 
therapeutic dose. Perhaps the high dose of ketoprofen decreases prostaglandin 
degradation thereby resulting in apparent potentiation of prostaglandin formation. 
Several NSAIDs inhibit the 15-hydroxy prostanoate dehydrogenase enzyme that 
oxidizes and inactivates PGE^ and PGF2o, at concentrations that are generally higher 
than for cyclooxygenase inhibition [393,394]. Perhaps the high dose, but not the 
therapeutic dose of ketoprofen has activity against this degradative enzyme in the joint 
thereby leading to a net increase in the concentration of PGEj in the synovial fluid.
There were no significant treatment effects on synovial fluid LTB4 
concentrations for ketoprofen or phenylbutazone. Previous studies have indicated that 
ketoprofen inhibits rabbit neutrophil [250,293] and human lung [292] lipoxygenase 
activity, while others have found no effect [290,293]. Lipoxygenase inhibition data
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varies considerably depending on the source of the enzyme and the species tested 
[293,295], Although not significant, most NSAIDs appeared to increase the LTB4 
concentrations as compared to saline at 3 hours. Phenylbutazone appeared to have the 
greatest potentiation followed by the high dose of ketoprofen. This effect has been 
reported previously for diclofenac, ketoprofen and aspirin in the guinea pig [293] and 
for indomethacin, ibuprofen and aspirin in man [392] and has been attributed to a 
diversion of arachidonic acid substrate after cyclooxygenase inhibition to the 
lipoxygenase pathway. The apparent of 5-lipoxygenase for arachidonic acid is 
comparable to that of cyclooxygenase. Since most cells with 5-lipoxygenase activity 
also contain cyclooxygenase, it is thought that the activated enzymes compete for 
arachidonic acid substrate in the same cell types [10].
Many horses were neutrophilic from 3 to 24 hours with a slight leukocytosis 
occurring at 12 hours. This effect most likely represented a mobilization of mature 
neutrophils from the marginal blood pool and the bone marrow maturation pool in 
response to the synovitis [395]. The reason for the effect of phenylbutazone on blood 
eosinophil and basophil numbers is unclear. However, the mean eosinophil and 
basophil numbers per for horses treated with phenylbutazone were within normal 
clinical limits. This effect is most likely artifactual as there are no reports of 
phenylbutazone increasing these white cells. On the contrary, toxic doses of 
phenylbutazone produce leukopenia in the horse [396,397].
Phenylbutazone was more effective than ketoprofen in alleviating many of the 
signs of pain and inflammation in this model of synovitis. These results are consistent
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to those obtained in models of carrageenan-induced subcutaneous inflammation where 
peak reduction in PGE^ exudate levels occurred at 6 hours [323]. High doses of 
phenylbutazone in the dog have been effective in both preventing and suppressing the 
inflammatory response from urate-induced joint inflammation [101]. Ketoprofen was 
effective in alleviating inflammation in this model, but did not result in inhibition of 
the leukotriene pathway as determined by the measurement of LTB4 in the synovial 
fluid.
CHAPTER 5
PHARMACOKINETICS AND SYNOVIAL FLUID LEVELS OF 
KETOPROFEN IN NORMAL HORSES AND HORSES 
WITH ACUTE SYNOVITIS
A. Introduction
Ketoprofen or (±)-2(3-benzoylphenyl)propionic acid is a nonsteroidal anti­
inflammatory drug (NSAID) of the propionic acid family that includes ibuprofen, 
naproxen, benoxaprofen, fenoprofen and carprofen. This agent has been used in 
human medicine in the treatment of arthritis and mild-to-moderate pain since its 
introduction in France in 1973. Ketoprofen, at an intravenous dose of 2.2 mg/kg, was 
approved by the United States Food and Drug Administration for alleviation of 
musculoskeletal pain and inflammation in the horse in 1990.
The plasma or serum pharmacokinetics of ketoprofen has been studied in 
humans [282,398], rabbits [287], rats [289], dogs [399], and horses [283,286]. 
Synovial fluid levels of ketoprofen have been measured in humans with various forms 
of arthritis [280,297,400,401]. Peak synovial fluid concentrations of total (plasma 
protein bound and free) ketoprofen in humans with arthritis are lower and occur later 
than do peak plasma concentrations [280]. However, the peak synovial fluid 




Water and small solutes, including most NSAIDs, cross the synovial membrane 
from plasma principally by diffusion through the intercellular, interstitial matrix of the 
synovium. This diffusion by small molecules is considered bi-directional [402]. 
Compounds that are lipid soluble may also cross the membrane through transcellular 
diffusion [402]. The extravascular pharmacokinetics of a particular drug depend on 
the agent’s molecular weight, lipid solubility, protein binding, plasma half-life and 
pKa. For example, ketoprofen (C16H140 3, molecular weight 254.29) has an octanol- 
buffer partition coefficient at pH 7.4 of approximately 1 with a pKa of 5.02 and a high 
percentage of plasma protein binding [399]. However, this pKa results in ionization 
of ketoprofen at a physiological pH. In contrast to ketoprofen, phenylbutazone 
(C19H20N2O2, molecular weight 308.37) has a similar pKa (4.8) and degree of protein 
binding, but is much more lipid soluble with an octanol-buffer partition coefficient of 
5.01 at a neutral pH and would be expected to cross biological membrane to a greater 
extent than ketoprofen [162].
Evidence indicates that synovial NSAID concentrations are higher in patients 
with joint inflammation than those in normal joints [403]. This is due to the increase 
in vascular permeability and blood flow, loss of endothelial integrity and hemorrhage 
that allows for the exudation of plasma proteins with the bound drug. Normally, 
only the free drug is able to diffuse freely between plasma and synovial fluid, but 
with inflammation, bound drug may enter into the synovial fluid [402]. In contrast 
to small molecules, plasma protein diffusion into the synovial fluid is a one-way 
transport mechanism [258]. Plasma protein concentrations in synovial fluid are
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normally low, but the permeability increases with joint inflammation [402,404], The 
increased protein concentration and drug receptor binding at the site of action may 
serve to increase the joint drug concentration of highly bound drugs [258,402],
The purpose of this study was to compare the pharmacokinetics of ketoprofen 
in healthy horses and those with experimentally-induced acute synovitis. More 
importantly, this study was designed to evaluate the concentration of ketoprofen at its 
site of action in animals with joint disease. Synovial fluid levels of ketoprofen in 
inflamed joints were compared to levels in normal joints in order to determine the 
effect of acute joint inflammation on the magnitude and duration of ketoprofen 
synovial fluid concentrations.
B. Materials and methods
1. Experimental animals
a. Normal horses
Three healthy geldings (2 American Quarter Horses and one Thoroughbred) 
and one Thoroughbred mare weighing from 406 to 554 kg and ranging from 5 to 12 
years of age were used. Horses were judged to be healthy and sound based on 
physical examination and lameness evaluation.
b. Horses with experimentally-induced synovitis
Four geldings (one American Quarter Horse and 3 Thoroughbreds) weighing 
from 437 to 509 kg and ranging from 8 to 12 years of age with carrageenan-induced 
synovitis of the left intercarpal joint were used. Prior to induction, horses were judged
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to be healthy and sound based on physical examination, lameness evaluation, synovial 
fluid analysis and radiographic examination of the left carpus.
All horses were vaccinated at least three weeks prior against eastern and 
western equine encephalomyelitis, influenza, tetanus (Equi-Flu EWT™, Coopers, 
Mundelein, IL) and rhinopneumonitis (Rhinomune™, SmithKline Beecham Animal 
Health, Exton, PA). The horses were dewormed with oxibendazole (Equipar™, 
Coopers, Mundelein, IL). Horses were housed in 10.9 x 12.5 feet stalls and were 
maintained on 5 pounds of a pelleted ration (Purina Horse Chow 100™, Purina Mills 
Inc., St. Louis, MO) containing: a minimum of 10% protein; 2% fat; a maximum of 
25 % fiber; and a vitamin/trace mineral supplement twice daily with mixed grass hay 
(11% protein, 1.4% fat, 24% fiber) and water provided ad libitum.
2. Drugs and reagents
a. Drug solution for administration
Ketoprofen (Ketofen™) was obtained commercially from Aveco Company, 
Inc., Fort Dodge, IA. Each ml of the sterile solution contained: 100 mg ketoprofen; 
L-arginine, 70 mg; citric acid to adjust pH to approximately 7; and benzyl alcohol, 
0.25 ml as a preservative.
b. Standard solutions
A stock solution of ketoprofen was prepared by dissolving 10 mg of the 
compound in 10 ml of methanol. The stock solution was serially diluted with 
methanol to produce working standard solutions of 100 /ig/ml, 10 /xg/ml, and 1 
(ig/ml. The working solution of fenoprofen was prepared by dissolving 10 mg of the
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compound in 10 ml of methanol. Ketoprofen and fenoprofen were obtained from 
Sigma Chemical Co., St. Louis, MO.
c. Solvents
Liquid chromatography grade solvents were obtained from commercial sources. 
Phosphate buffer (0.001M) for high performance liquid chromatography (HPLC) 
mobile phase was prepared by placing 68.027 p\ of o-phosphoric acid (44.6N) in 
triple distilled water sufficient to make 1 L total volume. The pH of this solution was 
adjusted to 7.4 with sodium hydroxide (2.157 ml of 1 N).
d. Water
Triple distilled, filtered water was prepared by passing through a Modulab™ 




Each horse was shaved over the entire carpal region 24 hours prior to drug 
administration. Indwelling catheters (14 gauge, 5.7 cm) (Quick-Cath™, Baxter 
Healthcare Corp., Deerfield, IL) were aseptically placed bilaterally in the jugular 
veins of each horse before each session.
b. Blood collection
Ketoprofen (2.2 mg/kg) as Ketofen™ and detomidine (Dormosedan™, Norden 
Laboratories, Lincoln, NE) were administered via the left jugular catheter. The right 
jugular catheter was used for blood collection before drug administration and at 3, 5,
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10, 15, 20, 30, and 45 minutes and at 1, 1.5, 2, 3, 4, 5, 6 , 9, 12, and 24 hours after 
drug injection for determination of plasma drug concentrations. The patency of each 
catheter was maintained after each blood collection with 3 ml of 100 lU/ml of 
heparinized saline. Before blood was collected, 2-3 ml was discarded to remove any 
residual heparin from the catheter. Blood (14 ml) was collected with a 18 gauge, 1.5 
inch needle and a 20 ml syringe and then placed immediately into 7 ml evacuated 
glass tubes containing 10.5 mg of ethylenediamine tetraacetate K3 (EDTA) as an 
anticoagulant (Vacutainer, Becton Dickinson, Rutherford, NJ). Tubes were 
immediately centrifuged at 2,000 rpm for 15 minutes (Dynac, Becton Dickenson and 
Company, Parsippany, NJ). Plasma was transferred into 15 ml polypropylene 
centrifuge tubes (Sarstedt, Newton, NC) and stored at -20° C until analyzed. 
Previous studies have shown that freezing does not affect ketoprofen concentrations 
in biological matrices [280,405].
c. Synovial fluid collection from normal horses 
Horses received detomidine HC1 intravenously (10 /xg/kg for the first dose and 
5.0 /xg/kg for subsequent doses) before each arthrocentesis as a sedative to reduce the 
risk of iatrogenic joint hemorrhage and trauma. In addition, all horses were nose 
twitched during arthrocentesis. Before each arthrocentesis the entire carpal area was 
scrubbed with Hibiclens™ (Stuart Pharmaceuticals, Wilmington, DE) and alcohol at 
least three times with a final scrub directly over the site for arthrocentesis. Sterile 
needles (20 gauge, 1 inch), syringes (12 ml or 20 ml) and gloves were used during 
each arthrocentesis. Synovial fluid was collected from the intercarpal joint before and
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at 1, 3, 6 , 9, 12, and 24 hours after drug administration for determination of 
ketoprofen. Synovial fluid (approximately 3.5 ml) was obtained altematingly from 
the left and right intercarpal joints due to the paucity of synovial fluid in these normal 
joints. Synovial fluid was placed into 2 ml evacuated glass tubes containing 3 mg of 
EDTA as an anticoagulant (Vacutainer, Becton Dickinson, Rutherford, NJ). The fluid 
was immediately centrifuged at 4° C and 2,500 rpm for 15 minutes (Eppendorf 
5415C, Brinkman Instruments, Westbury, NJ). The supernatant was stored in 1.5 ml 
polypropylene micro-centrifuge tubes (Dot Scientific, Inc., Flint, MI) at 20° C until 
analyzed.
d. Synovial fluid collection from horses with experimental synovitis
Arthrocentesis was accomplished as above except that acute inflammation was 
induced in the left intercarpal joints of these horses by the injection of 0.3 ml of 1 % 
solution of sterile carrageenan at the same time as ketoprofen administration (time 0). 
In these horses synovial fluid was obtained only from the inflamed left intercarpal 
joint at the times designated above. At each time point, the maximum volume of 
synovial fluid was withdrawn in order to reduce the degree of discomfort in the horse 
caused by joint effusion. The amount of synovial fluid withdrawn ranged from 2.5 
to 15 ml. Synovial fluid was processed as above.
4. Ketoprofen determination
The concentrations of ketoprofen in plasma and synovial fluid were determined 
by high performance liquid chromatograph (HPLC) analysis of ethyl acetate extracts
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of acidified samples. Fenoprofen was added to the samples before extraction as an 
internal standard.
Plasma and synovial fluid calibrators were prepared by adding ketoprofen and 
fenoprofen standard solutions to drug-free equine plasma and synovial fluid. For 
plasma, concentrations of 0.1, 0.5, 1, 10, and 40 fig of ketoprofen/ml of plasma were 
prepared. Ketoprofen was added to synovial fluid to make concentrations of 1, 0.5,
0.1, 0.05, and 0.025 fig/ml. These calibrators were prepared and analyzed daily in 
duplicate with each set of unknown samples.
a. Extraction
For plasma samples, 25 fil of 1000 /xg/ml fenoprofen was added to 500 fi\ of 
sample to achieve a final concentration of 50 fig/ml. For synovial fluid samples, 5 
fil of 1000 fig/ml of fenoprofen was added to 500 fil of sample to achieve a final 
concentration of 10 fig/ml. Plasma or synovial fluid samples were acidified with 0.5 
ml 1 N HC1 and 2.0 ml of ethyl acetate was added. Samples were vortexed for 30 
seconds, then centrifuged at 2,000 rpm for 15 min (Dynac, Becton Dickenson and 
Company, Parsippany, NJ). The ethyl acetate extraction was repeated. The upper 
organic layers were transferred to a separate tube and evaporated to dryness without 
heat under a flow of nitrogen. Samples were reconstituted in 250 fil of mobile phase 
solvent mixture, vortexed and filtered through a 0.45 fim teflon syringe filter (Poretics 




All analyses were performed using a Hewlett Packard 1090 high performance 
liquid chromatograph equipped with a variable volume auto-injector and a photodiode 
array detector set at 256 nm (10 nm bandwidth) with a reference spectrum of 550 nm 
(100 nm bandwidth). Instrument control, data acquisition, and peak integration were 
accomplished with Hewlett-Packard HPLC ChemStation software (Waldbronn, 
Germany). A 100 x 4.6 mm reversed phase column packed with 3 fim octadecylsilyl 
derivatized silica particles (Spherosorb™ ODS-2, 80 A pore) equipped with 10 x 4 
mm guard column (5 f i m ,  300 A pore) from Keystone Scientific (Bellefonte, PA) 
maintained at ambient temperature was used for all analyses.
The mobile phase consisted of 0.001 M phosphate buffer (pH 7.4) and 
acetonitrile delivered at a ratio of 85:15 or 82.45:17.55. The mobile phase was 
filtered through a 0.45 fim membrane filter (FP Vericel™, Gel man Sciences, Inc., 
Ann Arbor, MI) and degassed with helium immediately before use. A 10 fi\ aliquot 
of synovial fluid or plasma extract was injected at a rate of 833.3 /d/minute for 
analysis. The analyte and internal standard were eluted at a flow rate of 1 ml/minute 
The total run time was 8.5 minutes.
c. Linearity o f response
Plasma and synovial fluid concentrations were calculated by determining the 
peak height ratio of ketoprofen to the internal standard, fenoprofen for each incurred 
sample and calibrator. Five point calibration curves for ketoprofen in plasma and 
synovial fluid were prepared by plotting the peak height ratios against concentration
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using data derived from the average of duplicate injections. The slope, intercept and 
correlation coefficients for each of the calibration curves were determined before each 
analytical session.
d. Recovery
Relative recovery of ketoprofen from synovial fluid and plasma was evaluated 
by comparison of analyte peak heights of 5 injections of non-extracted standard 
solutions to peak heights of 5 extracted fortified samples. Percent recovery was 
determined for the lowest and highest concentrations of ketoprofen tested in synovial 
fluid and plasma.
e. Intra-assay variability
The within run precision was determined by replicate injections of the same 
sample run under identical conditions during the same analytical session. This was 
determined for fortified samples of the lowest and highest concentrations of ketoprofen 
tested in synovial fluid and plasma. The intra-assay variation of each concentration 
in each matrix was defined as the coefficient of variation of triplicate injections of the 
same sample run in duplicate so that n =6  per concentration. The coefficient of 
variation of each concentration was calculated from the mean and standard deviation 
of the peak height ratios.
f . Inter-assay variability
The between day precision was determined from samples of the same 
concentration extracted and analyzed under identical conditions during different 
analytical sessions. This was determined for fortified samples of the lowest and
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highest concentrations of ketoprofen tested in synovial fluid and plasma. The inter­
assay variability at each concentration in each matrix was defined as the coefficient 
of variation of 5 duplicate injections analyzed during 5 different analytical sessions. 
The overall inter-assay variation for each matrix was obtained from averaging the 
coefficient of variations from each concentration examined.
g. Plasma pharmacokinetic analysis 
The plasma ketoprofen concentration versus time data for each horse were 
analyzed by an automated curve-stripping procedure using the RSTRIP™ computer 
program (MicroMath Scientific Software, Salt Lake City, UT). This provided initial 
estimates of pharmacokinetic parameters and the best exponential disposition function 
to fit the data. These initial estimates were then used to generate a best fit by 
nonlinear least-squares regression analysis with equal weighting of the data using the 
MINSQ™ computer program (MicroMath Scientific Software, Salt Lake City, UT). 
Visual inspection of the fitted curves, examination of the plot of the residuals versus 
calculated concentration [406], and application of a modified Akaike’s information 
criterion [407] were used to determine the number of exponential terms required to 
describe the data. For the 2-compartment open model, the equation was:
Cp = A-e^1™' + B-e'BTimc 
where Cp is the plasma concentration, A = distribution phase intercept, a = 
distribution phase rate constant, B = elimination phase intercept, B = elimination 
phase rate constant. The MINSQ™ computer program calculated the following 
dependent variables: area under the plasma concentration versus time curve (calculated
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to infinity), AUC; the elimination rate from the central compartment, K̂ ,; the transfer 
rate from the first compartment to the second compartment, K12; the transfer rate from 
the second compartment to the first compartment, K21; the half-life of a , t,Aa; and the 
half-life of j8, tm . The following parameters were derived from standard kinetic 
formulas [408].
The total plasma clearance was calculated from:
CLx = Dose/ AUC 
where dose = dose of ketoprofen in fig/kg and AUC = A/a +  B/B.
The volume of the central compartment was calculated from the dose and the 
area under the curve:
Vc = Dose/AUC
The volume of distribution based on the area method was determined by the 
total clearance and elimination rate constant:
Vd(area) = CLj/B
The volume of distribution at steady state or the whole body estimate of the 
volume of distribution was calculated as follows:
Vd„ = Dose-AUMC/AUC2
The elimination half-life (tl/iB) was determined by the elimination rate constant:
t&e = ln(2)/B
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A noncompartmental method was used to determine the statistical moments 
[409]. The area under the first moment curve ( j Cp t-dt) was calculated from the 
intercepts and rate constants:
AUMC = A/a2 = B/B2 
The first statistical moment of the drug concentration time curve is the mean 
residence time (MRT) and is analogous to the half-life of compartmental analysis. 
This value represents the time for 63.2% of the dose to be eliminated and was 
calculated from the area under the curve and the area under the first moment curve 
[409]:
MRT = AUMC/AUC
h. Synovial fluid pharmacokinetic analysi 
The limited number of time-concentration data for synovial fluid in normal 
horses (3 points) and synovitis horses (4 points) did not allow for a calculation of a 
complete pharmacokinetic profile. However, the area under the curve and time- 
concentration data for each horse were calculated. The area under the time versus 
concentration curve (AUC) was determined for each horse by the Pharmacologic 
Calculation System computer program (Microcomputer Specialists, Philadelphia, PA) 
using the trapezoidal rule [410].
Plasma Statistical analysis 
The elimination half-life (t1/4B) was expressed as an arithmetic mean of four 
horses. In addition the half-life was expressed as the harmonic mean (Ht,A) based on 
the mean elimination rate constant. The harmonic is the more appropriate estimate
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of the half-life and always produces a lesser value than the arithmetic mean [411]. 
The harmonic mean is calculated as follows:
=  H / ( l / t iABji +  +  l/ti4B,n)
or
Htv4 =  ln(2)/B“
where B* = the mean elimination rate constant of four horses. The pseudo standard 
deviation (pSD) of the harmonic half-life was based on the jackknife variance and was 
estimated by the following:
PSD =V [(n-l)E (H r HtV2)2] 
where H; = the harmonic mean of n-1 values which is calculated n times deleting a 
different half-life value each time. Estimates of half-life, volume of distribution, 
AUC and Cp° (time 0 plasma concentration) are not considered to be normally 
distributed [412]. Therefore, all pharmacokinetic parameters were compared for 
normal horses and those with acute synovitis by the Mann-Whitney rank sum test 
[413] using SigmaStat (Jandel, Corp., San Rafael, CA). All results were considered 
significant when P < 0.05.
k. Synovial fluid statistical analysis 
Values for AUC from both groups of horses were compared by the Mann- 
Whitney rank sum test. Synovial fluid concentrations from both groups of horses 
were compared at each time using the Mann-Whitney rank sum test. Within each 
group, synovial fluid concentrations were compared to corresponding plasma
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concentrations with paired Student’s t tests [414] using SigmaStat (Jandel, Corp., San 
Rafael, CA). All results were considered significant when P < 0.05.
C. Results
1. Chromatography
The mobile phase composition reported by Satterwhite and Boudinot [405] of 
0.01 M phosphate buffer and acetonitrile (82.5:17.5) did not achieve adequate 
resolution of the analyte and the reported internal standard, naproxen when used with 
the 3 f i m  octadecylsilyl column. Several other internal standards were also tested 
using this system without success including, oxyphenbutazone, phenylbutazone and 
ibuprofen. Fenoprofen was determined to have adequate chromatography and a 
unique retention time as compared to the analyte when a mobile phase of 0.001 
phosphate buffer and acetonitrile was used with a ratio of 85:15 or 82.45:17.55. The 
latter mobile phase ratio was found to be optimal for some sessions using a newly 
purchased column. The limits of quantitation of ketoprofen in this system were 0.025 
f i g / ml in synovial fluid and 0.1 ^g/ml in plasma.
Chromatograms of blank plasma and synovial fluid are shown in Figures 17 
and 18. Chromatograms of plasma and synovial fluid from horses administered 
ketoprofen are shown in Figures 19 and 20. All chromatograms are expressed as 
milliabsorbance units (mAU) versus time. The retention time of ketoprofen in both 
fluids was 1.75 minutes. The retention time of fenoprofen varied slightly from 1.90 



































Figure 19: Liquid chromatogram of extracted plasma from a horse administered ketoprofen. The calculated 
ketoprofen (KETO) concentration was 11.89 ^g/ml. The sample was fortified with fenoprofen (FENO) at 50 







Figure 20: Liquid chromatogram of extracted synovial fluid from a horse administered ketoprofen. The 
calculated ketoprofen (KETO) concentration was 0.53 /xg/ml. The sample was fortified with fenoprofen (FENO) 
(10 /ig/ml) as an internal standard.
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there were no interfering substances eluting near the retention times for ketoprofen or 
fenoprofen in plasma or synovial fluid. The ultraviolet (UV) absorbance spectra of 
ketoprofen from non-extracted standards and incurred samples are shown in Figures 
21 and 22. Comparison of the UV spectra of ketoprofen from standards and incurred 
samples indicates excellent peak purity. The UV absorbance spectrum of fenoprofen 
is shown in Figure 23. Thus, ketoprofen and fenoprofen were differentiated based on 
both the unique retention time and UV absorbance spectrum of each compound.
a. Linearity o f response
Calibration curves of ketoprofen fortified plasma and synovial fluid were 
obtained using the mean peak height ratio values of duplicate injections. These curves 
were linear over the range of concentrations used (0.1 to 40 /ig/ml for plasma, and 
0.025 to 1.0 /xg/ml for synovial fluid) for each analytical session with correlation 
coefficients (r) ranging from 0.9964 to 0.9989.
b. Recovery
The mean relative recoveries of ketoprofen as determined by comparison of 
peak heights of five injections of standard solutions to five injections of extracted 
fortified samples were 100.2% ± 10.0 and 92.1% + 6.5% for synovial fluid samples 
containing 0.025 /xg/ml and 1.0 ptg/ml, respectively, with an overall mean recovery 
of 96.2 %. Mean relative recoveries of ketoprofen from fortified plasma samples were 
109.4% ± 13.4% and 89.8% ± 12.5% for samples containing 0.1 /ig/ml and 40.0 

















250  300  350  400  ’ ' 450  500  ' 550









300 450 500250 350 400 550
Figure 23: UV absorbance spectrum of fenoprofen from a liquid chromatogram of an extracted plasma sample.
Table 16: Recovery of ketoprofen as determined by the comparison of peak heights from 5 









0.025 100.2 (±  10.0) 0.10 109.4 (±  13.4)
1.000 92.1 (±  6.5) 40.0 89.8 (±  12.5)
OVERALL 96.1 OVERALL 99.6
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technique used showed excellent recoveries for synovial fluid and plasma and were 
similar to other methods using diethyl ether [405] and dichloromethane [283].
c. Intra-assay variability
The intra-assay variances for synovial fluid as expressed as the coefficient of 
variation ranged from 5.2% for the 1.0 ^g/ml concentration to 11.0% for the 0.025 
^g/ml level. The plasma values were 3.5% for the 0.1 /ig/ml concentration and 4.6% 
for samples containing 40.0 /tg/ml of ketoprofen (Table 17).
d. Inter-assay variability
The between session variability based on the coefficient of variation of five 
samples run during subsequent analytical sessions ranged from 8.0 % for fortified 
plasma samples containing 0.1 fig/ml of ketoprofen to 10.3% for fortified synovial 
fluid containing 0.025 fig/ml of ketoprofen (Table 17).
2. Plasma pharmacokinetics
Ketoprofen disposition in plasma for normal horses and those with acute 
synovitis was best described by a bi-exponential equation, except in one normal horse 
and one horse with acute synovitis which were better fitted to a mono-exponential or 
one-compartment model. These unusual animals were force-fitted to a two- 
compartment model which permitted comparison between horse groups. The bi­
exponential equation, Cp = A-e'“'T,me +  B-e'BTime, was used to determine the 
pharmacokinetic parameters of all horses where Cp = plasma concentration, A = 
distribution phase intercept, a = distribution phase rate constant, B = elimination 
phase intercept, and B = elimination phase rate constant. The individual coefficients
Table 17: Intra-assay variability as represented by the CV of 6 injections. Inter­
























of determination (correlation coefficient2 or r2) ranged from 0.96217 to 0.99753. This 
value is a measure of the fraction of the total variance accounted for by the model.
The mean total plasma ketoprofen concentration versus time curve for normal 
horses and horses with acute synovitis are shown in Figures 24 and 25 and the derived 
pharmacologic parameter values are outlined in Tables 18 and 19. The mean ± 
standard deviation (SD) plasma concentration of normal horses 3 minutes after dosing 
was 33.72 ±  0.43. The corresponding concentration in horses with acute synovitis 
was 23.61 + 1.96. The distribution phase intercept (A) of normal horses was 41.31 
+ 17.08. This value was significantly higher (P = 0.029) than the corresponding 
value in horses with acute synovitis, 24.65 ±  4.90. Both groups had a similar rapid 
distribution phase followed by slower elimination phase. At 4 hours post-dose plasma 
levels were 0.36 /ig/ml + 0.02 in normal horses and 0.16 /ig/ml ±  0.06 in horses 
with acute synovitis. Plasma ketoprofen concentrations were below the limit of 
quantitation by 5 hours. The harmonic plasma half-life (tV̂ B) + the pseudo standard 
deviation of the horses with acute synovitis was 0.55 hour + 0.21. This harmonic 
half-life was shorter (P = 0.029) than that of the normal horses, 0.88 hour ±  0.35. 
All other plasma pharmacokinetic parameters were not statistically different between 
horse groups.
3. Synovial fluid pharmacokinetics
Ketoprofen disposition in synovial fluid in normal horses was minimal with 
mean peak levels ±  SD of 0.39 /xg/ml + 0.03 occurring at one hour with levels 
falling to 0.08 /j.g/ml + 0.04 by 6 hours (Figure 26). Concentrations were below the
TIME ( h o u r s )
Figure 24: Plasma disposition curves of intravenous ketoprofen (2.2 mg/kg) in 4 normal horses. Mean 
ketoprofen concentrations in /xg/ml are presented as + standard deviations (SD). Inset graph represents 
























' - 1  





1 ! ! !
1 2  3 4
TIME ( h o u r s )
Figure 25: Plasma disposition curves of intravenous ketoprofen (2.2 mg/kg) in 4 horses with acute 
synovitis. Mean ketoprofen concentrations in ng/m\ are presented as + SD. Inset graph represents the 
natural log of plasma concentrations versus time.
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Table 18: Plasma pharmacokinetic parameters of intravenous ketoprofen (2.2 mg/kg) in normal horses and horses
with acute synovitis.
NORMAL HORSES SYNOVITIS HORSES
PARAMETER MEAN ST.DEV. RANGE MEAN ST.DEV. RANGE P
A (/tg/ml) 41.31 17.08 31.06-66.82 24.65 4.90 18.36-30.24 0.029*
a  (1/hr) 6.86 2.89 4.57-10.92 9.47 3.74 3.95-11.88 > 0.10
B (/tg/ml) 5.10 3.40 2.02-9.18 9.29 5.26 2.99-15.80 > 0.10
0  (1/hr) 0.79 0.31 0.42-1.10 1.27 0.49 0.67-1.83 > 0.10
Cp° (/tg/ml) 46.16 20.07 33.08-76.04 33.78 7.26 26.44-40.11 > 0.10
(1/hr) 3.73 1.05 2.84-5.25 3.37 0.56 2.62-3.83 > 0.10
K12 (1/hr) 2.44 1.45 1.33-4.47 3.67 1.93 0.99-5.58 > 0.10
Kn (1/hr) 1.47 0.78 0.67-2.28 3.69 2.03 1.01-4.51 > 0.10
P = Probability estimate 
’Statistically significant at P < 0.05
Table 19: Plasma pharmacokinetic parameters of intravenous ketoprofen (2.2 mg/kg) in normal horses and horses
with acute synovitis.
NORMAL HORSES SYNOVITIS HORSES
PARAMETER MEAN ST.DEV. RANGE MEAN ST.DEV. RANGE P
t%«* (hr) 0.11 0.04 0.06-0.15 0.09 0.06 0.05-0.17 > 0.10
Up (hr) 1.02 0.47 0.62-1.65 0.63 0.29 0.37-1.03 > 0.10
0 .88" 0.35b 0.55" 0 .21b 0.029"*
(hr) 0.20 0.05 0.13-0.24 0.23 0.04 0.18-0.26 > 0.10
MRT (hr) 0.76 0.25 0.56-1.11 0.62 0.13 0.57-0.75 > 0.10
AUC„ (/tg®hr/ml) 12.06 1.64 10.75-14.46 10.10 1.00 8.70-10.94 0.057
AUMC. (Kg'hrVml) 9.07 2.64 7.49-12.99 6.25 1.63 4.87-8.26 > 0.10
CLj (ml/hr®kg) 184.72 22.70 152.08-204.48 219.55 23.25 201.02-252.68 0.057
Vc (ml/kg) 52.67 16.50 28.93-66.48 66.55 12.40 54.83-77.80 > 0.10
Vd(area) (ml/kg) 276.30 139.16 138.20-319.16 195.27 77.46 112.51-299.04 > 0.10
Vds, (ml/kg) 142.30 52.53 85.63-211.74 134.79 27.21 94.24-151.74 > 0.10
P = Probability estimate 
"Harmonic mean 
bPsuedo Standard Deviation 
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Figure 26: Mean plasma and synovial fluid ketoprofen concentrations in jig/ml (+ SD) following 
intravenous ketoprofen (2.2 mg/kg) in 4 normal horses. Significantly different synovial fluid and plasma 
concentrations are indicated by (*).
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limit of quantitation in all normal horses by 9 hours. Synovial fluid ketoprofen 
concentrations at one hour were below (P = 0.015) corresponding plasma levels. 
Synovial fluid levels at 3 hours were not different from the corresponding plasma 
concentrations.
In contrast, synovial fluid disposition of ketoprofen in horses with acute 
synovitis was extensive with peak concentrations (2.53 /tg/ml + 0.39) occurring at 
one hour with levels falling to 0.06 /tg/ml +  0.02 by 9 hours. Concentrations were 
below the limit of quantitation by 12 hours. Although not significant, synovial fluid 
levels at 3 hours appeared greater than the corresponding plasma concentrations (P = 
0.09). In contrast to the normal horses, synovial fluid concentrations at one hour 
were not statistically different from one hour plasma levels (Figure 27). The average 
AUC for normal horses (1.37 /tg-hr/ml ±  0.38) was less (P = 0.029) than that of 
horses with acute synovitis (6.24 /tg-hr/ml + 2.41). At one hour post-dose, synovial 
fluid levels of ketoprofen in horses with acute synovitis were 6.5 times greater (P =
0.017) than normal horses. There was no difference in synovial fluid concentrations 
between the two groups at 3 or 6 hours.
D. Discussion
The harmonic means of plasma elimination half-lives of ketoprofen in both 
groups of horses were between 0.5 and 1 hour. This was expected based on the 
polarity of ketoprofen, as most polar compounds are rapidly excreted. The plasma 
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Figure 27: Mean plasma and synovial fluid ketoprofen concentrations in ng/ml (+ SD) following 
intravenous ketoprofen in 4 horses with acute synovitis.
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clearance. The three volumes of distribution for both groups were less than or 
approximately equal to the extracellular volume (200 ml/kg), which would also be 
expected for a polar drug. The steady state volume of distribution is largely 
dependent on the intravascular albumin binding which for most NSAIDs results in 
limited distribution volumes [415].
The mean harmonic plasma half-life of normal horses (0.88 hours +  0.35) 
was significantly higher than that of horses with acute synovitis (0.55 hours +  0.21). 
This may be due to the increased penetration of ketoprofen into the inflamed joint, 
particularly from 1 to 3 hours post-dose as compared to the normal joints. In 
addition, the inflamed joints of these horses may have acted as a sequestered site of 
elimination, as the synovial fluid withdrawn from horses with acute synovitis ranged 
from 2.5 to 15 ml as compared to approximately 3.5 ml in normal horses. However, 
this cannot be confirmed as elimination data from concurrent urinary and fecal 
ketoprofen levels were not obtained in this study. To date, there are two published 
studies on the plasma kinetics of ketoprofen in the horse. In the study by Sams et 
ah, 1993, the reported harmonic mean of the half-life after one dose of 2.2 mg/kg of 
intravenous ketoprofen was 1.6 hours with a range of 1.18 to 2.65 hours. After five 
daily intravenous doses the harmonic mean of the half-life was 1.3 hours with a range 
of 0.76 to 1.86 hours [283]. The half-life in normal horses in the present study 
ranged from 0.62 to 1.65 hours. Several differences in study design and 
pharmacokinetic analysis are evident in these two studies. There may be a breed 
difference in the pharmacokinetics of ketoprofen as most of the horses in the previous
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study were standardbreds weighing from 465 to 660 kg whereas most horses in this 
study were Thoroughbreds weighing from 406 to 554 kg. The ketoprofen disposition 
was described as a tri-exponential equation in the previous study whereas the data in 
this study were best described by a bi-exponential equation. In addition, blood was 
sampled in this study more often than in the Sams study, particularly during the early 
stages (17 times versus 13). Further, all three volumes of distribution and the total 
clearance values were lower in the present study as compared to data collected by 
Sams. Again, these differences may be accounted for in part by the larger horses 
used in the Sams study as these parameters are known to change in proportion to body 
weight [416].
The distribution phase intercept (A) of normal horses (41.31 /ig/ml + 17.08) 
was significantly greater than that of horses with acute synovitis (24.65 /xg/ml ± 
4.90). The significance of this effect is unknown. However, the other 
pharmacokinetic values were not different between groups with the exception of the 
harmonic half-life. This may be due to the effect of an outlier in the normal horse 
group with a particularly high distribution phase intercept value (66.82 /xg/ml).
Ketoprofen is a chiral compound with the center of asymmetry at C2. The 
commercial preparation is a racemic mixture of the R and S enantiomers. Upon 
administration many species show conversion of the biologically inactive R enantiomer 
to the active S enantiomer [417,418]. In humans, the there is an approximately 10% 
inversion of the R enantiomer to the S after oral administration with little 
stereoselectivity in the pharmacokinetics of these enantiomers. Therefore,
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nonstereospecific assays may be used to explain the pharmacokinetics of the individual 
enantiomers in man [284]. In a recent study by Jaussaud et ah, the plasma 
pharmacokinetics of ketoprofen enantiomers in the horse were evaluated after 
administration of the racemate by means of a stereoselective HPLC technique [286]. 
The plasma disposition curves were fitted to a bi-exponential equation. In contrast to 
humans, the ratio of the S to R enantiomer increased over time and attained a 70:30 
ratio at 50 minutes in the horse. The elimination half-lives of the enantiomers were 
not significantly different statistically but the clearance rate and initial concentration 
of the S enantiomer were lower than that of the R enantiomer. The total ketoprofen 
disposition curve closely paralleled the S enantiomer curve. Further, these authors 
noted a short elimination half-life (0.29 to 0.47 hours) as compared to the present 
study, which may be accounted for by their relatively short sampling interval of 90 
minutes.
Synovial fluid ketoprofen levels in normal horses were lower than plasma 
levels at one hour, but the drug reached an equilibrium between the joint and systemic 
circulation by 3 hours as synovial fluid levels approximated plasma concentrations at 
this time. In contrast, ketoprofen synovial fluid and ketoprofen levels in horses with 
acute synovitis reached equilibrium at one hour post-administration. In these horses 
with acute synovitis, synovial fluid concentrations at 3 hours tended to be higher than 
the corresponding plasma levels. In humans with arthritis this effect is common as 
synovial levels often exceed plasma levels after the equilibrium time [280]. This 
results from the relative sequestration of the drug in the synovial fluid with the lack
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of significant elimination occurring from the joint [402], In horses with acute 
synovitis the amount and persistence of ketoprofen in synovial fluid was greater than 
in normal horses. This was based on the significantly larger AUC, higher 
concentration at one hour and longer duration of synovial fluid ketoprofen quantitation 
for the horses with joint disease.
The effect of increased penetration of an NSAID into inflamed joints versus 
normal ones has been reported in several species. In humans, NSAID joint levels 
were higher in patients with synovial inflammation than normal non-inflamed joints. 
NSAIDs reached levels in inflamed chicken joints that were three times higher than 
in control joints. The inflamed joint levels approximated the corresponding plasma 
levels at 2 hours post-dose [265].
Distribution of a drug to the peripheral tissues depends on the physicochemical 
properties of the drug, the concentration of the drug in the plasma and tissue, the 
blood flow to the tissue, percentage of plasma protein binding and the affinity of the 
drug for the particular tissue [399,416]. Only free (unbound to plasma proteins) drug 
is available to penetrate the endothelium and enter the synovial fluid. However, in 
cases of synovitis, the damaged endothelial barrier allows transudation of plasma 
proteins along with frank hemorrhage into the joint space leading to the accumulation 
of albumin bound drug in the synovial fluid. NSAIDs bound to albumin are thought 
to be released by the degradation of albumin by lysosomal enzymes in sites of 
inflammation [257]. This one way flow of albumin serves to increase the tissue 
concentration of the drug [258]. Also the lowered pH of the inflamed environment
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serves to keep these planar, anionic molecules unionized and thus increase membrane 
permeability [247]. Ion trapping is postulated to occur intracellularly as the 
environment inside the cell is relatively alkaline compared to the acidic inflamed tissue 
[260,261,419].
The effects of protein binding on pharmacokinetics are greater for drugs that 
are highly bound to plasma proteins and are bound in a concentration dependent 
manner. For these drugs, small changes in binding often result in marked alterations 
in drug disposition [420]. In the horse, ketoprofen is greater than 90.0% bound to 
plasma proteins and this binding is constant over the range of therapeutic drug levels 
[283]. Plasma and synovial fluid protein binding was not determined in the present 
study. However, due to the reported linear protein binding in the horse, these data 
obtained from total drug analytical methods were used as an estimate of free drug 
kinetics. In addition, in humans there does not appear to be any difference in the 
degree of protein binding between plasma and synovial fluid for ketoprofen [280].
Certain drugs have a high affinity for tissues and undergo sequestration or 
depot formation. These drugs may reversibly or covalently bind to subcellular 
organelles, nucleic acids or cellular proteins and lipids. In cases of covalent binding 
the drug release is dependent on the cell life span [416]. The R-enantiomer of 
profens acts as a substitute for endogenous fatty acids and forms hybrid 
triacylglycerols. The drug may then be bound to lipid membranes for extended 
periods of time [236,417]. Data from rat studies based on unbound drug disposition 
suggest that ketoprofen has dose-dependent binding to tissue components [415]. This
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tissue binding may account for the low reported urine recovery of ketoprofen (57.2%) 
in horses [283].
CHAPTER 6
EFFECT OF KETOPROFEN AND PHENYLBUTAZONE ON CHRONIC 
PAIN AND DIGITAL VEIN EICOSANOID LEVELS 
IN LAMINITIC HORSES
A. Introduction
Laminitis has been cited as one of the major causes of chronic hoof pain in the 
horse [198]. Laminitis is classified as chronic after 48 hours of continual pain from 
a laminitic episode or when ventral deviation or rotation of the distal phalanx occurs 
[200]. It is associated with debilitation, hypertension, lameness and hoof pain which 
may last for the life of the animal. The complex syndrome of equine laminitis has 
multiple etiologies with a complex and poorly understood pathophysiology [199]. The 
pathology within the foot is a manifestation of a systemic metabolic disorder that 
affects the cardiovascular, endocrine and renal systems.
This disease is no longer defined as inflammation of the laminae of the foot, 
but is more precisely defined as a peripheral vascular disease [200] characterized by 
ischemic necrosis of the epidermal laminae, microvascular thrombosis, epithelial 
hyperplasia, and hemorrhage [220,224-226]. It has been hypothesized that the laminar 
ischemia develops acutely due to decreased capillary perfusion from opening of 
arteriovenous shunts and vasoconstriction [220].
Bacterial endotoxin has been implicated as an inciting cause in laminitis. Many 
horses with endotoxemia develop laminitis [220] and horses with carbohydrate
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overload-induced laminitis have increased plasma endotoxin levels and lameness [221]. 
Endotoxemia is associated with increased plasma levels of leukotriene B4 (LTB4) [222], 
prostaglandin Ej (PGEj) as well as other eicosanoids. The administration of 
nonsteroidal anti-inflammatory drugs (NSAIDs) prevents many of the effects of 
experimentally induced endotoxemia [223]. Eicosanoids have been implicated as 
mediators in laminitis due to the powerful vaso- and venoconstriction produced by 
PGF^ and thromboxane [217] along with the well known hyperalgesic effects ofPGEj 
[157,158] and LTB4 [166]. However, the association between endotoxin-induced 
eicosanoid production and the development of laminitis remains a theory due to the 
inability to produce laminitis following endotoxin administration. Further, 
concentrations of eicosanoids have not been measured in horses with acute or chronic 
laminitis [220].
NSAIDs are commonly administered to reduce the pain and suffering 
associated with laminitis and allow the animal to more comfortably stand and 
ambulate, thereby promoting blood flow to the foot and reducing the adverse effects 
of long term recumbency. According to Hood [199], horses that are treated with 
analgesics early in the course of the disease have a lower incidence of rotation of the 
distal phalanx than those treated later. NSAIDs are thought to be particular useful in 
treating the coagulopathy within the foot because of their inhibitory effects on 
eicosanoid formation and platelet function [199,234]. Previously, phenylbutazone (4.4 
mg/kg) has been regarded as the single most important therapeutic agent in treating
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laminitis [231,233]. The effects of the recently approved NSAID, ketoprofen have 
not been evaluated in horses with laminitis.
The purpose of this study was to determine if horses with chronic laminitis 
have increased digital vein levels of PGE2 and LTB4 as compared to normal horses. 
An increase in the concentration of eicosanoids in the venous drainage of the foot 
would lend further evidence that these metabolites play a role in mediating the pain 
and pathology within the foot. The digital vein was chosen as a sampling site due to 
the difficulty in obtaining laminar tissue for eicosanoid level determination in live 
horses. Horses were evaluated both at rest and after a brief exercise period in order 
to determine if eicosanoids are released into the circulation after mild concussion to 
the laminitic foot.
Provided that there were higher eicosanoid concentrations in laminitic versus 
normal horses, the severity of hoof pain in these laminitic animals was to be 
correlated with the eicosanoid concentrations. These horses were then to receive 
ketoprofen and phenylbutazone in order to determine the magnitude and time course 
of the eicosanoid inhibitory effects of these NSAIDs in animals with chronic laminitis. 
Further, this study objectively quantitated and compared the analgesic effects of 
phenylbutazone and the newly approved NSAID, ketoprofen in horses with chronic 
hoof pain by means of an electronic hoof tester. The approved therapeutic doses of 
ketoprofen (2.2 mg/kg) and phenylbutazone (4.4 mg/kg) were used. In addition, the 
phenylbutazone molar equivalent dose of ketoprofen (3.63 mg/kg) was tested in the 
laminitic animals in order to compare the potency of ketoprofen and phenylbutazone.
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B. Materials and methods
1. Experimental animals
a. Normal horses
Six healthy Thoroughbred mares ranging from 7 to 18 years of age were used 
to determine digital vein PGEj and LTB4 concentrations. Horses were judged to be 
healthy and sound based on physical examination and lameness evaluation.
b. Horses with chronic laminitis
Six horses (4 geldings, 2 mares; 4 American Quarter Horses, 1 Thoroughbred, 
and 1 Morgan) diagnosed with chronic laminitis ranging from 3 to 22 years of age 
were used for the collection of digital venous blood for determination of PGEj and 
LTB4 concentrations. Seven horses with chronic laminitis (4 mares, 3 geldings; 5 
Quarter Horses, 1 Thoroughbred and 1 Morgan) ranging from 3 to 18 years of age 
were used in determining the analgesic effects of ketoprofen and phenylbutazone. The 
diagnosis was based on: 1) degree of lameness as evaluated at a walk, trot and while 
turning on a concrete surface; 2) hoof abnormalities associated with chronic laminitis 
such as diverging hoof growth patterns with wider growth rings at the heel, subsolar 
or mural abscesses, a convex shaped sole, and the presence of a ’seedy toe’ or an 
abnormally large white line [200]; 3) radiographic evidence of laminitis such as 
ventral deviation or rotation of the third phalanx as determined by Stick’s method 
[228] (mean rotation + standard error, 13.75° ±  2.25), and osteolysis with 
demineralization of the distodorsal aspect of the third phalanx [234]; 4) response to
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the hoof tester, particularly over the sole midway between the apex of the frog and 
the toe; and 5) clinical history of a laminitic episode [231].
All horses were vaccinated at least three weeks prior against eastern and 
western equine encephalomyelitis, influenza, tetanus (Equi-Flu EWT™, Coopers, 
Mundelein, IL) and rhinopneumonitis (Rhinomune™, SmithKline Beecham Animal 
Health, Exton, PA). The horses were dewormed with oxibendazole (Equipar™, 
Coopers, Mundelein, IL). Horses were housed in 10.9 x 12.5 feet stalls and were 
maintained on 5 pounds of a pelleted ration (Purina Horse Chow 100™, Purina Mills 
Inc., St. Louis, MO) containing: a minimum of 10% protein; 2% fat; a maximum of 
25 % fiber; and a vitamin/trace mineral supplement twice daily with mixed grass hay 
(11% protein, 1.4% fat, 24% fiber) and water provided ad libitum.
2. Drugs and reagents
a. Drug solutions for administration 
Ketoprofen (Ketofen™) was obtained commercially from Aveco Company, 
Inc., Fort Dodge, IA. Each ml of the sterile solution contained: 100 mg ketoprofen; 
L-arginine, 70 mg; citric acid to adjust pH to approximately 7; and benzyl alcohol,
0.25 ml as a preservative. Phenylbutazone (Butazolidin™) was obtained commercially 
from Coopers Animal Health, Inc., Kansas City, KS. Each ml of the sterile solution 
contained: phenylbutazone, 200 mg; sodium hydroxide to adjust pH to between 9.5 
and 10.0; and benzyl alcohol, 10.45 mg as a preservative.
196
3. Experimental protocol
a. Collection o f blood from digital veins
Blood was collected from 6 normal horses and 6 horses with chronic laminitis 
before and after trotting for 5 minutes on a concrete surface. The lateral region of 
the metacarpophalangeal joint of each normal and laminitic horse was shaved and 
scrubbed with a povidone-iodine preparation and alcohol before each venipuncture. 
Horses were restrained in a stanchion and nose twitched during venipuncture. Blood 
was collected from the digital vein at the level of the metacarpophalangeal joint with 
a 20 gauge, 1.0 inch needle. One to 2 ml of blood were discarded before collection 
of 10 ml into chilled evacuated siliconized glass tubes (Vacutainer, Becton Dickinson, 
Rutherford, NJ) containing 3.3 /tg/ml of BW755C (Wellcome Research Laboratories, 
Beckenham, Kent, England) as an inhibitor of ex vivo eicosanoid synthesis and 10 
mg/ml of the anticoagulant, disodium ethylenediamine tetraacetate (EDTA) purchased 
from Sigma Chemical Company, St. Louis, MO. Tubes were immediately centrifuged 
at 2,000 rpm for 15 minutes at 4°C (Beckman J21-B, Palo Alto, CA). The platelet 
poor plasma was transferred into 15 ml polypropylene centrifuge tubes (Sarstedt, 
Newton, NC) and stored at -20°C until analyzed.
b. Quantitation o f nociceptive thresholds in horses with chronic
laminitis
Ketoprofen (2.2 mg/kg and 3.63 mg/kg), phenylbutazone (4.4 mg/kg) and 
saline as a control were administered via the left jugular vein to 7 horses with chronic 
laminitis. The following methods were used to evaluate analgesia before
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administration of NSAIDs (baseline) and at 3, 6 and 24 hours post-treatment. 
Nociceptive or pain thresholds were determined in the test animals using a calibrated 
electronic hoof tester according to the method of Kamerling, et al., [421-423]. This 
device is a standard hoof tester equipped with a load cell welded to the tip of one jaw. 
The tension/compression load cell (Sensotec Model 31, Columbus, OH) had 10 V 
excitation, 2 mV/V output and a load capacity of 250 pounds. The calculated full 
scale accuracy was 0.15% with 0.15% linearity and hysteresis.
The hoof tester was manually applied to the solar surface of each forefoot in 
the traditional fashion [377]. Gradually increasing force over 2 seconds was applied 
at 16 separate loci on the solar and posterior surfaces of each forefoot (Figure 28). 
The force in Newtons required to produce a hoof withdrawal response by the 
laminitic horse was designated the hoof compression threshold (HCT). A ’response’ 
to hoof compression was considered painful when the hoof was withdrawn from the 
examiner’s hand or a contraction of the antebrachial musculature was noted by the 
examiner and an independent observer. The examiner terminated hoof compression 
at the initiation of the withdrawal response to avoid tissue damage. Loci that did not 
result in hoof withdrawal or muscle contraction by the end of the 2 second 
compression were deemed ’non-responsive’. The peak analog output (mV) of the hoof 
tester transducer was converted to Newtons and recorded for each locus by a computer 
(Commodore 64, England) equipped with customized software designed to test 
nociceptive thresholds.
Left Hoof R ight H oof
LATERALLATERAL MEDIAL
Figure 28: Diagram showing the position of the 16 loci tested on the solar surface of the left and right forefeet 
of the laminitic horses. Locus 16 is tested by applying the hoof tester to the medial and lateral heel bulbs.
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During baseline hoof testing sessions, the computer recorded the peak force 
applied to each locus and an independent observer entered (into the computer) whether 
the locus was ’responsive’ or ’non-responsive’. All loci were tested again at 3, 6 and 
24 hours after drug (or saline) administration. However, in the responsive loci, HCTs 
were elicited using a compression cutoff of 50% above baseline. This was calculated 
by the computer for each baseline locus which was ’responsive’ to hoof compression. 
The computer was equipped with an audible bell that signaled when 50% above 
baseline HCT had been reached so that the examiner could terminate compression. 
Therefore, post-treatment compression in the ’responsive’ loci was terminated either 
when a withdrawal response was initiated by the horse or the cutoff value was 
reached. ’Non-responsive’ loci received approximately the same pressure on post­
treatment sessions as baseline, unless the loci became responsive in a post-treatment 
session. In that case compression was terminated when a withdrawal response was 
initiated.
The number of responsive (pain sensitive) loci on each foot was recorded 
during each hoof test session and expressed as a percentage of the total number of loci 
tested per horse. A subjective assessment of the hoof withdrawal response following 
hoof compression was made by the examiner. A subjective grade of 0 to 4 was used 
to indicate the weakest to strongest response as follows:
Grade 0: No response to hoof compression.
Grade 1: The horse contracted the antebrachial musculature with mild
extension of the shoulder, but the foot was not moved appreciably.
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Grade 2: The horse extended the shoulder and briefly attempted to withdraw 
the foot from the examiners grasp.
Grade 3: Moderate excursion of the limb and foot occurred, but the foot was 
not removed from the examiners grasp.
Grade 4: The horse quickly and forcefully withdrew the limb and attempted 
to place the foot on the ground.
c. Evaluation o f lameness in laminitic horses 
Lameness was assessed {lameness score) immediately before each hoof test 
session according to a modified Obel scale [200] as follows:
Grade 1: The horse exhibited a normal gait at a walk. The trot showed a 
shortened stride with an audible cadence abnormality, but showed even head 
and neck lifting for each foot.
Grade 2: The walk was stilted, but showed no abnormal head or neck lifting. 
The trot showed obvious lameness with uneven head and neck lifting. A 
forefoot could be lifted off the ground easily.
Grade 3: The lameness was obvious at a walk and trot. The horse resisted 
attempts to have a forefoot lifted and was reluctant to move.
Grade 4: The horse experienced difficulty bearing weight at rest or was very 
reluctant to move.
Preliminary studies indicated that this scale was not sensitive to subtle changes in 
lameness that occur over time in laminitic horses e.g., head and neck lifting becoming 
more/less pronounced. Further, numerical rating scales consisting of only 4 lameness
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grades are known to be less sensitive compared to other grading schemes [424]. 
Consequently, the above enumerated scale was expanded to include 3 divisions per 
grade by adding a 4- or - to each lameness grade to indicate the degree of severity 
associated with the score. Therefore, this modified lameness scale ranged from 0 
(sound) to 12 (non-weight bearing).
4. Eicosanoid determination
a. Extraction
Plasma obtained from digital venous blood was extracted using a liquid/liquid 
extraction technique prior to determination of PGE2 and LTB4 by enzyme-linked 
immunosorbent assay (ELISA) [333]. Four ml were extracted for both the LTB4 and 
PGE2 assays. All samples were processed in duplicate. Plasma was acidified and 
then three volumes of ethyl acetate were added to extract the eicosanoids. After 
vortexing, centrifugation and separation of aqueous and organic layers, the ethyl 
acetate was evaporated under nitrogen. Samples were then dissolved in phosphate 
buffer just prior to the ELISA procedure. For a more complete description of the 
extraction procedure and recovery information refer to Chapter 3.
b. ELISA
Quantitation of plasma eicosanoids was achieved using commercially available 
PGE2 and LTB4 ELISA kits (Advanced Magnetics, Cambridge, MA) [425]. These 
assays were based on the principle of a competitive ELISA where PGEj or LTB4 in 
the sample competed with fixed amounts of alkaline phosphate labelled PGE2 or LTB4 
for binding to the specific rabbit antibody bound to the microtiter well. Results were
202
determined by means of a Dynatech MR5000 ELISA micro-titer plate reader 
(Dynatech Laboratories, Alexandria, VA). Absorbance (read at 410 nm) was 
correlated with concentration by means of a standard curve ranging from 10 to 5000 
pg/ml. Quantitation of unknown samples was achieved by averaging the absorbance 
of sample duplicates and calculation of the concentration from the standard curve. All 
sample concentrations were then corrected for extraction efficiency. For a more 
complete description of the ELISA procedure see Chapter 3.
5. Statistical design and data analysis
a. Eicosanoid concentrations
PGE2 and LTB4 plasma concentration data were analyzed using a univariate 
analysis of variance for a split-plot design [389] where group (normal or laminitic) 
constituted the main plot and status (resting digital vein or post-exercise digital vein) 
was the subplot [386,387]. When indicated, multiple comparisons between groups or 
status categories were performed using a Tukey’s w Procedure [388]. Differences 
between groups or status categories were considered significant when P < 0.05.
b. Nociceptive thresholds and lameness grade
Each laminitic test subject received ketoprofen (2.2 mg/kg and 3.63 mg/kg), 
phenylbutazone (4.4 mg/kg) and saline intravenously according to a Latin square 
design [385]. Horses received one treatment per week for four weeks. The study was 
performed in a double-blind fashion as neither the person performing the analgesic 
tests nor the injector were aware of the treatment.
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To minimize variance in pain thresholds over experimental days, all data were 
expressed as percent change from baseline for each horse at each post-treatment time 
within a given session. In addition, HCT (for responsive loci) and subjective grade 
of hoof withdrawal reaction data were expressed as an average over all baseline 
responsive loci for each horse at the post-treatment times. Data were analyzed using 
one-way analysis of variance (ANOVA) for repeated measures [386,387]. When 
indicated by ANOVA, multiple comparisons were performed using a Tukey’s w 
Procedure [388]. Differences between treatments at each time were considered 
significant when P < 0.05.
C. Results
1. Digital vein eicosanoid concentrations
Mean digital vein PGE2 and LTB4 concentrations are shown in Figure 29. 
Within each group (normal and laminitic), there were no differences in resting and 
post-exercise PGEz digital vein concentrations. Between groups, there were no 
differences in digital vein concentrations of PGEj. The mean PGE  ̂ digital vein 
concentration for the two groups was 187.18 pg/ml. For the LTB4 digital vein 
concentrations, there were no differences in resting and post-exercise levels within 
groups (normal and laminitic). As with PGEj, there were no differences in digital 
vein concentrations of LTB4 between groups. The mean LTB4 digital vein 
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2. Nociceptive thresholds and lameness grade
The effect of NSAIDs and saline on HCTs in horses with chronic laminitis is 
shown in Figure 30. Ketoprofen (3.63 mg/kg) significantly increased the HCT as 
compared to saline at 3 and 6 hours post-treatment. At 3 and 6 hours after treatment, 
the horses administered this dose of ketoprofen tolerated an average increase in 
compressive force (as compared to baseline) of 19.74% and 23.35%, respectively. 
Even though there were significant effects as compared to saline, there were no 
differences between NSAIDs at 3 or 6 hours.
In order to determine the degree of variation in compression applied to a non- 
responsive locus over the course of time, the coefficient of variation (CV) of non- 
responsive loci HCT’s elicited during the experimental day was determined. This 
value was obtained for each of 4 non-responsive loci in 4 horses by obtaining the 
mean and standard deviation of HCTs elicited at hoof test sessions before treatment 
and at 3, 6 and 24 hours after treatment. An overall CV was calculated by averaging 
all individual CVs across horses. Non-responsive locus CVs for an experimental day 
ranged from 1.18% to 9.50%. The overall average CV for a total of 16 loci in 4 
horses was 3.81% with a standard deviation of 2.30.
The percentage of responsive loci per horse was unaffected by any treatment 
at 3 hours after drug dosing (Figure 31). However, at 6 hours all NSAIDs produced 
a lower percentage of responsive loci as compared to the saline control (29.49%). By 
24 hours, ketoprofen at 3.63 mg/kg (-3.87%), and phenylbutazone (-2.50%) continued 
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Figure 30: Effect of NSAIDs and saline on mean hoof compression thresholds (+ SEM) in 7 laminitic 
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Figure 31: Effect of NSAIDs on mean percentage of responsive or pain sensitive loci (+ SEM) in 7 
laminitic horses. Dissimilar superscripts indicate statistically significant treatment differences at P < 
0.05.
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(30.48%), with apparent recovery in the horses treated with 2.2 mg/kg of ketoprofen 
(7.19%). There were no differences among NSAIDs at 6 or 24 hours. The number 
of responsive loci in horses administered saline increased over time while there was 
very little change in horses administered NSAIDs.
The 3.63 mg/kg dose of ketoprofen (-8.25%) reduced the subjective grade of 
hoof withdrawal response at 3 hours when compared to saline (9.89%). All NSAIDs 
reduced this grade at 6 hours (Figure 32). By 24 hours, only the 3.63 mg/kg dose of 
ketoprofen (-9.63%) had reduced the grade of withdrawal response as compared to 
saline (11.64%). There were no differences among NSAIDs at any of the times 
tested.
At 3 hours post-treatment, there were no significant effects on the lameness 
grade (Figure 33). By 6 hours, only the 3.63 mg/kg dose of ketoprofen (-21.43%) 
reduced the lameness grade when compared to saline (14.29%). There were no 
significant differences between individual NSAIDs. This effect continued through the 
24 hour post-treatment period.
D. Discussion
In the 7 horses with chronic laminitis, the digital vein concentrations of PGE2 
and LTB4 were not significantly different from corresponding concentrations in the 6 
normal horses. Further, there was no difference in the digital vein concentrations of 
PGE2 and LTB4 after a brief exercise period in any of the horses. These results show 
that horses with hoof pain and lameness from chronic laminitis do not have an
3 0
□ K etoprofen  3.63 m g /k g  i.v.
■ K etoprofen  2.2 m g /k g  i.v.
















- 2 0  -
- 3 0
0 3 6 159 12 18 21 24 27
TIME ( h r s )
Figure 32: Effect of NSAIDs and saline on mean subjective grade of hoof withdrawal response (±  SEM)















K etoprofen 3 .63  m g /k g  i.v. 
K etoprofen 2.2 m g /k g  i.v. 











Q 3 6 9 12 15 18 21 24 27
TIME ( h r s )
Figure 33: Effect of NSAIDs and saline on mean lameness grade (±  SEM) in 7 laminitic horses.
Dissimilar superscripts indicate statistically significant treatment differences at P < 0.05.
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increase in the plasma eicosanoids in the venous drainage of the foot as compared to 
normal horses even after mild concussion to the foot. These data do not support the 
hypothesis that eicosanoids play a role in mediating the pain and pathology of chronic 
laminitis. However, it must be noted that eicosanoids were not measured in laminar 
tissue which is the site of pathology within the foot. It may be that tissue 
concentrations were not sufficiently elevated to increase levels in the venous blood. 
Other researchers have been able to demonstrate increased circulating levels of 
eicosanoids with a local disease state. An increased plasma leukotriene concentration 
has been reported in children with asthma as compared to healthy subjects [426]. 
Similarly, significantly higher than normal venous plasma prostaglandin and 
thromboxane levels have been described in calves [427] and humans with lung disease 
[428]. Further, plasma PGEj [140] and serum LTB4 [141] levels of patients with 
rheumatoid arthritis are reportedly higher than normal controls and the time course 
of changes of PGEj in blood plasma levels reflects the disease dynamics [140]. It is 
possible that eicosanoids may play a role only in the acute phase of the laminitis 
where hoof pain and the circulatory changes are more pronounced [220].
The overall average PGE2 level in the digital veins of normal and laminitic 
horses was 187.18 pg/ml. Plasma PGE  ̂ levels obtained from other species which 
range from 14.35 to 517 pg/ml [333,349,427,429]. The mean LTB4 level in digital 
plasma as determined in normal and laminitic horses was 74.71 pg/ml. This is 
approximate to the plasma levels in humans which are reported to be less than 100 
pg/ml [430]. It should be noted that eicosanoid concentrations vary considerably
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depending on the sampling site, species, extraction and method of quantitation. It is 
theorized that actual circulating eicosanoid levels do not exceed 2 pg/ml [24]. 
Therefore, even minor trauma occurring during collection of blood plasma may result 
in ex vivo formation of eicosanoids which accounts for the wide range of 
concentrations reported [24]. These reported values then cannot be regarded as 
absolute and should only be used for comparison when obtained under identical 
circumstances.
One of the objectives of this study was to correlate the severity of hoof pain 
in these laminitic animals with the eicosanoid concentrations, provided that there were 
higher eicosanoid concentrations in laminitic versus normal horses. These horses 
were then to be administered ketoprofen and phenylbutazone in order to determine the 
magnitude and time course of the eicosanoid inhibitory effects of these NSAIDs. This 
objective could not be accomplished due to the lack of significant eicosanoid 
differences in laminitic versus normal horses
Although the pain and lameness in these laminitic horses could not be 
definitively attributed to eicosanoids, both effects were reduced by the systemic 
administration of NSAIDs. Statistically significant overall treatment effects were 
observed for all measures of nociceptive threshold and lameness. However, 
ketoprofen at a dose of 3.63 mg/kg (1.65 times the approved therapeutic dose) 
produced a more pronounced and longer lasting reduction in most of the objective and 
subjective indices of pain and lameness. For lameness grade and HCT, the high dose 
of ketoprofen produced the only significant treatment effects that were different from
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saline upon multiple comparison. This dose of ketoprofen produced effects even at 
24 hours for 3 of the 4 pain tests, including lameness grade. However, it should be 
noted that there were no significant differences between the NSAIDs at any of the 
times for all 4 tests. These treatment means were within + 20% of one another. The 
hoof is somewhat limited in terms of sensitivity as a bioassay for analgesia. This 
device is better at demonstrating the pain relieving effects of potent central analgesics 
[425].
In this study, horses that were administered saline became progressively more 
lame and the number of responsive loci along with the grade of withdrawal response 
increased over the course of the hoof test session as compared to horses administered 
NSAIDs. This would indicate that these animals were becoming hyperalgesic 
(excessive sensitivity to mechanical stimuli) and hyperpathic (an abnormally 
exaggerated subjective response to painful stimuli) [155]. It is known that NSAIDs 
usually do not completely block pain, but primarily reverse the hyperalgesia associated 
with painful conditions [163]. These agents reduce the peripheral afferent discharge 
from hyperalgesic regions [197,266], and also have central anti-hyperalgesic effects 
[272,305] that may not be dependent on eicosanoid inhibition [258,276]. The results 
of this study indicate that NSAIDs reduced the hyperalgesia associated with chronic 
laminitis.
Ketoprofen is approved at a intravenous dosage rate of 2.2 mg/kg, once daily. 
This dose of ketoprofen did not produced any significant effects on hoof pain or 
lameness at 24 hours. This would not support the recommended once daily dosing
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interval for ketoprofen at the 2.2 mg/kg dose. It appears that laminitic horses might 
benefit from a slightly increased dosage rate of ketoprofen. This dose was not 
associated with any apparent clinical toxicity in the animals in this study. Although 
more extensive toxicity studies are needed, one study has shown that up to five times 
the therapeutic dose (11.0 mg/kg,IV) produced no evidence of toxicity after 15 days 
[309].
This study also served to further evaluate the electronic hoof tester and the 
model of chronic pain in horses. There was close agreement among the data from all 
4 pain tests which supports the accuracy and validity of the subjective measures of 
hoof pain and lameness (subjective grade of hoof withdrawal, lameness score) as 
compared to the objective measures (HCT, number of responsive loci). The degree 
of variation in compression applied to a non-responsive locus as determined by the 
CVs of non-responsive loci HCT’s elicited during the experimental day was minimal. 




Carrageenan-induced synovitis of the equine carpus proved to be self-limiting 
and reproducible model of acute inflammation. The synovitis was associated with 
quantifiable increases in prostaglandin (PGE2) and leukotriene B4 (LTB4) 
concentrations in synovial fluid along with other measurable joint inflammatory 
responses. PGE2 concentrations rose dramatically over time with peak levels 
occurring at 9 hours, with gradual decreases to near baseline at 48 hours. LTB4 
concentrations in synovial fluid peaked early in the inflammatory process at 3 hours 
then quickly returned to baseline. The primarily neutrophilic cellular influx into the 
synovial fluid was extensive, with peak levels occurring from 6 to 9 hours. These 
findings are consistent with other forms of carrageenan-induced inflammation. The 
inflammation was apparently non-septic and transient as horses returned to soundness 
by 48 hours with no subsequent clinical signs of degenerative joint disease.
Phenylbutazone decreased the concentrations of PGE2 from 6 to 12 hours post­
dose, whereas the therapeutic and equi molar doses of ketoprofen were associated with 
more short lived prostaglandin inhibitory effects. There was no ketoprofen dose- 
response relationship observed for prostaglandin concentrations or any of the other 
parameters. Further, the therapeutic dose of ketoprofen inhibited prostaglandin 
production to a greater extent than the higher dose at 6 and 9 hours post-dose. This 
may in part be due to the small difference in the two doses chosen and the variability
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associated with PGE2 measurement. Future studies using ketoprofen at doses of 4.4 
mg/kg and higher, and perhaps in vitro experiments on the effect of ketoprofen on 
prostaglandin metabolizing enzymes, would possibly clarify this effect.
Although ketoprofen and phenylbutazone had no significant influence on 
synovial fluid LTB4 concentrations, all drugs appeared to elevate the levels as 
compared to saline at the time of peak increases. Phenylbutazone appeared to have 
the greatest potentiation followed by the therapeutic dose of ketoprofen. This effect 
has been reported for many nonsteroidal anti-inflammatory drugs (NSAIDs) and has 
been attributed to a diversion of arachidonic acid substrate after cyclooxygenase 
inhibition to the lipoxygenase pathway. Based on these experiments in this study, 
ketoprofen was not an inhibitor of lipoxygenase. Other reports have both confirmed 
and refuted these results, as inhibition of cyclo- and lipoxygenase enzymes by 
NSAIDs varies depending on the dose, species, metabolite measured and the model 
of inflammation. These studies do support data from other species suggesting that 
leukotrienes are involved in joint inflammation, and development of drugs which 
inhibit their synthesis may be of therapeutic value.
Phenylbutazone was more effective than ketoprofen in alleviating many of the 
clinical signs of pain and inflammation in this model of acute synovitis. 
Phenylbutazone had activity lasting as long as 24 and 48 hours post-dose for some of 
these measures of joint inflammation.
The plasma half-life of the therapeutic dose of ketoprofen was less than one 
hour. Horses with acute synovitis had significantly shorter plasma half-lives than
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normal horses. This can be attributed to the significantly higher synovial fluid 
concentration of ketoprofen in horses with acute synovitis. In addition, ketoprofen 
may have been sequestered in the inflamed joint as the synovial fluid levels were 
greater than plasma concentrations at 3 hours post-administration. Synovial fluid 
levels of ketoprofen in horses with acute synovitis were detectable from 1 to 9 hours 
post-dose while this dose produced significant anti-inflammatory activity from 3 to 9 
hours. Data from other studies suggest that ketoprofen and other NSAIDs may bind 
to tissue components for substantial lengths of time in a dose-dependent manner. Such 
data may help to explain the relatively long duration of action in comparison to the 
short plasma half-life of these drugs.
Digital vein eicosanoid concentrations were not different between horses with 
chronic laminitis and normal horses. These data do not support the hypothesis that 
eicosanoids play a role in mediation of the pain and pathology of chronic laminitis. 
However, eicosanoids may play a role locally in the laminar tissue without producing 
measurable concentrations in the digital vein. Alternatively, these compounds may 
be released during the acute phase of the laminitis where hoof pain and circulatory 
changes are more pronounced. Although the pain and lameness in the laminitic horses 
could not be attributed to eicosanoids, both effects were reduced by the systemic 
administration of NSAIDs at doses which reduced PGEz in synovial fluid. The high 
dose of ketoprofen produced a more pronounced and longer lasting reduction in most 
of the measures of hoof pain and lameness than the other NSAIDs. This dose 
produced effects lasting for 24 hours for most of the pain tests, including lameness
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grade. The therapeutic dose of ketoprofen was effective in 2 of the 4 pain tests at 6 
hours. Horses administered saline became progressively more lame and had 
increasing hoof pain over the course of the experimental session as compared to 
horses administered NSAIDs. These results indicate that rather than producing 
analgesia, these NSAIDs reduced the hyperalgesia associated with chronic laminitis. 
This effect has been well documented for NSAIDs and may be independent of 
eicosanoid inhibition. The severity of hoof pain could not be correlated with 
eicosanoid concentrations in the horses with chronic laminitis due to the lack of 
significant differences in normal and laminitic horses.
Procedures for extraction and measurement of PGE2 and LTB4 equine plasma 
and synovial were evaluated. The solid phase extraction procedure that was developed 
resulted in adequate recovery for both compounds from equine biological samples. 
An enzyme-linked immunosorbent assay (ELISA) was used for quantitation of LTB4 
and PGEz that had not been previously documented in the horse. Available 
information suggested that considerable cross reactivity with PGEj occurred in the 
PGE2 ELISA while the LTB4 was very specific. The results from the validation 
procedures for the PGEj ELISA indicated that the assay was specific for this 
compound in equine synovial fluid.
In conclusion, the results of these studies indicate that NSAIDs differ in 
potency and efficacy depending on the type of pain and inflammation present. In 
acute experimentally-induced synovitis, where the duration of clinical signs lasted 
approximally 48 hours, phenylbutazone was more potent in relieving the joint
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inflammation and pain than either the therapeutic or the equimolar dose of ketoprofen. 
In naturally occurring chronic laminitis, where horses experience pain and pathology 
within the foot for months or years, the high dose of ketoprofen was more potent than 
either the therapeutic dose of ketoprofen or the equimolar dose of phenylbutazone.
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